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1. The paraganglion system
Paraganglia are small bodies of chromophil cell clusters associated with the ganglia of 
the autonomic nervous system. The paraganglion system consists of the adrenal medulla, 
the largest paraganglion in the human body, the sympathe  c paraganglia, and the 
parasympathe  c paraganglia[1,2]. The sympathe  c paraganglia are associated with the 
ganglia of the paravertebral sympathe  c trunk, the organ of Zuckerkandl, and the celiac, 
renal, suprarenal and hypogastric plexuses (fi gure 1)[2].
Figure 1. The adrenal medulla and extra-adrenal sympathe  c paraganglia. Adapted from: Lee et al. 
Am. J. Roentgenol. 187 (2006) 492-504.
The parasympathe  c paraganglia consist of the intravagal bodies and the branchiomeric 
paraganglia in the medias  num and head and neck region, most notably located in the 




Figure 2. The parasympathe  c branchiomeric paraganglia. Adapted from: Lee et al. Am. J. 
Roentgenol. 187 (2006) 492-504.
Paraganglia contain a parenchymal and a stromal component. The parenchymal 
component is of neuroectodermal origin. During embryogenesis, neuronal precursor cells 
migrate from the neural crest to loca  ons along the cranial nerves, sympathe  c trunk and 
greater blood vessels, where they develop into the paraganglionic type 1 or chief cells. The 
stromal component is of mesenchymal origin en contains the type 2 or sustentacular cells, 
as well as other stromal components such as blood vessels[3]. Type 1 and 2 cells form a 
specifi c confi gura  on known as the “Zellballen”: small clusters of type 1 cells surrounded 
by type 2 cells and other stromal components (fi gure 3)[4]. 
The exact func  on of the paraganglion system is not fully known. The adrenal medulla, 
the inner part of the adrenal gland, produces the catecholamines adrenalin, noradrenalin 
and dopamine: hormones that regulate heart rate, blood pressure, metabolism, and 
cause vasoconstric  on and bronchiole dilata  on. The organs of Zuckerkandl are thought 
to be important regulators of the embryonic homeostasis and blood pressure through 
the produc  on and release of catecholamines during early gesta  on, and they normally 
start to regress in the third trimester. The caro  d and aor  c bodies func  on as peripheral 
chemoreceptors sensi  ve to changes in arterial oxygen levels, and to a lesser degree also 
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to carbon dioxide levels and arterial pH. Arterial hypoxia, hypercapnia and acidosis cause 
excita  on of the paraganglionic type 1 cells. This signal is relayed by the aff erent fi bers 
of the glossopharyngeal and vagal nerves to the central cardiorespiratory centers in the 
medulla oblongata, which regulate cardiac output and respira  on (see paragraph 4.2.3: 
oxygen sensing at the caro  d body, and paragraph 5.1: the discovery of the caro  d body 
func  on)[5]. 
 
Figure 3. Microscopy of hematoxylin and eosin (H-E) stained caro  d body paraganglioma  ssue 
showing the type 1 and 2 cells in the classic Zellballen confi gura  on. This characteris  c architecture 




2. Neoplasia of the paraganglion system
The nomenclature of the neoplasia arising from the paraganglion system is equivocal 
and has changed over  me. The terms ‘chemodectomas’, ‘chromaffi  n tumors’, ‘glomus 
tumors’, ‘paragangliomas’ and ‘pheochromocytomas’ have all been used interchangeably. 
The current classifi ca  on according to the World Health Organiza  on (WHO) designates 
tumors origina  ng from the paraganglia in the head and neck region as ‘paragangliomas’, 
accompanied by the site of origin, i.e. ‘caro  d body paraganglioma’. The term ‘pheo-
chromocytoma’ is reserved for tumors arising in the adrenal medulla, and ‘extra-adrenal 
paraganglioma’ for tumors developing in sympathe  c paraganglia elsewhere in the 
retroperitoneal space, the abdomen, or the thorax[6]. 
However, some authors argue that the WHO classifi ca  on is too refi ned, and as the 
dis  nc  ons between the subgroups are largely based on arbitrary conven  ons, consensus 
on the terminology of paraganglion tumors has thus far remained elusive. As a result, the 
term ‘pheochromocytoma’ is also used to describe all paraganglion tumors located outside 
of the head and neck region, or all paraganglion tumors located within the abdomen, or 
it is reserved for paraganglion tumors that secrete catecholamines and cause associated 
symptoms (see paragraph 2.3: ‘func  onal paragangliomas’)[6-8]. The use of the term 
‘glomus tumor’ when referring to a head and neck paraganglioma, a remnant of the 19th 
century terminology for head and neck paraganglia, is quite persistent among physicians, 
but is be  er avoided because this term describes a completely diff erent histological 
en  ty (namely a painful cutaneous tumor arising from neuromyoarterial glomus cells, 
characteris  cally located under the fi nger nails)[6,9,10].
Paragangliomas are usually slow growing and highly vascular tumors. The typical 
architecture of normal paraganglion  ssue, the ‘Zellballen’ confi gura  on consis  ng 
of type 1 and type 2 cells (fi gure 3), is usually maintained in the tumor, although in 
pheochromocytomas it may be less prominent[4,6,11]. It has been demonstrated that the 
tumorigenic component is formed by the type 1 or chief cells, and that the type 2 stromal 
cells show expansion under the infl uence of the type 1 cells[12]. 
2.1 Paragangliomas of the head and neck
Paragangliomas of the head and neck are rare tumors, represen  ng approximately 0.6% of 
all head and neck neoplasms[13]. The incidence is es  mated to be between 1:1.000.000 
and 1:100.000, based on pooled data from Dutch pathology laboratories and surgical 
pa  ents[4,14,15]. Due to the benign natural course of the disease, paragangliomas will 
not be surgically removed in a substan  al propor  on of the pa  ents and it is therefore 
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likely that these fi gures represent an underes  ma  on of the actual incidence[15,16]. 
Necroscopy rates for caro  d body paragangliomas of 1:13.4000 to 1:3.860 also point 
towards a higher incidence[15,16]. The incidence of paragangliomas seems to be 
infl uenced by environmental factors that facilitate paraganglioma forma  on, such as high 
al  tude, and by gene  c factors, such as the regional clustering of paraganglioma pa  ents 
due to a common hereditary trait, as can be seen in the Netherlands (see: ‘gene  cs of 
paraganglioma’, ‘tumor biology of paragangliomas’, and chapters 2, 3 and 4). 
The majority of head and neck paragangliomas comprises of caro  d body tumors, arising 
in the caro  d bifurca  on (approximately 61%). Approximately 19% is located along the 
vagal nerve, 12% are found in close rela  on to the jugular bulb or tympanic nerve, and 8% 
is located elsewhere in the head and neck region, most frequently along the larynx, the 
trachea or the aor  c arch[4]. 
Symptoms of head and neck paragangliomas vary with the tumor localiza  on. Most 
tumors are characterized by slow and expansive growth, but approximately 10-15% of the 
head and neck paragangliomas show a more aggressive, rapidly progressive behavior[17]. 
The most common symptom is a non-painful palpable neck mass or pharyngeal bulging. 
In addi  on, cranial nerve invasion or compression and subsequent dysfunc  on may occur, 
especially of the facial, glossopharyngeal, vagal, spinal accessory and hypoglossal nerves, 
because of their close anatomical rela  ons with the jugulotympanic, vagal and caro  d 
paraganglia. In case of tympanic or jugulotympanic tumors there may be conduc  ve 
hearing loss and  nnitus, which is pulsa  le in typical cases. Pa  ents with func  onal 
paragangliomas can present with symptoms and signs of catecholamine excess (see 
paragraph 2.3: ‘func  onal paragangliomas’)[18]. A number of paragangliomas do not 
produce any clinical symptoms, and 6-16% are found as incidentalomas on imaging studies 
or through screening of paraganglioma families[18,19].
Diagnosis
The diagnosis of head and neck paragangliomas is based on the pa  ent and family history, 
clinical inves  ga  on of the ears, the pharynx and the neck, biochemical screening for 
catecholamine excess (see paragraph 2.3: ‘func  onal paragangliomas’), and radiology. 
Detailed radiological examina  ons are essen  al for the diagnosis. The classic way of 
visualizing head and neck paragangliomas is digital subtrac  on angiography (DSA), which 
shows paragangliomas as highly vascular lesions. It is considered the gold standard in the 
diagnosis of small head and neck paragangliomas and for the iden  fi ca  on of the vascular 
anatomy and main contribu  ng blood vessels[20,21]. It is especially useful when surgery 
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is considered, because in addi  on to its role in the evalua  on of the vascular structures, 
the angiography procedure may also be used to eliminate the main blood supply to the 
tumor or to perform a preopera  ve balloon occlusion test of the internal caro  d artery 
(see paragraph 2.1: ‘therapy’)[20-22]. The disadvantages of the DSA technique are the 
need for catheteriza  on (usually through the femoral artery) and the lack of visualiza  on 
of the exact extension of the tumor and its rela  ons to surrounding structures. 
Nowadays DSA has largely been replaced by high resolu  on computed tomography 
(HRCT or CT) and magne  c resonance imaging (MRI). While both techniques are useful 
in assessing tumor extension, evalua  ng its anatomical rela  ons, and detec  ng mul  ple 
paragangliomas within the head and neck region if present, MRI is the preferred modality 
because of its be  er visualiza  on of so    ssues[20]. In addi  on, the CT imaging exposes 
the pa  ent to radia  on (albeit in a very low dose) and the contrast used might provoke 
catecholamine release in pa  ents that are not pre-treated with alpha- or beta-blockers, 
although this complica  on was not found in recent studies[23-25]. The most accurate MRI 
technique in the detec  on of head and neck paragangliomas is a pre-and post-contrast 
enhanced 3D Time of Flight (TOF) MR angiography[20,26]. In both CT and MR imaging, it 
is essen  al to assess tumor extension in the axial as well as in coronal planes.
Func  onal imaging techniques like 131I-metaiodobenzylguanidine (MIBG) scin  graphy, 
18F-fl uorodopamine or 18F-fl uorodihydroxyphenylalanine positron emission tomography 
(FDA-PET and FDOPA-PET, respec  vely) have a high specifi city for paragangliomas because 
they detect abnormal isotope uptake by noradrenalin transporters in paraganglioma 
 ssue[27,28]. They are useful when in doubt of the diagnosis and in whole-body screening 
for func  onal paragangliomas and pheochromocytomas, but a reduced sensi  vity of MIBG 
and FDA-PET has been described in extra-adrenal and malignant paragangliomas[27-30]. 
18F-fl uorodeoxyglucose (FDG)-PET is effi  cient in whole-body screening for metabolically 
ac  ve  ssue. As such, it is not very specifi c for paragangliomas or pheochromocytomas, 
but it is useful in screening for mul  ple tumors and has been shown to be a superior tool 
in the detec  on of paraganglioma metastases[27,28,30]. The lack of anatomical detail in 
the images, a disadvantage of PET imaging, can nowadays be overcome by combining PET 
and CT techniques, crea  ng a single superposed image[20].
Defi ni  ve confi rma  on of the diagnosis is obtained by histopathology and the iden  fi ca  on 
of the pathognomonic ‘Zellballen’ confi gura  on within the tumor  ssue. However, because 
of the high vascularity of these tumors and the risk of profuse bleeding upon biopsy, 
 ssue samples for histopathology are rarely available prior to the surgical resec  on of 
the tumor. Nevertheless, if the origin of the lesion is uncertain and the diagnosis can not 
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be reliably made upon physical examina  on and imaging alone, one may consider fi ne 
needle aspira  on biopsy (FNAB). Although the cytologic features of a paraganglioma are 
not very specifi c and cytology alone is therefore not suffi  cient for a reliable diagnosis of 
paraganglioma, the FNAB technique has been found to be safe and is some  mes required 
in order to rule out other types of malignancy[31,32]. 
Classifi ca  on
Diff erent classifi ca  on systems exist for diff erent primary paraganglioma sites in the head 
and neck region. For caro  d body tumors, the classifi ca  on according to Shamblin et al. is 
widely used[33]. Shamblin type I tumors are localized within the caro  d bifurca  on but do 
not involve the internal or external caro  d artery; Shamblin type II tumors are adherent 
or par  ally surround one or both of these vessels; Shamblin type III tumors encase the 
internal and external caro  d arteries, and extend to the hypoglossal nerve (fi gure 4). The 
Shamblin type can be evaluated preopera  vely using CT or MRI imaging. The Shamblin 
type is posi  vely correlated with the size of the tumor as caro  d body tumors become 
more adherent to caro  d vessels as they increase in diameter, and there is a correla  on 
between the Shamblin classifi ca  on and outcome a  er surgery, as cranial nerve injury 
(par  cularly to the vagal, the superior laryngeal, hypoglossal or facial nerve) is more likely 
to occur in larger tumors[33-35].
Figure 4. The classifi ca  on of caro  d body tumors according to Shamblin. The top row shows the 
axial views; the bo  om row shows the sagi  al views of Shamblin type 1, 2 and 3 paragangliomas 
(PGL). The classifi ca  on is based on the rela  ons of the tumor with the internal caro  d artery (ICA), 
the external caro  d artery (ECA), the vagal nerve (X), the hypoglossal nerve (XII) and the superior 
laryngeal nerve (SLN). Adapted from Arya et al. Am J Neuroradiol 29 (2008) 1349-1354.
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Paragangliomas involving the temporal bone (tympanic and jugulotympanic tumors) are 
generally classifi ed according to Fisch (table 1 and fi gure 5)[36,37]. This classifi ca  on is 
primarily based on the extension of the tumor in the temporal bone and the involvement 
of the internal caro  d artery, the jugular bulb, and the intracranial space. Jugulotympanic 
paragangliomas can be classifi ed preopera  vely using CT for Fisch type A and B 
paragangliomas, and a combina  on of CT and MRI for type C and D tumors. The Fisch 
type dictates the surgical approach necessary for tumor removal[37,38].
As of yet, no universally accepted system exists for the classifi ca  on of vagal body tumors. 
The key features in the tumor descrip  on of vagal body tumors include the tumor size and 
its rela  ons to the skull base and the internal and external caro  d arteries[39].
Figure 5. Schema  c representa  on of the classifi ca  on of temporal bone paragangliomas according 
to Fisch[36]. Type A, B, and C paragangliomas and their rela  ons to the sigmoid sinus, the facial 
(VII), glossopharyngeal (XI), hypoglossal (XII), vagal (X) and spinal assessory (XI) nerves, the internal 
caro  d artery (ICA) and the labyrinth (Lab) are shown in a sagi  al view, type D is depicted in an 
axial view. Type A tympanic paragangliomas originate on the cochlear promontory and are limited 
to the mesotympanic space in the middle ear. Type B tympanic paragangliomas are limited to the 
middle ear and mastoid. Type C jugulotympanic paragangliomas show erosion of the bone covering 




Table 1. The classifi ca  on of temporal bone paragangliomas according to Fisch[36]. Combina  ons of 
C and D types are used to classify extended jugulotympanic paragangliomas.
Type Name Extension
A Tympanic paraganglioma Limited to mesotympanum. No bone erosion.
B Limited to hypotympanum, mesotympanum and mastoid. No 
erosion of jugular bulb.
C Jugulotympanic paraganglioma Erosion of jugular bulb. Subclassifi ca  on by degree of caro  d canal 
erosion:
C1 no invasion of caro  d canal
C2 invasion of ver  cal trajectory of caro  d canal 
C3 invasion of horizontal trajectory of caro  d canal
C4 invasion of formane lacerum and cavernous sinus
D Intracranial extension, either extradural (De) or intradural (Di).
De1 intracranial extradural extension < 2cm
De2 intracranial extradural extension > 2cm
Di1 intracranial intradural extension < 2cm
Di2
 
intracranial intradural extension > 2cm
Therapy
Today, there are 4 main strategies in the management of head and neck paragangliomas: 
surgical excision, emboliza  on, radiotherapy, and watchful wai  ng.
The obvious benefi t of surgical resec  on of paragangliomas is the removal of the tumor 
mass and the possibility of histological evalua  on of the resec  on specimen, allowing for 
defi ni  ve confi rma  on of the diagnosis. Furthermore, future morbidity or progression 
to malignancy may be prevented. The surgical approach depends on the loca  on of the 
paraganglioma within the head and neck region, the extension of the tumor, and its 
rela  ons to adjacent structures. Surgery varies from rela  vely uncomplicated resec  ons 
of Shamblin type 1 caro  d body tumors and rela  vely straigh  orward middle ear and 
mastoid approaches in Fisch A and B type tympanic tumors, to extended head and neck 
surgery and infratemporal fossa approaches in Shamblin type 3 caro  d body tumors 
and Fisch C and D type jugulotympanic tumors[34,35,37,38]. Due to the high vascularity 
of paragangliomas and their close anatomical rela  onships with the caro  d artery, the 
jugular vein, mul  ple cranial nerves, and/or the skull base, there is a defi nite risk of 
surgical complica  ons. Complete removal of the tumor is not always possible or may 
result in signifi cant morbidity or even mortality, especially in larger tumors and tumors 
invading the skull base[15,21,37,40,41]. The cranial nerves that are most at risk when 
a surgical resec  on is performed are the glossopharyngeal, vagal, spinal assessory and 
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hypoglossal nerves in vagal and caro  d body tumors; and the facial, ves  bulocochlear, 
glossopharyngeal, vagal, spinal assessory and hypoglossal nerves in jugulotympanic 
tumors[35,37,39,41]. In vagal body tumors, the vagal nerve is almost always transected 
as vagal body tumors arise from its nodose ganglion[39,41]. The risk of peropera  ve 
cranial nerve injury is not always readily assessable preopera  vely, as even in pa  ents 
without preopera  ve cranial nerve defi cit, infi ltra  on or encasement of cranial nerves 
by paraganglioma  ssue is present in 50% of the cases[42]. Cranial nerve defi cit is 
especially incapacita  ng when cranial nerves are bilaterally aff ected, as this precludes the 
compensa  on of func  on from the contralateral side. 
A possible addi  onal complica  on of bilateral resec  ons of caro  d body paragangliomas 
specifi cally is the loss of the regula  on of the hypoxic ven  latory response, resul  ng in 
immediate hypoven  la  on and respiratory acidosis (see paragraph 4.2.3: ’the hypoxia 
pathway’)[43].
In larger vagal, caro  d body and temporal bone paragangliomas, intraopera  ve control 
of the caro  d arteries and jugular vein is compulsory, and gra  ing or sacrifi ce of these 
structures is some  mes necessary[41]. Whereas unilateral sacrifi ce of the jugular vein is 
generally well tolerated, bilateral resec  on or liga  on may lead to elevated intracranial 
pressure and neurological sequelae[44,45]. If the need for liga  on or par  al resec  on of 
the internal caro  d artery is an  cipated, a preopera  ve intraluminal balloon occlusion 
test is recommended to evaluate the eff ects on the brain[20]. 
In order to minimize surgical diffi  culty and risk of uncontrollable bleeding, emboliza  on 
of the main contribu  ng blood vessels prior to the excision of the paraganglioma can be 
very helpful, especially in vagal and jugulotympanic tumors. In tympanic and caro  d body 
tumors, the benefi ts of this procedure are not so clear[20,21,37,46-48]. Emboliza  on is also 
performed as a primary pallia  ve therapy for symptoma  c or malignant paragangliomas as 
it may reduce tumor size, however the eff ects are almost always temporary, as alterna  ve 
blood supply will develop and the tumor retains its poten  al to grow[49,50]. 
The third treatment op  on, radiotherapy, can be used as a primary treatment or as an 
adjuvant therapy a  er incomplete surgical resec  on of a paraganglioma[21,51]. As a single 
modality therapy, it has a much reduced risk of intraopera  ve bleeding and cranial nerve 
injury[21,52,53]. Because eradica  on of head and neck paragangliomas is not achieved 
by radiotherapy, the objec  ve is local control of tumor growth, and one of the obvious 
drawbacks is therefore the persistence of the tumor mass[20]. Other disadvantages include 
the possible long-term eff ects of irradia  on such as osteoradionecrosis of the skull base, 
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poten  al induc  on of malignancy, and an increased surgical diffi  culty and risk if resec  on 
proves to be necessary at a later stage[54,55]. Furthermore, there is evidence from 
histopathology that the tumor response to radiotherapy is unpredictable[56]. With the 
advent of stereotac  c radiotherapy and ‘gamma-knife’ strategies, irradia  on of adjacent 
normal  ssue has been reduced while reported local tumor control rates (90-92%) are 
comparable to conven  onal radiotherapy[51,52,57]. However, as the natural course of 
most paragangliomas is characterized by no or very slow growth, it is diffi  cult to ascertain 
whether a non-growing paraganglioma a  er radiotherapy is the result of tumor control 
by successful radiotherapy or due to the indolent natural course of the disease[20,39,58].
The fourth op  on in the management of head and neck paragangliomas consists of a policy 
of watchful wai  ng, also called ‘wait and scan’. No interven  on is performed, and tumor 
growth is monitored regularly with repeated MRI. Surgery or radiotherapy is undertaken 
only if there is evidence of tumor growth or impending complica  ons. The disadvantage 
of this strategy is the persistence of the tumor and its poten  al to grow, however, most 
head and neck paragangliomas are characterized by slow growth, a substan  al number of 
head and neck paragangliomas will not become symptoma  c, and the eff ects of cranial 
nerve palsy are o  en be  er mediated if the paresis is slowly progressive due to tumor 
growth as opposed to sudden paralysis due to surgical injury[19,20,39,58].
Not surprisingly, the op  mal treatment strategy for head and neck paragangliomas is 
subject of much debate in the literature[21,22,53,58,59]. The choice of treatment modality 
and  ming require a mul  disciplinary approach, and are tailored to the individual pa  ent, 
depending on symptoms, tumor loca  on, tumor stage, mutlifocality, catecholamine 
excess (see below), heredity and the causa  ve gene muta  on[15]. Surgical resec  on of 
paragangliomas is considered either when the tumor is small and total removal is not 
likely to cause signifi cant cranial nerve injury and associated morbidity, or when cranial 
nerve defi cit has already been caused by the tumor and complete resec  on is unlikely 
to cause addi  onal problems. A ra  onale for surgical interven  on is the an  cipa  on of 
complica  ons due to progression of tumor extension towards cranial nerves, the skull 
base, or the caro  ds[15,20,21]. Furthermore, surgical resec  on is the therapy of choice 
in func  onal paragangliomas (see below). Radiotherapy, stereotac  c radiotherapy or 
‘gamma knife’, although considered by some as the primary treatment of choice in all 
paragangliomas, are primarily used as a pallia  ve treatment in malignant paraganglioma, 
or in progressive paragangliomas in which surgery is deemed to confer a high risk of 
signifi cant morbidity[15,20,21,52]. A conserva  ve treatment strategy consis  ng of closely 
monitoring the natural course of the disease without interven  on (´wait and scan’), 
seems, at least ini  ally, appropriate for many asymptoma  c pa  ents, elderly pa  ents, 
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pa  ents with mul  ple and bilateral paragangliomas, tumors with extensive temporal 
bone involvement and tumors caused by a gene muta  on that is characterized by a mild 
disease phenotype[15,20,21,39].
2.2 Pheochromocytomas and extra-adrenal paragangliomas
Pheochromocytomas and extra-adrenal paragangliomas, together described as sympathe  c 
paragangliomas, are tumors closely related to head and neck paragangliomas. Sympathe  c 
paragangliomas are rare tumors, with an es  mated incidence between 1:500.000 and 
1:50.000[60,61]. About 80% of the sympathe  c paragangliomas originate from the adrenal 
medulla and are called pheochromocytomas. The remaining 20%, called extra-adrenal 
paragangliomas, occur elsewhere in the sympathe  c paraganglia, most frequently in the 
abdomen and pelvis, less frequently in the thorax[29]. Extra-adrenal paragangliomas 
more o  en progress to metasta  c disease than either pheochromocytomas or head and 
neck paragangliomas [62]. 
The symptoms of pheochromocytomas are usually caused by the secre  on of 
catecholamines or their metabolites by the tumor, and include hypertension (in about 
60%) which may be fl uctua  ng or sustained, paroxysmal palpita  ons, headache, agita  on, 
excess swea  ng and pallor. 
The diagnosis of pheochromocytomas and extra-adrenal paragangliomas is based 
on biochemical screening for catecholamine excess (see paragraph 2.3: ‘func  onal 
paragangliomas’) and radiology. Both abdominal CT and MRI are sensi  ve modali  es 
for the detec  on of abdominal masses. As described above, some authors prefer MRI 
because no iodine containing contrast is needed to adequately visualize the tumor. 
The mainstay of pheochromocytoma therapy is surgical resec  on. The preferred technique 
is a par  al or cor  cal sparing adrenalectomy via a laparoscopic or retroperitoneoscopic 
approach, as this minimizes surgical risk and morbidity[63-66]. Bilateral endoscopic cor  cal 
sparing adrenalectomies should be considered in bilateral pheochromocytomas or in case 
of a gene  c predisposi  on for developing bilateral disease, although there is debate as 
to whether par  al adrenalectomy is associated with an increased long-term recurrence 
rate in hereditary cases[63,66-68]. Total adrenalectomy is indicated in malignant pheo-
chromocytomas and some  mes unavoidable in benign pheochromocytomas, especially 
in large tumors or recurrent disease[66,68]. If performed bilaterally, total adrenalectomy 
carries the risk of poten  ally life-threatening post-opera  ve Addisonian crises and 
necessitates lifelong cor  coid supplementa  on therapy[66,69]. Adrenalectomy via an 
open laparotomy is nowadays rarely indicated, even in large tumors (i.e. tumors with a 
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diameter exceeding 6 cm)[70]. There is debate as to whether open procedures should 
be performed in malignant pheochromocytomas and extra-adrenal paragangliomas. 
Most authors agree that it is indicated in case of large malignant tumors, local invasion, 
or if resec  ons of neighboring organs are required[66,71-73]. Because of the risk of 
catecholamine excess during, and catecholamine deple  on a  er an adrenalectomy 
procedure, peri-opera  ve treatment with α- and β- adrenoreceptor antagonists, calcium 
channel blockers and/or catecholamine synthesis-inhibitors is mandatory (see paragraph 
2.3: ’func  onal paragangliomas’).
2.3 Func  onal paragangliomas
A propor  on of the neoplasia of the paraganglion system is ‘func  onal’, i.e. they 
secrete vasoac  ve catecholamines like dopamine, adrenalin and noradrenalin and/or 
their metabolites. Excess catecholamine secre  on is a well-known feature of adrenal 
pheochromocytomas and extra-adrenal paragangliomas, but rela  vely rare in head and 
neck paragangliomas (1-5%)[18]. The majority of func  onal paragangliomas produce 
noradrenalin, a few secrete dopamine or adrenalin[74,75]. Catecholamine secre  ng 
tumors are best detected through the evalua  on of the urine or plasma concentra  ons 
of metanephrine and normetanephrine, metabolites of catecholamines. Plasma free 
metanephrine measurements are the most accurate diagnos  c tool, with a superior 
sensi  vity (97-99%) and specifi city (86-97%)[15,74,76,77]. The next best technique, 
24-hours urinary metanephrine and normetanephrine measurements, has a comparable 
high sensi  vity (96-97%) but lower specifi city (45-82%)[15,74]. The la  er is s  ll widely 
used in the Netherlands due to be  er availability[15]. 
Biochemical screening should be performed if a pa  ent’s signs or symptoms indicate a 
func  onal paraganglioma, in case of a gene  c risk for the development of paraganglioma-
pheochromocytoma syndrome, and in all pheochromocytomas and extra-adrenal para-
gangliomas (see: ‘gene  cs of paragangliomas’)[15,27,29]. If catecholamine secre  on is 
present in head and neck paragangliomas, it causes the same symptoms as it does in 
pheochromocytomas (hypertension, palpita  ons, headache, agita  on, excess swea  ng and 
pallor). Prolonged exposure to high levels of catecholamines can result in hyperglycemia, 
electrolyte disturbances and cardiovascular complica  ons such as cardiac hypertrophy, 
myocardial infarc  on or heart failure. Mul  ple organ failure, shock and sudden death 
by stroke or cardiac arrest due to catecholamine excess have been reported[29,78,79]. 
Because of these poten  ally life-threatening condi  ons, surgical excision is the treatment 
of choice in func  onal paragangliomas[15,27]. Peri-opera  ve measures consis  ng of pre-
opera  ve volume expansion by intravenous saline, stringent intra-opera  ve monitoring, 
and treatment with α- and β- ardrenoreceptor antagonists, calcium channel blockers and/
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or catecholamine synthesis-inhibitors are compulsory to counter cri  cal hypertensive 
crises and compensatory hypotensive episodes due to manipula  on and removal of the 
tumor[29,65]. 
2.4 Malignancy
Most paragangliomas are benign tumors, i.e. they do not metastasize and are characterized 
by an expansive rather than an invasive growth pa  ern. However, some paragangliomas, 
especially those within the petrous bone, show erosion of the surrounding bone, some 
show microvascular invasion, and some do metastasize. As of yet, no defi nite histologic 
criteria for malignancy have been established in paragangliomas[6]. Even in malignant 
paragangliomas and their metastases, the well diff eren  ated architecture of normal 
paraganglion  ssue is usually maintained[4,11]. Factors such as a higher mito  c rate, tumor 
cell spindling, altered nuclear morphology, aberrant DNA-ploidy, necrosis, and capsular or 
microvascular invasion are reported to be more prevalent in malignant paragangliomas, 
but all are also found in benign paragangliomas[4,6,11]. Immunohistochemical markers 
such as Ki-67, Cyclin-D1, p53, p21, p27, BCL-2 and MDM-2 have been shown to be of 
li  le use in predic  ng malignant behavior in paragangliomas[6,11]. Malignancy in 
paragangliomas is therefore defi ned as the occurrence of metasta  c paraganglioma cells 
in non-neuroendocrine  ssue. 
Paraganglioma metastases are most frequently confi ned to cervical lymph nodes (69%). 
Distant metastases are iden  fi ed in 31% of malignant head and neck paragangliomas, and 
the distant predilec  on sites include bone, lung and liver[80]. 
Several studies have assessed clinical factors that may predict malignancy in paraganglioma 
pa  ents. Features such as a young age at diagnosis, pain as an accompanying symptom, 
a rapidly enlarging tumor mass, a large tumor size, and a medias  nal or extra-adrenal 
abdominal tumor localiza  on all seem to be associated with an increased risk of 
malignancy, but none of these features are proof of malignancy in themselves[11,81,82]. 
Tumors that secrete catecholamines may be malignant or benign in nature. There is some 
debate as to whether dopamine secre  on is indica  ve of extra-adrenal tumor localiza  on 
and malignancy, but recent studies show that dopamine secre  on is not uncommon in 
benign head and neck paragangliomas (19-23%), and that it is not related to metasta  c 
disease or outcome[75,83-85]. The risk of developing malignant paraganglioma or 




The management of malignant paragangliomas is challenging. More aggressive treatment 
strategies are aimed at eradica  on and/or control of tumor growth both at the primary 
and metasta  c site. In case of head and neck paragangliomas with metastases limited to 
regional lymphe nodes, surgical resec  on of the primary tumor combined with a neck 
dissec  on is the treatment of choice if feasible. In this pa  ent group, no clear benefi cial 
eff ect of adjuvant radiotherapy has been found if resec  on margins are nega  ve[80]. In 
case of incomplete resec  ons, adjuvant therapy may consist of emboliza  on, radiotherapy, 
systemic chemotherapy (with cyclophosphamide, vincris  ne and dacarbazine) or 
combina  ons thereof[80,86-88]. In case of incurable metasta  c disease, pallia  ve 
treatment strategies include surgical tumor debulking, emboliza  on, pharmacological 
blocking of catecholamine secre  on, pallia  ve conven  onal radiotherapy, metabolic 
targeted radiotherapy with 131I-MIBG, and/or systemic chemotherapy[80,86-88]. 
A recent development is the advent of possible targeted molecular therapies. 
Currently, several are being inves  gated in pa  ents with malignant paraganglioma and 
pheochromocytoma[71,72,89-93]. Promising results have been reported of temozolomide 
and thalidomide combina  on therapy, of suni  nib (a tyrosine kinase inhibitor), and of 
somatosta  n analogues, but their eff ec  veness has not yet been validated by clinical 
trials[71;72;90-93]. As surgical resec  ons confer a risk of surgical complica  ons as 
men  oned above, and the non-surgical interven  ons can be complicated by bone marrow 
depression and a fatal sudden increase in catecholamine levels due to tumor necrosis, 
treatment of incurable metasta  c disease should only be considered if the quality of life is 
threatened by symptoms caused by local tumor extension or catecholamine excess[86-88]. 
A policy of watchful wai  ng may be considered a viable op  on in pa  ents with stable 
metasta  c disease and mild symptoms[86-88]. 
Due to the rarity of malignant paragangliomas and the number of diff erent strategies and 
regimens that have been applied over  me, data on the outcome of these interven  ons 
are largely retrospec  ve, not fully comparable, and o  en biased, and the lack of controlled 
prospec  ve trials hampers the recommenda  on of specifi c therapies[80,86,87].
Without taking treatment strategies into account, pa  ents with malignant head and 
neck paragangliomas have a reported overall fi ve year survival rate of 55-60%[80,86,94]. 
Survival is greatly infl uenced by the site of the metastasis, as the fi ve year survival rate 
of pa  ents with metasta  c disease limited to regional lymph nodes (77%) is signifi cantly 
be  er than of those with distant metastasis (12%)[80]. Furthermore, survival seems to 
be infl uenced by the causa  ve gene, as the fi ve year survival rate a  er fi rst metastasis is 
37% in pa  ents carrying a muta  on in the SDHB gene, whereas it is 67% in the absence of 
SDHB muta  ons (see: ‘gene  cs of paragangliomas’)[94].
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3. Gene  cs of paragangliomas
3.1 NF1, RET, and VHL
The knowledge of paraganglioma gene  cs has long been limited to muta  ons in genes 
causing neurofi bromatosis type 1 (the NF1 gene), mul  ple endocrine neoplasia (MEN) 
type 2a and 2b (the RET gene), and Von Hippel-Lindau syndrome (the VHL gene)[6]. 
Whereas pheochromocytomas are a well-known element of the tumor spectrum of 
these syndromes, head and neck paragangliomas caused by NF1, RET or VHL muta  ons 
are rare and almost never occur as the sole manifesta  on of the disease. NF1, RET or 
VHL muta  ons and their associated syndromes are discussed briefl y with a focus on their 
relevance in head and neck paragangliomas and pheochromocytomas.
NF1
Neurofi bromatosis type 1 (NF1) is caused by muta  ons in the NF1 gene located on 17q11. 
It encodes the neurofi bromin 1 protein, a nega  ve regulator of the Ras intracellular 
signaling pathway which is involved in cell growth, diff eren  a  on and survival (table 
2). NF1 is the most common tumor syndrome of the peripheral nervous system, with a 
prevalence of 1 in 3000[95]. The syndrome consists of cutaneous and peripheral nerve 
neurofi bromas, and is also associated with gastrointes  nal tumors, gliomas and myeloid 
leukemia. The es  mated prevalence of pheochromocytomas in NF1 pa  ents is 0.1- 6%, 
although necroscopy rates are higher (3-13%)[95]. As a rule, pheochromocytomas do 
not occur without other manifesta  ons of neurofi bromatosis, most o  en neurofi bromas 
and café-au-lait spots on the skin[95;96]. The mean age at diagnosis of the fi rst pheo-
chromocytoma is approximately 41 years, bilateral adrenal involvement occurs in 27%, 
extra-adrenal localiza  ons are infrequent (5%), and the malignancy rate is 6%[96]. Head 
and neck paragangliomas associated with NF1 have been reported but are extremely 
rare[97,98]. In a recent interna  onal study including 809 head and neck paraganglioma 
pa  ents that were not linked to muta  ons in succinate dehydrogenase (see paragraph 
3.2: ‘the succinate dehydrogenase genes’), no NF1 muta  ons were iden  fi ed[97,98].
RET
Muta  ons in the RET proto-oncogene (located on 10q11) cause MEN type 2 syndromes. RET 
encodes a receptor tyrosine kinase and func  ons as the receptor for extracellular signaling 
molecules of the glial cell line-derived neurotrophic factor (GDNF) family (table 2)[99]. 
MEN type 2 syndromes can be divided into MEN type 2a, characterized by the occurrence 
of medullary thyroid carcinoma, pheochromocytoma, and primary hyperparathyroidism, 
and MEN type 2b, characterized by medullary thyroid carcinoma, pheochromocytoma, 
mucosal neuroma and a marfanoid habitus[99]. In MEN type 2 syndromes, the risk of 
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developing a pheochromocytoma is high (50%), and if a pheochromocytoma is found, 
mul  focal or bilateral tumors are common (50-80%), but extra-adrenal paragangliomas 
are rare (3%), as is pheochromocytoma malignancy (3%)[99,100]. RET muta  on carriers 
seldom develop head and neck paragangliomas (in approximately 0.1%)[98].
VHL
Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by muta  ons in 
the VHL gene located on 3p25-26 (table 2). VHL encodes a subunit of the VHL ubiqui  n 
ligase complex, a key component in the degrada  on of hypoxia inducible factor (HIF) 
1α, 2α and 3α subunits (see paragraph 4.2.3: ‘the hypoxia pathway’, and fi gure 8)[101]. 
Specifi c homozygous recessive muta  ons in the VHL gene do not cause tumors, but a 
rare form of hereditary polycythemia called Chuvash syndrome[101]. Pa  ents with the 
VHL tumor syndrome carry heterozygous muta  ons and the disease is inherited in an 
autosomal dominant way[101]. In these heterozygous VHL muta  on carriers, VHL acts 
as a tumor suppressor gene, i.e. loss of the wild type allele is required for tumorigenesis. 
Muta  ons predispose to a variety of tumor types, including hemangioblastoma of the 
re  na and central nervous system, clear cell renal carcinoma, neuroendocrine pancrea  c 
tumors and endolympha  c sac tumors[95,101,102]. Pheochromocytomas are found in 
20% of VHL pa  ents, and the mean age at diagnosis of the pheochromocytoma is 28 
years[95,102]. In the pediatric pheochromocytoma popula  on, VHL muta  ons are the 
predominant cause of the disease (accoun  ng for 40% of the cases)[95,102]. Most VHL-
linked pheochromocytomas are benign and bilateral[95]. Head and neck paragangliomas 
are found in less than 1% of VHL cases, and VHL muta  ons account for approximately 
2% of the head and neck paraganglioma popula  on[98,103]. Almost all VHL-linked head 
and neck paraganglioma pa  ents have addi  onal manifesta  ons and/or a posi  ve family 
history of VHL disease[98]. 
3.2 The succinate dehydrogenase genes
In 2000, Baysal et al. in collabora  on with the Paraganglioma research Group Leiden, 
discovered that muta  ons in succinate dehydrogenase subunit D (SDHD), a subunit of the 
mitochondrial succinate dehydrogenase complex (SDH), cause hereditary head and neck 
paraganglioma syndrome type 1 (PGL1)[104]. This breakthrough discovery ini  ated the 
iden  fi ca  on of other SDH genes as the causes of the PGL2, PGL3 and PGL4 paraganglioma 
syndromes. Parts of this overview have been adapted from chapter 2, which reviews the 




The SDHD gene is located on the long arm of chromosome 11 (11q23). The mapping of 
its locus on 11q23 and its subsequent iden  fi ca  on as the cause of PGL1 syndrome was 
greatly facilitated by the concentra  on of large PGL1 kindreds in the proximity of the city of 
Leiden, located in the western part of the Netherlands[104-107]. The discovery of SDHD, a 
nuclear gene encoding an anchoring subunit of SDH, was the fi rst  me that a mitochondrial 
protein was iden  fi ed as a tumor suppressor (fi gure 7). It was furthermore the fi rst protein 
with a role in the intermediary metabolism to be directly linked to tumorigenesis[104]. 
SDHD-linked paraganglioma syndrome is characterized by the forma  on of benign head 
and neck paragangliomas, and metasta  c disease is rare (0-10%)[62,108-112]. SDHD-
linked pa  ents have a high risk of developing mul  ple paragangliomas (30-74%), and are 
also at risk of developing a concurrent pheochromocytoma (7-53%)[62,108-110,113]. The 
diagnosis is generally made in the third or fourth decade of life (mean age at diagnosis 
25- 38 years)[62,108,109]. The penetrance of SDHD muta  ons is high upon paternal 
transmission (87-100%), although not all paraganglioma pa  ents develop tumor-related 
symptoms[19,62,109,114-116]. Maternal transmission of disease is extremely rare (see 
paragraph 4.3: ‘inheritance of head and neck paraganglioma syndromes’)[117]. In the 
Netherlands, muta  ons in SDHD are the major cause of head and neck paragangliomas, 
probably due to the occurrence of mul  ple Dutch founder muta  ons (see also chapters 3 
and 4)[118,119]. The incidence of SDHD muta  ons and the clinical characteris  cs of SDHD-
linked paraganglioma syndrome in the Netherlands are further discussed in chapters 3, 4 
and 5.
SDHC
In 2000, SDHC, located on chromosome 1 (1q23), encoding another SDH anchoring 
subunit, was found to be the causa  ve tumor suppressor gene in paraganglioma syndrome 
PGL3 (fi gure 7)[120]. Muta  ons in SDHC are primarily associated with benign head and 
neck paragangliomas, although extra-adrenal paragangliomas, pheochromocytomas and 
malignancy have been reported in SDHC-linked cases[110,120-123]. The average age at 
diagnosis is 38-46 years[110,121]. Muta  ons in SDHC are a rare cause of paragangliomas, 
with only 19 index cases and 30 aff ected pa  ents reported to date[124]. In the 
Netherlands, SDHC muta  ons represent less than 0.5% of the muta  ons found in SDH 
genes (chapter 3)[125]. The inheritance of SDHC-linked disease is autosomal dominant, 
and the penetrance of SDHC muta  ons is as yet unknown, but the very low incidence of 




In 2001, SDHB, located on chromosome 1 (1p35-36.1), encoding the cataly  c iron-sulfur 
SDH subunit, was linked to paraganglioma syndrome PGL4 (fi gure 7)[126]. It acts as a 
tumor suppressor gene and it has been shown to be the dominant cause of hereditary 
paraganglioma syndrome in many parts of the world[62,108]. SDHB-linked paraganglioma 
syndrome is characterized by a high rate of extra-adrenal paragangliomas (52-84%), while 
pheochromocytomas (18-28%) and head and neck paragangliomas (27-31%) are less 
frequently found[62,108,109]. The mean age at diagnosis is 30-37 years, and up to 38% 
of SDHB muta  on carriers develop metasta  c disease[62,103,108-110,121]. Most SDHB-
linked tumors present with catecholamine excess; 10% of the tumors is biochemically 
silent or produces dopamine only[62,127]. The inheritance of SDHB-linked disease is 
autosomal dominant, and the penetrance of SDHB muta  ons is es  mated to be 26-35%, 
much lower than that of SDHD muta  ons, which explains why SDHB muta  ons are more 
o  en found in isolated paraganglioma pa  ents[128,129,129-131]. In the Netherlands, 
SDHB muta  ons seem to be remarkably uncommon, and account for only 3% of the head 
and neck paraganglioma pa  ents and 6% of all SDH muta  ons (chapters 3 and 4)[111,125].
SDHAF2
The gene encoding succinate dehydrogenase assembly factor 2 (SDHAF2, formerly known 
as SDH5), is located on the long arm of chromosome 11 (11q13). In 2009, it was linked 
to head and neck paraganglioma syndrome PGL2 (table 2)[132]. SDHAF2 acts as a tumor 
suppressor and does not encode a SDH subunit, but a co-factor related to the func  on of 
the SDHA fl avoprotein subunit. The p.Gly78Arg missense muta  on is the only pathogenic 
muta  on in SDHAF2 known to date[133-135]. SDHAF2-linked paraganglioma syndrome 
is characterized by the forma  on of benign head and neck paragangliomas[133,135]. 
Most pa  ents develop mul  ple head and neck tumors (70-91%), but no extra-adrenal 
paragangliomas, pheochromocytomas, or malignant paragangliomas have been reported 
in associa  on with SDHAF2 muta  ons[111,133,135]. The mean age at diagnosis is 33-
34 years[111,133]. SDHAF2-linked disease is characterized by the same parent-of-
origin dependent inheritance pa  ern as SDHD-linked paraganglioma syndrome, i.e. no 
paragangliomas develop upon maternal transmission of the SDHAF2 muta  on, whereas 
the risk of disease upon paternal transmission of the muta  on is very high (88-100%)
[132,133]. The SDHAF2 muta  on is currently only found in a large Dutch paraganglioma 
kindred and an unrelated Spanish family[134]. In the Netherlands, it accounts for 7% 
of SDH muta  on carriers, and approximately 4% of the head and neck paraganglioma 




SDHA, located on 5p15, is a highly polymorphic gene encoding the fl avoprotein subunit of 
SDH (fi gure 7)[136]. Un  l recently, no associa  on between this major cataly  c subunit of 
SDH and paraganglioma forma  on could be established. Instead, homozygous recessive 
SDHA muta  ons were associated with Leigh syndrome, a rare mitochondrial defi ciency 
resul  ng in encephalopathy, myopathy, developmental retarda  on, loss of vision, loss 
of hearing, and a limited life expectancy[137]. In 2010, a heterozygous SDHA germ line 
muta  on was iden  fi ed in a single pa  ent with a func  onal extra-adrenal paraganglioma 
of the abdomen. Loss of the wild type SDHA allele was found in the tumor  ssue of this 
pa  ent, sugges  ng that SDHA can act as a tumor suppressor in paragangliomas too[138]. 
The prevalence of SDHA muta  ons in the head and neck paraganglioma popula  on 
remains to be clarifi ed. Its late iden  fi ca  on as a tumor suppressor and the isolated 
presenta  on of the reported SDHA-linked pa  ent indicate that SDHA muta  ons are a rare 
cause of paraganglioma suscep  bility[138]. The reasons for this infrequent associa  on 
of SDHA muta  ons with paragangliomas are currently unknown. One explana  on might 
be that muta  ons that eliminate all SDHA ac  vity are incompa  ble with life. It has been 
shown that both the homozygous SDHA muta  ons causing Leigh syndrome as well as 
the heterozygous SDHA muta  on causing paraganglioma result in SDH defi ciency (see 
paragraph 4.1: ‘succinate dehydrogenase’)[137-139]. However, in pa  ents with Leigh 
syndrome, considerable residual cytoplasmic SDHA immunostaining and ac  vity can 
s  ll be detected, indica  ng that SDHA stability is aff ected but SDHA func  onality is not 
completely lost[137]. There is evidence that SDHA has a cellular func  on addi  onal to 
its enzyma  c role in the TCA cycle, as a component of the mitochondrial ATP-sensi  ve 
potassium channel[140,141]. Possibly, muta  ons that interfere with this other func  on 
are not tolerated. 
An alterna  ve explana  on for the scarcity of SDHA-linked paragangliomas is a low 
observed frequency of soma  c 5p15 loss[138,142]. Assuming that SDHA acts as a tumor 
suppressor gene in paragangliomas, loss of heterozygosity (LOH) targe  ng the wild type 
SDHA allele on 5p15 is an essen  al step in SDHA-linked tumorigenesis. The LOH at 5p15 
may be prevented by local epigene  c factors or the LOH may simultaneously aff ect other 
genes in the close proximity of SDHA that are vital to the survival of the cell[138,140].
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3.3 Other genes in paragangliomas and pheochromocytomas
Recently, germ line muta  ons in other genes that are not directly linked to SDH have also 
been iden  fi ed in paraganglioma and pheochromocytoma pa  ents. Although to date they 
do not seem to be very prevalent in the head and neck paraganglioma popula  on, these 
discoveries may contribute to our insight in the tumorigenic pathways that are implicated 
in paraganglioma tumorigenesis (see: ’molecular biology of paragangliomas’), and are 
therefore discussed briefl y.
TMEM127
In 2010, muta  ons in a three-spanner transmembrane protein, transmembrane protein 127 
(TMEM127), have been iden  fi ed as a cause of familial and isolated pheochromocytomas, 
and recently also of extra-adrenal paragangliomas and paragangliomas of the head and 
neck[143,144]. Muta  ons in TMEM127, located on 2q11, cause hereditary paraganglioma-
pheochromocytoma syndrome with autosomal dominant inheritance, and LOH of the wild 
type TMEM127 allele is observed in tumors indica  ng that TMEM127 acts as a tumor 
suppressor gene (table 2)[143]. The func  on of TMEM127 is currently not fully known, 
but ini  al insights suggest that TMEM127 is a nega  ve regulator of the mechanis  c target 
of rapamycin (mTOR) pathway (see paragraph 4.4: ‘other mechanisms in paraganglioma 
tumorigenesis’)[143]. Clinically, TMEM127-linked pa  ents are characterized by the 
occurrence of pheochromocytomas, which are frequently bilateral (in 35-50%), a 
compara  ve late onset of disease (mean age at diagnosis 42.8-45.3 years), and a low 
malignancy rate (0-5%)[143,145]. The penetrance of TMEM127 muta  ons awaits detailed 
inves  ga  on, the fi rst data suggest it is high but incomplete (an age related penetrance of 
64% by the age of 43-55 years)[143-145]. The prevalence of TMEM127 muta  ons in the 
paraganglioma and pheochromocytoma popula  on seems low, recently a total of in 20 
pa  ents carrying 19 diff erent muta  ons could be iden  fi ed in an interna  onal cohort of 
990 paraganglioma-pheochromocytoma pa  ents (2%)[145]. 
PHD2
In 2008, a muta  on in EGLN1, located on 1q42, was reported to be associated with an 
abdominal extra-adrenal paraganglioma in a single isolated pa  ent (table 2)[146]. EGLN1 
encodes HIF-prolyl hydroxylase 2 (PHD2), an enzyme involved in the degrada  on of 
hypoxia inducible factor 1 alpha (HIF-1α). PHD2 muta  ons have also been associated 
with erythrocytosis, a rare neoplas  c disorder causing an elevated red blood cell count, 
and the pa  ent who developed the recurrent func  onal paraganglioma suff ered from 
this condi  on too[146,147]. LOH of the wild type EGLN1 allele was observed in the 
tumor, which indicates that PHD2 may act as a tumor suppressor in paraganglioma 
tumorigenesis[146]. The disrup  on of PHD2 func  on caused by this PHD2 muta  on could 
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result in tumorigenisis through a pathway similar to that of defec  ve SDH (see paragraph 
4.2.3: ‘pseudo-hypoxic drive’ and fi gure 8)[146].
KIF1B
Also in 2008, kinesin family member 1B (KIF1B), located on 1p36, was iden  fi ed 
as the causa  ve tumor suppressor gene in a cancer-prone family suff ering from 
mul  ple tumors, including neuroblastomas, ganglioneuromas, leiomyosarcomas, and 
pheochromocytomas[148]. It was found to act in a pro-apopto  c pathway downstream of 
prolyl-hydroxylase 3 (PHD3), a pathway that is involved in the development of neuronal 
precursor cells. Muta  ons in KIF1B could protect from apoptosis, causing aberrant 
survival of neuronal precursor cells that may later give rise to pheochromocytomas 
(see paragraph 4.3: ’abnormal development of neuronal precursor cells’, and fi gure 9)
[148-150]. Transcrip  on analysis suggests that KIF1B-linked pheochromocytomas are 
more closely related to NF1- and RET-, than to VHL- and SDH-associated tumors[149].
MAX
In 2011, exome sequencing iden  fi ed muta  ons in the MYC associated factor X gene 
(MAX) in hereditary pheochromocytoma pa  ents that had tested nega  ve for muta  ons 
in SDHA, SDHAF2, SDHB, SDHC, SDHD, NF1, RET, and VHL[151]. In all, 12 pa  ents carrying 
8 diff erent MAX muta  ons have been described, with an early mean age at diagnosis of 
32 years, and high rates of bilateral pheochromocytomas (67%) and malignancy (25%), 
although these characteris  cs might in part refl ect the selec  on criteria of the study[151]. 
As of yet, no MAX muta  ons have been reported in head and neck paragangliomas.
MAX, located on 14q23, behaves as a tumor suppressor gene[151]. MAX is a member 
of the basic helix-loop-helix leucine zipper (bHLHZip) family, which also includes 
myelocytomatosis viral oncogene homolog (MYC) and MAX dimeriza  on protein 1 
(MXD1). This family of transcrip  on factors regulates cell prolifera  on, diff eren  a  on and 
apoptosis, and is linked with the mTOR pathway, the pathway to which TMEM127 is linked 
as well[151,152]. Muta  ons in MAX could lead to pheochromocytoma tumorigenesis 
through these prolifera  ve pathways or through interference with apoptosis and neuronal 
development via the same pathway as KIF1B (see 4.3: ’abnormal development of neuronal 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Considerable diff erences in the propor  on of hereditary cases and rela  ve muta  on 
frequencies have been reported in diff erent pa  ent cohorts and diff erent parts of the 
world. In recent studies that have evaluated pa  ents with at least one head and neck 
paraganglioma, approximately 18-33% are reported to present with a posi  ve family 
history, and pathogenic gene muta  ons can be iden  fi ed in 31-55% of the head and neck 
paraganglioma pa  ents, most frequently in SDHD (19-79%) and SDHB (9-34%), and less 
frequently in SDHC (0-14%), VHL (0-2%) or RET (0-0.1%)[17,103,110,155,156]. 
In the Netherlands, the incidence of head and neck paraganglioma and the percentage of 
paraganglioma pa  ents with a posi  ve family history appear to be dispropor  onately high, 
due to the prevalence of Dutch founder muta  ons in SDH genes[118,119]. The rela  ve 
frequency of SDH muta  ons in the Netherlands and the gene  cs of Dutch paraganglioma 
pa  ents are further evaluated in chapters 3 and 4. 
3.4 Inheritance of head and neck paraganglioma syndromes
The inheritance pa  ern of paraganglioma syndrome diff ers considerably depending 
on the causa  ve gene involved (Table 2). While TMEM127-, SDHB- and SDHC-linked 
paraganglioma families show normal autosomal dominant inheritance, SDHD and 
SDHAF2-linked families show a virtually exclusive paternal transmission of tumor 
suscep  bility[115,116,132,133]. Whereas muta  ons in SDHD and SDHAF2 can be 
inherited both via the maternal and paternal lines, tumor forma  on following maternal 
transmission of a muta  on is exceedingly uncommon[115-117]. The absence of maternal 
transmission of disease in SDHD-linked paraganglioma families is sugges  ve of maternal 
imprin  ng of the SDHD gene[115]. However, the actual blocking of transcrip  on by 
methyla  on of the SDHD gene itself has never been demonstrated, and SDHD shows 
bi-allelic expression in non-paraganglioma  ssue[114,157,158]. Recently, it has been 
hypothesized that  ssue specifi c hypermethyla  on of a maternal allele fl anking the SDHD 
gene causes the imprinted inheritance of SDHD-linked disease. This fl anking element 
is presumed to encode an alterna  ve promotor of a non-coding RNA sequence in the 
vicinity of the SDHD promotor on 11q23[158]. The func  on of this non-coding RNA 
sequence however is unknown, and evidence of a regulatory role in SDHD expression 
is lacking. Although diff eren  al methyla  on of its puta  ve alterna  ve promotor was 
found, diff eren  al expression of the non-coding RNA sequence, the predicted result 
of diff eren  al methyla  on of its alterna  ve promotor, could not be established in the 
majority of cases (86%). Moreover, no allelic imbalance was found for SDHD. In contrast, 
the report iden  fi ed bi-allelic expression of SDHD in all non-paraganglioma  ssues 
including the adrenal gland, in accordance with previous reports, and it is therefore highly 
unlikely that the reported diff eren  al hypermethyla  on in the vicinity of SDHD actually 
Chapter 1
34
aff ects SDHD expression[115,158]. Furthermore, diff eren  al hypermethyla  on was not 
found in SDHD-linked paragangliomas, and it consequently does not seem to play a role 
in the inheritance of SDHD-linked disease. An addi  onal argument against hypotheses 
involving maternal imprin  ng of SDHD itself, or a selec  ve reduc  on of the expression of 
the maternal SDHD allele due to other epigene  c factors, is that it does not explain the loss 
of the wild type maternal SDHD allele that is observed in SDHD-linked paragangliomas and 
pheochromocytomas[114,158-160]. If the expression of the wild type allele was already 
signifi cantly reduced by imprin  ng phenomena, its loss would not confer an increased 
predisposi  on to tumorigenesis. Furthermore, these models do not explain the similar 
exclusive paternal transmission of disease observed in SDHAF2-linked cases[132,133].
A decisive factor in the parent-of-origin-dependent inheritance of SDHD- and SDHAF2-
linked disease seems to be the loca  on of SDHD and SDHAF2 on chromosome 11. Both 
SDHD and SDHAF2 are located on the long arm of chromosome 11 (on 11q23 and 11q13 
respec  vely), while TMEM127 (2q11), SDHB (1p35-36) and SDHC (1q23), genes that do 
not show a parent-of-origin eff ect, are not.
Although the SDHD and SDHAF2 genes are not imprinted themselves, chromosome 11 
harbors the main cluster of imprinted genes of the human genome, on its short arm at 
11p15.5. This region consists of a telomeric and a centromeric imprinted domain, both 
containing puta  ve tumor suppressor genes. This suggests a model in which a maternally 
expressed, paternally imprinted gene, located within this imprinted 11p15.5 region, is 
an essen  al ini  ator or modifi er of tumor development in SDHD- and SDHAF2-linked 
paraganglioma syndromes[114]. According to this model, tumor forma  on is not ini  ated 
upon loss of the wild type SDHAF2 or SDHD allele alone, but only upon the combined loss 
of the wild type SDHAF2 or SDHD allele on the long arm of chromosome 11 and the ac  ve 
maternal tumor suppressor allele located within the imprinted 11p15.5 region. In case of a 
paternally inherited muta  on in SDHAF2 or SDHD, this can be achieved in a single event, i.e. 
the soma  c loss of the whole maternal copy of chromosome 11 (fi gure 6). The infrequent 
maternal transmission of tumor suscep  bly in SDHAF2 and SDHD-linked families would 
then be explained by the fact that it takes at least two separate events to eliminate both 
the paternal wild type SDHAF2 or SDHD allele on the long arm of chromosome 11 and the 
ac  ve maternal copy of a paternally imprinted tumor suppressor gene on the 11p15.5 
region (fi gure 6)[114]. In support of this model, mul  ple studies have found evidence for 
LOH targe  ng the 11p15 region and for the selec  ve loss of maternal chromosome 11 
alleles in SDHD-linked paragangliomas and pheochromocytomas[114,158,159,161].
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Figure 6. Model for the parent-of-origin-dependent transmission of SDHD-linked paraganglioma 
syndrome. The model is applicable to SDHAF2-linked disease as well. Maternal (M) and paternal 
(P) chromosome 11 copies are represented with the wild type (green band) and mutant (green 
star) SDHD alleles located on the long arm (11q23), and the ac  ve allele (red band) and imprinted 
allele (red band struck through) of a tumor suppressor gene on the short arm (11p15.5). (a) SDHD 
muta  on inherited via the father. Loss of the whole maternal chromosome 11 copy targets both 
the wild type SDHD allele and the maternal 11p region containing the ac  ve tumor suppressor 
allele in a single event, resul  ng in tumor forma  on. (b) SDHD muta  on inherited via the father. 
In case of loss of heterozygosity (LOH) targe  ng only the wild type maternal SDHD allele on 11q, 
the ac  ve maternal tumor suppressor allele on 11p15.5 is not aff ected and tumor development is 
inhibited. In case of maternal inheritance of the SDHD muta  on, a second hit targe  ng the wild 
type paternal allele by, for example, a dele  on of the paternal 11q region (c) or even the whole 
paternal chromosome 11 (d) will leave the maternal 11p15.5 region intact and tumor forma  on 
is not ini  ated. When the SDHD muta  on is maternally transmi  ed, at least two separate events 
are required to inac  vate both the wild type SDHD allele and the ac  ve allele of the imprinted 
tumor suppressor gene on 11p15.5. To date, true maternal transmission of SDHD-linked disease has 
been found in associa  on with loss or disrup  on targe  ng both the wild type paternal SDHD allele 
and the maternal chromosome 11p15.5 region, either by two separate LOH events (reported by 
Tobias et al.), or by an altered imprin  ng status at 11p15.5 in combina  on with loss of the wild type 
paternal SDHD allele (described by Pigny et al.), or (e) through a recombina  on on chromosome 11 
followed by loss of the wild type paternal SDHD allele and maternal 11p15.5 region (observed by 
Bayley et al.). Apparently, these sequences of events occur very rarely in vivo.
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To date, very few cases of true maternal transmission of paragangliomas associated with 
SDHD muta  ons have been reported. Pigny et al. have described a pa  ent that developed 
a tympanic paraganglioma a  er inheri  ng a SDHD muta  on via his mother. Unlike his 
unaff ected family members, he had also acquired an altered methyla  on profi le and 
therefore probably an altered imprinted status of H19, a known paternally imprinted tumor 
suppressor on 11p15.5[117,162]. However, in this case the diagnosis of paraganglioma was 
not confi rmed by histopathology, and loss of the paternal SDHD allele or altera  ons in H19 
expression could not be evaluated in the tumor  ssue[114,117,163]. The second report 
of maternal transmission iden  fi ed a pheochromocytoma in a maternally derived SDHD 
muta  on carrier, a  er two separate LOH events had resulted in loss of the paternal wild 
type SDHD allele and loss of the maternal 11p15.5 region in the tumor[164]. A third case 
of maternal transmission of SDHD-linked disease was observed by Bayley and co-workers 
(presented in 2011 by Bayley et al. at the Interna  onal Symposium of Phaeochromocytoma 
and Paraganglioma, Paris, France). In this case, it was demonstrated that an en  re copy 
of chromosome 11 was lost a  er soma  c recombina  on on chromosome 11, resul  ng in 
loss of the paternal wild type SDHD allele and the maternal 11p15.5 region in the pa  ents’ 
pheochromocytoma (fi gure 6). These rare observa  ons, or ‘excep  ons to the rule’, are 
all consistent with the proposed model, and point to the maternal 11p15.5 region as an 
essen  al addi  onal factor in paraganglioma forma  on. The model explaining the parent-
of-origin dependent inheritance of SDHD- and SDHAF2-linked paraganglioma syndrome is 
presented in chapter 7.
Altered expression of 11p15.5 imprinted genes, especially H19 and insulin-like growth 
factor 2 (IGF2), has been linked to other tumors and tumor syndromes, such as the 
Beckwith-Wiedemann syndrome (BWS), a pediatric developmental disease characterized 
by overgrowth, organomegaly, and a predisposi  on for various benign and malignant 
tumors, including, interes  ngly, pheochromocytomas[165,166]. LOH of 11p15.5 region is 
also observed in nephroblastoma, embryonal rhabdomyosarcoma, hepatoblastoma and 
adrenal cor  cal carcinoma, and in these tumors too, it has been shown that the LOH 
specifi cally targets maternal alleles[167]. In VHL-related pheochromocytomas, loss of 
maternal 11p15.5 alleles is also frequently observed, sugges  ng that the maternal 11p15.5 
region has an important role in the tumorigenesis of paraganglioma-pheochromocytoma 
syndromes irrespec  ve of the causa  ve gene[168-170]. Moreover, the parent-of-origin-
dependent inheritance described in focal hyperplasia of Langerhans islets causing 
congenital hyperinsulinism (FoCHI), a disease caused by genes that like SDHD and SDHAF2 
are located outside of the imprinted region on chromosome 11, and its associa  on with 
altered expression of 11p15.5 imprinted genes, suggest that this model for parent-of-
origin dependent inheritance of disease suscep  bility may have implica  ons beyond the 
spectrum of paraganglioma-pheochromocytoma syndromes[171]. 
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4. Molecular biology of paragangliomas
In recent years, great progress has been made in elucida  ng the processes that lead 
from gene muta  ons to paraganglioma forma  on. Especially since the discovery of the 
SDH genes in hereditary paraganglioma syndrome, the understanding of the role of the 
cellular metabolism and hypoxia in tumor forma  on has evolved. The genes that cause 
paraganglioma forma  on, and the processes they regulate, are diverse and several 
pathways may be implicated in paraganglioma tumorigenesis. In this paragraph, the 
current models and insights in the tumor biology of paragangliomas are discussed. These 
models are not mutually exclusive, probably mul  ple mechanisms interact, and the 
rela  ve role of each of these mechanisms in paraganglioma forma  on is not yet defi ned.
4.1 Succinate dehydrogenase 
Most genes currently known to cause hereditary paraganglioma syndrome, SDHAF2, 
SDHB, SDHC, SDHD, and the recently implicated SDHA gene, encode subunits or co-factors 
of succinate dehydrogenase (SDH). SDH is an enzyme anchored to the inner membrane 
of mitochondria, which couples the oxida  on of succinate to fumarate in the tricarboxylic 
acid cycle (TCA cycle, also known as Krebs cycle), with the transfer of electrons as the 
complex II component of the electron transport chain. It thus connects the TCA cycle 
with the mitochondrial respiratory chain, which places SDH at the center of two of the 
essen  al energy producing processes of the cell. SDH consists of a cataly  c domain 
formed by the SDHA fl avoprotein, which is involved in succinate binding and oxida  on, 
the SDHB iron-sulfur protein, which is involved in the electron transfer, and a membrane-
anchoring domain formed by the hydrophobic SDHC and SDHD subunits that also play a 
role in passing electrons through the electron transport chain (fi gure 7). SDHAF2 encodes 
a protein that is involved in the incorpora  on of the fl avin-adenine-dinucleo  de (FAD) 
group into the SDHA subunit.
It has been demonstrated that muta  ons in each of these subunits or co-factors result 
in compromise of enzyma  c func  on of the SDH complex[132,138,172-174]. The loss of 
SDH func  on is thought to interfere both with the TCA cycle as well as the mitochondrial 
respiratory chain, and it is therefore not readily apparent how defects in SDH can ini  ate 




Figure 7. Schema  c representa  on of the succinate dehydrogenase (SDH) complex, or mitochondrial 
complex II, and its dual role in the tricarboxylic acid cycle (TCA, blue circle) and the electron transport 
chain (ETC, black arrow). SDH consists of four subunits, SDHA (A), SDHB (B), SDHC (C) and SDHD (D). 
SDHA and SDHB form its cataly  c domain, while SDHC and SDHD anchor the complex to the inner 
membrane of the mitochondrion. The electron fl ow within complex II is depicted by the red arrows. 
During the oxida  on of succinate to fumarate by SDHA, its FAD group is reduced to FADH2 by two 
electrons. The electrons are then transferred through the iron–sulphur groups in SDHB to SDHC and 
SDHD, where ubiquinone (Q), bound to the mitochondrial inner membrane, is reduced to ubiquinol 
(QH2). Ubiquinol transfers its electrons to complex III, further in the electron transport chain (not 
shown).
4.2 The Warburg hypothesis
Already in 1926, the biochemist O  o Warburg postulated that cancer was caused by 
defects in the oxida  ve phosphoryla  on within mitochondria, a  er observing that cancer 
cells display high rates of glycolysis even in aerobic condi  ons, an eff ect he named ‘aerobic 
glycolysis’. This metabolic shi  , known as the ‘Warburg eff ect’, has since been recognized 
as a feature of many cancer types. The concept that disrup  ons in the mitochondrial 
respira  on can actually cause cancer has long been controversial however (see paragraph 
5.3: ’the Warburg controversy’). Today, the discovery of muta  ons in SDH subunits as 
a cause of paragangliomas and pheochromocytomas serves as a clear example of the 
tumorigenic poten  al of defi cient TCA cycle components. 
The molecular basis for the ini  a  on of tumor growth by defec  ve SDH has not been 
fully elucidated. Currently, there are three main models that link SDH disrup  on with 
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neoplas  c growth: an increase in the forma  on of reac  ve oxygen species, a decrease 
in apoptosis or programmed cell death, and an ac  va  on of hypoxia pathway signaling 
under normoxic condi  ons (or ‘pseudo-hypoxic drive’)[175-177]. 
4.2.1 Reac  ve oxygen species
Reac  ve oxygen species (ROS) are highly reac  ve molecules containing oxygen. ROS are 
produced by the electron transport chain, predominantly at the site of complex I and 
complex III, as electrons are transferred to oxygen molecules. Although ROS produc  on 
does not seem to take place at complex II (SDH) under physiological condi  ons, muta  ons 
in SDH subunits have been associated with increased levels of ROS[175,178,179].
It is currently unknown how muta  ons in SDH subunits lead to ROS produc  on, but 
there are several hypotheses. First, mutant SDH might not conduct the electrons that are 
released in the process of the oxida  on of succinate, resul  ng in a buildup of electrons at 
the FAD site of the SDHA subunit (fi gure 7). When suffi  cient electrons have accumulated, 
this site could overfl ow, leading to a direct transfer of electrons to oxygen, thus crea  ng 
ROS[175,176,180]. Alterna  vely, the oxida  on of succinate to fumarate may be reversed 
at the SDH complex under hypoxic condi  ons, genera  ng ROS in the process[175]. Both 
hypotheses involve an ac  ve cataly  c domain of SDH, whereas it has been shown that 
SDH muta  ons disrupt its enzyme ac  vity[172,176]. A third hypothesis states that the 
SDH complex has a role in reducing the levels of ROS produced by other electron transfer 
chain components using its heme group, and that muta  ons in SDH interfere with this 
func  onality[180,181]. 
The ac  ons of ROS are diverse and in the light of tumorigenesis seemingly contradictory. 
On the one hand, ROS are known ini  ators of apoptosis[175]. On the other hand, the 
produc  on of ROS can induce neoplas  c growth by causing direct damage to the DNA, 
including strand breaks, cross-links and base modifi ca  ons which may result in replica  on 
errors, altered gene expression, genomic amplifi ca  on or LOH[175,182]. In addi  on, 
increased ROS produc  on is associated with increased hypoxia pathway signaling and 
hypoxia-induced transcrip  on, processes that have been shown to play a key role in 
paraganglioma tumorigenesis (see paragraph 4.2.3: ‘pseudo-hypoxic drive’)[173,183]. 
In paragangliomas, excess ROS produc  on might be the result of defects in SDH caused by 
muta  ons in SDH genes and subsequent LOH of wild type SDH alleles. Alterna  vely, ROS 
produc  on may already be increased in heterozygous SDH muta  on carriers that have not 
yet lost the wild type SDH allele, and the high levels of ROS might drive the LOH of SDH 
genes. Whether or not heterozygous SDH muta  ons cause ROS excess is s  ll a ma  er of 
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debate. Interes  ngly, heterozygous Sdhd mutant mice exhibit slight changes in caro  d 
body physiology that may implicate increased levels of ROS (see paragraph 4.9: ‘insights 
from mouse models’)[43,184].
4.2.2 Evasion of apoptosis
In addi  on to their role in the energy supply of the cell, mitochondria have a central 
role in programmed cell death or apoptosis. Apoptosis may be induced by increasing the 
permeability of the mitochondrial membrane, resul  ng in the release of apoptogenic 
proteins such as cytochrome-c into the cytosol, or by interfering with the bioenerge  c 
processes within the mitochondria. Evasion of apoptosis is one of the acquired hallmarks 
of neoplas  c growth[185]. Several mechanisms may cause insensi  vity to apopto  c 
signals in paragangliomas. First, in SDH mutant paragangliomas, SDH defi ciency causes 
the oxida  ve phosphoryla  on to operate at subop  mal levels. This causes an induc  on of 
glycolysis as the alterna  ve energy producing pathway, through upregula  on of glycoly  c 
enzymes such as hexokinase and glycerylaldehyde-3-posphatase (GAPD). Hexokinase and 
GAPD are proteins that are implicated in the regula  on of diverse other cellular processes, 
including apoptosis, and the induc  on of glycolysis could thus have an an  -apopto  c 
eff ect[175,186]. Alterna  vely, SDH defi ciency causes an accumula  on of succinate (see 
paragraph 4.2.3: ‘the hypoxia pathway’), which in turn can inhibit the pro-apopto  c 
ac  vity of prolyl-hydroxylase 3 (PHD3) (see paragraph 4.3: ‘abnormal development of 
neuronal precursor cells’)[150,176,187]. 
A third link between SDH and apoptosis that has been put forward, is a decrease rather than 
an increase in ROS produc  on under hypoxic condi  ons due to defects in SDH, which would 
interfere with the pro-apopto  c signal transduc  on by ROS in mitochondria[188;189].
A fourth mechanism involves the B-cell lymphoma 2 (BCL-2) family of apoptosis regula  ng 
proteins. Two of its members, BCL-2 and BCL-xl, have been shown to counteract the 
pro-apopto  c signaling by ROS and hypoxia, and prevent the release of cytochrome-c 
from the mitochondrial membrane[190-192]. The upregula  on of BCL-2 and BCL-xl is a 
known response to hypoxia and has been observed in paragangliomas[193-195]. Another 
member of the BCL-2 family, BCL-2 interac  ng protein 3 (BNIP3), acts as a promoter of 
apoptosis, and has been shown to be repressed in certain SDHB-linked tumors[196].
There are several observa  ons that implicate blocked apoptosis in SDH-linked para-
ganglioma tumorigenesis. Douwes Dekker et al. found very few morphological stages 
of apoptosis and no DNA strand breaks sugges  ng a reduced apopto  c ac  vity in 
paragangliomas[193]. In addi  on, it has been shown that whereas short periods of 
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SDH defi ciency can induce apoptosis, prolonged SDH defi ciency can result in an absent 
apopto  c response and induc  on of tumorigenesis[178,179]. Further evidence for the 
role of SDH in apoptosis comes from the study of new possible an  -cancer agents such as 
vitamin E analogs, that are able to induce apoptosis only in the presence of func  onal SDH 
and not in SDH defi cient cells[197].
4.2.3 The hypoxia pathway
Long before the iden  fi ca  on of any of the genes now known to play a role in para-
gangliomas, it was recognized that living at high al  tude increases the risk of caro  d 
body hyperplasia and caro  d body tumors[198,199]. In addi  on, caro  d body hyperplasia 
also occurs in pa  ents suff ering from cys  c fi brosis or cyano  c heart disease, condi  ons 
associated with compromised gas exchange in the lungs[200]. This increased prevalence 
of paragangliomas in condi  ons characterized by low oxygen levels and the central role 
of the caro  d body in oxygen sensing suggested that hypoxia or defects in the oxygen 
sensing mechanism play a role in the tumorigenesis of paragangliomas. 
Oxygen sensing at the caro  d body
Corneille J.F. Heymans was the fi rst to demonstrate the role of the caro  d body as a 
peripheral arterial chemoreceptor and regulator of respira  on and oxygen homeostasis 
(see paragraph 5.2: ‘the discovery of the caro  d body func  on’)[5]. Oxygen sensing 
takes place in the type 1 or chief cells, primarily within the caro  d body[201]. Type 1 
cells are polymodal chemoreceptors that are sensi  ve not only to low oxygen, but also 
to carbon dioxide, extracellular pH, and glucose levels, however the oxygen sensing 
ability is what makes the caro  d body essen  al in the adap  ve hyperven  latory refl ex 
response[200]. Hypoxia elicits the release of two classes of neurotransmi  ers by the chief 
cells: conven  onal neurotransmi  ers such as acetylcholine, catecholamines, substance 
P and adenosine triposphate (ATP), and unconven  onal neurotransmi  ers such as nitric 
oxide (NO) and carbon monoxide (CO)[43,202]. Acetylcholine and ATP in par  cular seem 
to be responsible for the excita  on of aff erent endings of the caro  d sinus nerve and 
to increase impulse traffi  c to the brain stem, thus regula  ng the hypoxic ven  latory 
response[43,200,202]. 
Acute hypoxia response
There are two main models for caro  d body oxygen sensing: the ‘membrane model’, 
designa  ng potassium channels as the ini  ators of the response to hypoxia, and the 
‘mitochondrial model’, which involves heme containing proteins like nitric oxide synthetase 
(NOS), hemoxygenase 2 (HO-2), NADPH oxidase, and/or the mitochondrial complexes such 
as SDH as the main hypoxia responsive elements[43,202]. Thus far, the iden  fi ca  on of 
Chapter 1
42
one specifi c compound as the central oxygen sensor remains elusive. Several interac  ng 
molecular mechanisms are believed to be involved but the full complexity of the process 
is not yet en  rely understood.
Central to the membrane model of oxygen sensing is the concept that hypoxia induces 
an altered conductance of potassium channels located in the membrane of type 1 cells, 
which causes depolariza  on and the infl ux of calcium in the cytosol, triggering the release 
of neurotransmi  ers[43,200,202]. There are several pathways that might link hypoxia 
to potassium channel func  on and probably diff erent types of potassium channels are 
involved. It has been hypothesized that low oxygen levels could directly alter the open 
probability of potassium or calcium channels in type 1 cells, causing depolariza  on 
and transmi  er release[43,201]. Alterna  vely, potassium channels can be aff ected by 
increased levels of ROS or decreased levels of ATP as a result of hypoxia (see below)[202].
In the mitochondrial model, heme containing compounds such as NOS, HO-2, NADPH 
oxidase, and/or the mitochondrial complexes such as SDH are viewed as the primary 
star  ng-point of the ven  latory response to hypoxia. This response may be regulated by 
NOS through the produc  on of nitric oxide (NO), which may play a role in suppressing 
sensory discharge in type I cells under normoxic condi  ons, and may have modula  ng 
eff ects on hypoxia induced neurotransmi  ers[201]. A reduced ac  vity of NOS results in 
low levels of NO, relieving its inhibitory eff ect on type 1 cells[201]. Whether or not NOS 
ac  vity and NO levels are actually altered by hypoxia within type 1 cells is yet unclear, but 
NO produced in nearby nerve terminals might also exert this modula  ng eff ect[43,202].
Hemoxygenase 2 could be involved in oxygen sensing through the regula  on of carbon 
monoxide (CO) levels. Hemoxygenase 2 is capable of endogenous produc  on of CO in 
type 1 cells, in a process that is oxygen dependent. Endogenous CO is thought to exert 
an inhibitory infl uence on caro  d body func  on, but the eff ects of CO on oxygen sensing 
seem to be of a dual nature: high concentra  ons of CO inhibit NOS ac  vity and augment 
sensory discharge in type 1 cells (see above)[201-203].
The mechanism linking the non-mitochondrial enzyme NADPH oxidase or the mitochondrial 
electron transport chain complexes, including SDH, to oxygen sensing in the caro  d body 
involves the produc  on of ROS by these enzymes as a func  on of the amount of oxygen 
available to the cell. Low concentra  ons of oxygen result in decreased levels of ROS, which 
would in turn alter the open probability of the potassium channels[43,201]. In addi  on, 
mitochondrial complexes could alter the conductance of ATP-dependent potassium 
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channels, causing depolariza  on and transmi  er release, through a reduced produc  on 
of ATP in response to low oxygen levels[43,201]. 
Chronic hypoxia
Chronic hypoxia, i.e. an exposure to hypoxic condi  ons las  ng several hours or longer, 
induces a number of morphological, electrochemical and physiological adapta  ons that 
increase the responsiveness of oxygen sensing mechanisms, promote oxygen delivery 
to  ssues, and adjust the cellular metabolism to limited oxygen availability[43,202]. 
Most of these eff ects are regulated through hypoxia inducible factor 1 (HIF-1). HIF-1 is 
a heterodimeric transcrip  on factor composed of the HIF-1α and HIF-1β subunits. HIF-
1β is cons  tu  vely expressed, whereas HIF-1α levels increase exponen  ally as oxygen 
levels decrease. Under normoxic condi  ons, HIF-1α levels are reduced, primarily by the 
ac  vity of prolyl-hydroxylases (PHDs) 1, 2 and 3, which modify HIF-1α so that it can be 
ubiqui  nated by a complex consis  ng of the Von Hippel-Lindau protein (pVHL) and an 
E3 ubiqui  n-protein ligase, a  er which it is targeted for proteasomal degrada  on. Under 
hypoxic condi  ons, HIF-1α degrada  on by PHDs is inhibited either by depriva  on of 
oxygen (a substrate of the PHDs), or as a result of oxida  on of the iron group within 
the PHDs by ROS, resul  ng in accumula  on of HIF-1α. Subsequently, HIF-1α translocates 
to the nucleus and dimerizes with the HIF-1β subunit, forming the HIF-1 transcrip  on 
factor[204,205]. HIF-1 binds to hypoxia response elements (HREs) and ac  vates the 
transcrip  on of a large number of genes that are involved in cell prolifera  on, survival, 
apoptosis, glucose transport and metabolism, angiogenesis, cytoskeletal structure and 
mo  lity, and extracellular matrix metabolism (see also chapter 6)[205-207]. 
Two other isoforms of HIF-1α exist: HIF-2α and HIF-3α. HIF-2α is a protein with extensive 
similarity to HIF-1α, its degrada  on is also regulated in an oxygen-dependent way by 
PHDs, it also dimerizes with HIF-1β, and it regulates the transcrip  on of an overlapping, 
but not iden  cal set of genes. HIF-3α is transcrip  onally regulated by HIF-1 and acts as an 
inhibitor of HIF-1[205,206]. 
The tumorigenic eff ects of hypoxia
Both HIF-1α and HIF-2α overexpression is associated with the development and behavior 
of a large variety of neoplasms. It has been shown to increase resistance to chemotherapy, 
radiotherapy and photodynamic therapy, and to promote tumor growth, vasculariza  on, 
metastasis, and mortality in melanomas, oligodendromas, astrocytomas, and mul  ple 
types of carcinoma[183,206]. The eff ects of HIF-1α and HIF-2α overexpression are not 
universal however, and the biological consequences of HIF-1 ac  va  on depend on the 
specifi c subset of genes that responds[183,206]. The HIF-1 ac  va  on can be induced by 
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intratumoral hypoxia in areas distal to blood vessels and on the border of necro  c cells, 
or by gene  c altera  ons to hypoxia pathway components (see paragraph 4.2.3: ‘pseudo 
hypoxic drive’)[183,205]. 
Pseudo-hypoxic drive
In some tumors, the tumorigenic eff ects of hypoxia are induced under normoxic condi  ons, 
an eff ect known as the ‘pseudo-hypoxic drive’. This pseudo-hypoxic drive can be caused 
by gene  c muta  ons that aff ect pathways regula  ng the transcrip  onal ac  vity HIF-1 
in an oxygen-independent way[204]. In SDH-linked tumors, there are several possible 
routes linking the ac  va  on of HIF-1 with SDH defi ciency (fi gure 8). The fi rst involves the 
produc  on of ROS as a result of SDH disrup  on (see paragraph 4.2.1: ‘reac  ve oxygen 
species’). When suffi  cient amounts of ROS accumulate, ROS can oxidize the iron group 
within PHDs, thereby decreasing PHD ac  vity and increasing HIF-1α (and HIF-2α) stability. 
As explained above, blocking of HIF-1α degrada  on will lead to increased HIF-1 mediated 
transcrip  on and ac  va  on of the hypoxia pathway (fi gure 8)[175]. In addi  on, there is 
evidence that ROS can increase HIF-1 stability directly (fi gure 8)[208]. The second route 
is through the accumula  on of succinate, the substrate of SDH in the TCA cycle. In the 
cytosol, succinate is also present as a product of the conversion of α-ketoglutarate by 
PHDs. The accumula  on of succinate in the mitochondrion as a result of SDH defi ciency, 
and the subsequent transport of excess succinate to the cytosol, leads to high levels of 
cytosolic succinate, which prevents the forward hydroxyla  on of HIF-1α by PHDs, resul  ng 
in increased HIF-1 ac  vity (fi gure 8)[175,209,210].
An alterna  ve pathway linking SDH defi ciency with HIF-1 ac  vity is through the reduced 
ac  vity of other hydroxylases, such as the factor inhibi  ng HIF (FIH). FIH reduces HIF-1 
mediated transcrip  on by preven  ng the recruitment of co-ac  vators[205,211,212]. 
Hydroxyla  on of HIF by FIH, like hydroxyla  on of HIF by PHDs, requires the co-factors 
iron and oxygen and α-ketoglutarate as a co-substrate, and FIH ac  vity can be blocked by 
ROS and high levels of succinate in the same way as PHD ac  vity (see above), resul  ng in 
increased HIF-1 transcrip  on[212]. 
There is ample evidence implica  ng the hypoxia pathway in paraganglioma tumori-
genesis. First, HIF-1α and HIF-2α stabiliza  on, the accumula  on of succinate, and 
its inhibitory eff ect on PHDs have all been demonstrated in SDH defi cient cells and 
paragangliomas[209,210]. Second, the fact that paragangliomas and pheochromocytomas 
can be caused by muta  ons in SDH subunits as well as by muta  ons in VHL and PHD2, 
points towards the hypoxia pathway in paraganglioma tumorigenesis because of the role 
that SDH, VHL and PHD2 all have in the stabiliza  on of HIF-1α and HIF-2α[213]. Third, HIF-1 
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regulated genes have been shown to be overexpressed in SDH-linked paragangliomas 
and pheochromocytomas, and this is a very plausible explana  on for some of the clinical 
characteris  cs of paragangliomas, such as their typical high vascularity (see paragraph 
4.4: ‘angiogenesis’)[173,213]. 
 
Figure 8. Schema  c representa  on of the pseudo-hypoxic drive. Defects in succinate dehydrogenase 
(SDH), prolyl-hydroxylase 2 (PHD2) and the Von Hippel-Lindau protein (pVHL) all inhibit the 
degrada  on of hypoxia-inducible factors HIF-1α and HIF-2α. The HIF alpha subunits subsequently 
combine with HIF-1β to form the transcrip  on factor HIF-1. HIF-1 ac  vates the transcrip  on of 
a mul  tude of genes involved in glucose metabolism, angiogenesis, survival, cell mo  lity and 
extracellular matrix metabolism. The stabiliza  on of HIF-1α and HIF-2α subunits can be induced 
in several hypoxia-independent ways: defects in SDH interfere with the oxida  on of succinate to 
fumarate in the TCA cycle, resul  ng in accumula  on of succinate. Succinate is transported to the 
cytosol, where it blocks the ac  vity of PHD 1, 2, and 3 by product inhibi  on. Alterna  vely, defects 
in SDH result in the produc  on of reac  ve oxygen species (ROS), which disable PHDs by oxidizing 
the iron group within, or may contribute to the stability of HIF-1α directly. Muta  ons in PHD2 can 
aff ect its ability to catalyze the hydroxyla  on of HIF-1α. Muta  ons in the Von Hippel-Lindau protein 
(pVHL) disrupt HIF-1α ubiqui  na  on. 
4.3 Abnormal development of neuronal precursor cells
An alterna  ve hypothesis for the development of paragangliomas and pheochromocytomas 
explains their tumorigenesis not primarily by defects in the cell metabolism or pseudo-
hypoxia, but through the faulty development of sympathe  c neuronal precursor cells 
that give rise to the sympathe  c nervous system as well as to the paraganglionic type 1 
cells. During normal development, damaged or unneeded precursor cells origina  ng from 
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the neural crest are disposed of by apoptosis in a process called ‘developmental culling’. 
This process is regulated by growth factors, most notably nerve growth factor (NGF) 
through a pathway involving the c-Jun protein and prolyl-hydroxylase 3 (PHD3, encoded 
by EGLN3) (fi gure 9). Under normal circumstances, the precursor cells undergo apoptosis 
when NGF becomes limi  ng, but it has been demonstrated that pheochromocytoma cells 
might escape the developmental culling by blocking apoptosis through the c-Jun/PHD3 
pathway[150]. This model for paraganglioma and pheochromocytoma development is 
a  rac  ve because the SDH genes, NF1, RET, VHL, KIF1B and MAX can all be linked to this 
essen  al mechanism in the development of the paraganglion system (fi gure 9)[149,151]. 
Moreover, there is some evidence from knockout mouse models that associates the 
developmental stages of the nervous system with pheochromocytoma forma  on (see 
paragraph 4.5: ‘insights from mouse models’). However, the hypothesis implies that the 
second hit targe  ng the wild type allele of these tumor suppressor genes occurs very early 
in life, or that heterozygous muta  ons already exert an inhibitory eff ect on this pathway. 
In case of SDH muta  ons, there is currently no evidence to support that heterozygous 
SDH muta  ons result in succinate accumula  on, and it is therefore uncertain whether 
heterozygous SDH muta  ons can induce aberrant survival of neuronal precursor cells 
(fi gure 9). 
4.4 Other mechanisms in paraganglioma tumorigenesis
Cell cycle arrest
The process of the replica  on of cells, called the cell cycle, comprises of mul  ple 
phases: the G1- or growth phase, the S- or DNA replica  on phase, the G2 phase in which 
microtubules are formed, and fi nally, the M- or mito  c phase in which the actual division 
of nuclear DNA takes place. Each transi  on into the next phase is guarded by a checkpoint 
that is very  ghtly regulated through mul  ple complex mechanisms. In order to a  ain 
uncontrolled prolifera  on, a hallmark of cancer, the neoplas  c cell must evade these 
checkpoints, and in most forms of cancer the mito  c rate, i.e. the propor  on of replica  ng 
cells, is high. In paragangliomas however, a very low mito  c rate has been observed, and 
a large number of cells seem to be stranded in the G2 phase of the cell cycle, indica  ng 
that some cell cycle regula  on is s  ll opera  ve[193]. The low mito  c rate might explain 
the indolent behavior and slow growth that characterizes most paragangliomas. Cell cycle 
arrest can be caused by hypoxia, through upregula  on of tumor protein 53 (p53), one of 
the most well-known regulators of the cell cycle and apoptosis, which regulates the G2/M 
checkpoint through a complex cascade. Muta  ons in p53 confer a growth advantage as the 
cell is less able to respond to hypoxia or DNA damage with cell cycle arrest and apoptosis, 
and p53 muta  ons are implicated in a vast array of neoplasms, but are an infrequent 
fi nding in paragangliomas[193,214]. It is therefore conceivable that the cell cycle arrest 
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observed in paragangliomas is the result of the intact response of p53 to pseudo-hypoxia 
caused by SDH defi ciency, however, p53 overexpression also is not a characteris  c of most 
paragangliomas[193,214]. 
 
Figure 9. Almost all paraganglioma and pheochromocytoma genes converge on the pro-apopto  c 
pathway that is involved in the developmental culling of neuronal precursor cells. NTRK1, the 
receptor for nerve growth factor (NGF), collaborates with the RET tyrosine kinase receptor (RET) 
to regulate NGF and glial cell line- derived neurotrophic factor (GDNF) signals. Loss of NGF leads to 
apoptosis under normal condi  ons. Muta  ons (red stars) in neurofi bromin 1 (NF1) interfere with 
downstream signaling by the NTRK1 receptor. Muta  ons in the Von Hippel-Lindau protein (VHL) 
cause induc  on of the JunB protein, which in turn antagonizes the pro-apopto  c ac  vity of c-Jun. 
The upregula  on of c-Jun can also be blocked by muta  ons in MYC associated factor X (MAX) through 
altered ac  vity of myelocytomatosis viral oncogene homolog (MYC). The hydroxyla  on ac  vity of 
prolyl-hydroxylase 3 (PHD3), which is transcrip  onally ac  vated by c-Jun, can be blocked through 
product inhibi  on by increased levels of cytosolic succinate. The accumula  on of succinate can be 
caused by disrupted enzyma  c ac  vity of succinate dehydrogenase (SDH) due to muta  ons in the SDH 
subunits. Kinesin family member 1B (KIF1B) regulates apoptosis downstream from PHD3, and KIF1B 
muta  ons may therefore also result in blun  ng of the pro-apopto  c signal through this pathway.
An alterna  ve pathway that links pseudo-hypoxia with cell cycle arrest is through the 
upregula  on of cyclin-dependent kinase inhibitor 1 (CDKN1A or p21) by HIF-1. The p21 
protein is regulated by p57, but is also a transcrip  onal target of HIF-1[207;215]. The p21 
protein is capable of inducing cell cycle arrest in G1/S- and G2/M transi  ons, and has 
been shown to be expressed in paragangliomas[193,215]. Interes  ngly, prolonged G2/M 
Chapter 1
48
arrest through induc  on of p21 is also associated with polyploidisa  on, another feature 
frequently encountered in the nuclei of type 1 paraganglioma cells[114,193,215]. 
Whereas p21 and p57 have been studied in paragangliomas, many other pathways that 
regulate the cell cycle have yet to be inves  gated, and the exact mechanism of cell cycle 
arrest in paragangliomas remains to be elucidated[193,214].
Angiogenesis
Paragangliomas are characterized by a highly vascular stroma and close rela  ons to 
adjacent vascular structures. Histologically, the ‘Zellballen’ clusters of type 1 and type 
2 cells are surrounded by a very prominent capillary network[4,216]. The mechanism 
by which tumors induce the sprou  ng and development of blood vessels from exis  ng 
vasculature, called angiogenesis, is an essen  al step in neoplas  c growth and progression, 
as the expanding tumor requires increasing amounts of nutrients and oxygen to sustain 
itself[212,217]. One of the cri  cal triggers of angiogenesis is hypoxia within a tumor, and 
virtually all of the central mediators in the process, such as vascular endothelial growth 
factor (VEGF), platelet derived growth factor b (PDGFB), stromal derived factor 1 (SDF1), 
angiopoie  n 2 (ANGPT2), fi broblast growth factor 2 (FGF2), and important receptors 
are regulated through the hypoxia pathway by HIF-1 (see also chapter 6)[205-207,218]. 
Both the stabiliza  on of HIF-1α and HIF-2α lead to the expression of angiogenic factors, 
but there is evidence that HIF-2α has a more prominent role in angiogenesis[212]. In 
paragangliomas, angiogenesis could be ini  ated by pseudo-hypoxia signaling (see 
paragraph 4.2.3: ’pseudo-hypoxic drive’). HIF-1α, HIF-2α and various HIF-1 target genes 
involved in angiogenesis such as FGF2, VEGF, and VEGF receptor 1, have indeed been 
shown to be upregulated in type 1 cells of paragangliomas and pheochromocytomas, 
indica  ng that the pseudo-hypoxic drive is responsible for the vascular nature of these 
tumors[196,219,220].
Prolifera  ve pathways 
The recent discovery of TMEM127 and MAX as a tumor suppressors in hereditary 
paraganglioma and pheochromocytoma syndromes, and their roles as regulators of the 
mTOR pathway and the MYC-MAX-MXD1 family of transcrip  on factors respec  vely, 
indicate that HIF-independent prolifera  ve pathways may also play a role in paraganglioma 
forma  on (see paragraph 3.3: ‘other genes in paragangliomas and pheochromocytomas’)
[143,151]. Gene expression studies have indicated that pheochromocytomas may be 
classifi ed into two broad categories: one consis  ng of VHL and SDH-related tumors, and 
another consis  ng of NF1 and RET-related tumors (see paragraphs 3.1 and 3.2)[213]. The 
VHL/SDH associated tumors are characterized by an expression signature of angiogenesis, 
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hypoxia, and a suppression of the mitochondrial oxida  ve response and TCA cycle 
components, consistent with their role in HIF-1 regulated transcrip  on (see paragraph 
4.2.3: ‘pseudo-hypoxic drive’). The NF1/RET associated tumors are characterized by 
upregula  on of a dis  nct set of biological programs, including transla  on, protein 
synthesis, and kinase signaling, in agreement with their respec  ve gene func  ons (see 
paragraph 3.1: NF1, RET, and VHL) [213]. The transcrip  onal profi le of TMEM127-related 
tumors shows similari  es with the NF1/RET cluster, and mTOR signaling has been shown 
to be important in NF1 associated tumorigenesis as well[213,221]. However, whereas 
TMEM127-linked tumors are associated with the mTOR signaling pathway, NF1 and RET-
linked tumors are more closely associated with the mitogen-ac  vated protein kinase 
(MAPK) pathway[143,213]. MAX has been linked to both the mTOR and MAPK pathways 
through the MYC-MAX-MXN1 network[152,222]. 
The MAPK and mTOR pathways are highly complex, and regulate a mul  tude of cellular 
processes including transcrip  on, cell prolifera  on and survival, and both pathways 
have been implicated in various forms of cancer[223,224]. Here, the MAPK and mTOR 
pathways will not be discussed in detail, but some interes  ng links to the hypoxia 
pathway exist. Like the hypoxia pathway, both MAPK and mTOR signaling can be induced 
by hypoxia and oxida  ve stress, both MAPK and mTOR signaling can be induced by 
growth factors that are known HIF-1 target genes, and both MAPK and mTOR pathways 
have a regula  ng eff ect on HIF-1 transcrip  onal ac  vity (and vice versa), illustra  ng the 
intricacy and interdependence of the diff erent pathways that may lead to paraganglioma 
tumorigenesis[205,218,223-225].
4.5 Insights from mouse models
Several studies have reported on the eff ects of inac  va  on of genes associated with 
paragangliomas and pheochromocytomas in gene  cally modifi ed mice (knockout 
mouse models). Whereas paraganglioma development is extremely rare in mice, life-
span studies of laboratory mouse strains report a risk of 0-5% for the development 
of pheochromocytomas, and a higher prevalence in several gene  cally engineered 
strains[226]. Mice are the most widely used species for the knockout technique, because 
they are the closest related animal species in which the technique can be applied with 
rela  ve ease. Mouse models can be used to study the eff ect of specifi c gene muta  ons 
and evaluate determinants of tumor behavior. The available models for the paraganglioma 
and pheochromocytoma genes that have been discussed in former paragraphs will be 




Several studies have demonstrated that homozygous disrup  ons of the Sdhd gene 
(Sdhd -/-) in mice invariably result in mortality early in embryogenesis[184,227,228]. In 
heterozygous Sdhd knockout mice (Sdhd +/-), the response of the caro  d body to acute 
hypoxia remains largely intact, although a higher rest-excitability and basal catecholamine 
release has been demonstrated, probably due to potassium channel dysfunc  on and 
persistent calcium infl ux (see paragraph 4.2.3: ‘oxygen sensing at the caro  d body’)
[43,184,228]. A possible explana  on for this phenomenon, linking Sdhd muta  ons and 
potassium channel func  on, could be an (increased) produc  on of ROS by defec  ve SDH 
in Sdhd +/- mice, however, this has not yet been clearly demonstrated[184].
In heterozygous Sdhd mutants, SDH ac  vity is reduced, but no specifi c disease phenotype 
develops, although a slight caro  d body hyperplasia has been observed[184,227,228]. 
Apparently, in Sdhd +/- mice the loss of one Sdhd allele is suffi  ciently compensated by 
transcrip  on from the wild type allele in order to escape paraganglioma forma  on[227]. 
In addi  on, a Sdhd/H19 double knockout mouse model also did not show increased 
paraganglioma or pheochromocytoma suscep  bility, and H19 may thus, at least in mice, 
not be a modifi er gene in paraganglioma development as proposed in the model for 
parent-of-origin-dependent inheritance (see paragraph 3.4: ‘inheritance of head and neck 
paraganglioma syndromes’)[227]. On the other hand, the lack of paraganglioma forma  on 
in Sdhd knockout mice may also be explained by a great number of other unknown 
physiological or gene  c factors, and diff erences in genotype-phenotype correla  ons 
between mouse and man are not uncommon[227]. Furthermore, inducible  ssue-specifi c 
Sdhd knockouts are not yet available and the eff ects of heterozygous germ-line Sdhd 
defects and subsequent LOH in paraganglion  ssue have not been studied[227]. 
Vhl
In Vhl knockout mice, the loss of both Vhl alleles (Vhl -/-) results in embryonic lethality 
during mid-gesta  on, due to lack of placental vasculogenesis[229,230]. A specifi c homo-
zygous Vhl muta  on at codon 200 is compa  ble with life and results in mild polycythemia, 
which resembles the homozygous recessive VHL muta  on causing hereditary 
polycythemia in man (Chuvash syndrome)[229]. Heterozygous Vhl knockout mice (Vhl +/-) 
develop cavernous liver hemangiomas and some  mes renal cysts (both rarely associated 
with VHL muta  ons in humans), but paragangliomas or pheochromocytomas are not 
reported[226,229,230]. The reason for this phenotypic divergence between mouse and 




Like Sdhd and Vhl, the Nf1 null state (Nf1 -/-) is lethal in mice[231]. Heterozygous knockout 
mice (Nf1 +/-) do not develop neurofi bromas and astrocytomas, the hallmark tumors of 
human NF1 muta  ons, but heterozygous muta  ons involving exon 31 of the mouse Nf1 
gene have been associated with pheochromocytoma forma  on[226,231]. In the Nf1-
linked tumors, the wild type Nf1 allele is lost, indica  ng that Nf1 is a pheochromocytoma 
tumor suppressor gene in mice[226]. Microarray gene expression studies of Nf1 knockout 
pheochromocytomas show an expression signature of early central and peripheral 
nervous system development, in line with the concept of persistent neuronal precursor 
cells and disrupted developmental culling as a cause of pheochromocytoma forma  on 
(see paragraph 4.3: ‘abnormal development of neuronal precursor cells’)[232]. 
Ret
The human MEN type 2B syndrome, consis  ng of medullary thyroid carcinoma, 
pheochromocytoma, mucosal neuroma and marfanoid skeletal changes, is predominantly 
caused by one specifi c muta  on at codon 918 in exon 16 of the human RET gene (see 
paragraph 3.1: ‘NF1, RET and VHL’)[95]. The corresponding Ret muta  on in mice produces 
a phenotype with comparable lesions in the mouse thyroid and adrenal medulla[233]. 
Homozygous (RetMEN2B/RetMEN2B) mice develop bilateral adrenal chief cell hyperplasia 
early in life, which invariably progresses to pheochromocytoma[233]. A minority of 
heterozygous mutants (RetMEN2B/+) also develop adrenal chief cell hyperplasia (in 16%) and 
pheochromocytomas (in 2%), but later in life[233]. Interes  ngly, extra-adrenal chief cell 
nodules were also observed in homozygous mutant mice, but the head and neck region 
was not inves  gated in this model[233]. The RetMEN2B/RetMEN2B mice display the highest 
frequency of pheochromocytoma forma  on of any mouse model to date. Based on 
observa  ons in the RetMEN2B mouse model, it has been hypothesized that gain-of-func  on 
Ret muta  ons such as RetMEN2B cause adrenal tumors through abnormal migra  on, 
prolifera  on and survival of neuronal precursor cells (see paragraph 4.3: ‘abnormal 




The major steps, and the people that took them in the development of our current 
understanding of the paraganglion system and the neoplasms that stem from it, deserve 
some special considera  on, because (in the words of Goethe): “die Geschichte einer 
Wissenscha   ist die Wissenscha   selbst”.
5.1 The discovery of the caro  d body
The discovery of the caro  d body and its recogni  on as an anatomical en  ty is widely 
a  ributed to Albrecht von Haller (1708-1777), who named it the ‘exiguum caro  cum’, 
although it was his student Taube who in 1743 published the fi rst anatomical descrip  on 
of what he called the ‘ganglion minutem’[234,235]. 
  
Albrecht von Haller (1708-1777)
Von Haller was a Swiss scholar and veritable ‘homo universalis’, with contribu  ons in 
the fi elds of anatomy, medicine, botany, physiology, philosophy, poli  cs and poetry. He 
started his studies in medicine in 1724 in Tübingen, but went to Leiden in 1725 to con  nue 
under the famous Herman Boerhaave. While in Leiden, he also studied anatomy and 
surgery with Bernhard Siegfried Albinus. In 1727, at the age of eighteen, he graduated 
doctor medicinae under Boerhaave a  er wri  ng a thesis on an otolaryngological topic, 
proving that a recently discovered ‘salivary duct’ was in fact a blood vessel. He wrote an 
extensive seven-volume book about his learning in Leiden: ‘Erläuterungen zu Boerhaaves 
Ins  tu  ones’. He later went on to study in London, Oxford, Paris, and Basel before he was 
eventually appointed chair of medicine, anatomy, botany and surgery at the University 
of Gö   ngen in 1736. Von Haller was an avid researcher and a prolifi c writer. The body of 
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work he produced was immense, covering all fi elds of human knowledge, most notably 
botany, anatomy and poetry. His most famous contribu  ons to the fi eld of medicine were 
his recogni  on of the mechanism of respira  on, the autonomous func  on of the heart, 
and the descrip  on of nerve and muscle ac  vity. Another great passion, botany, led him 
to mountaineer in the Alps in search of specimen for his enormous plant collec  on and 
botanic garden. These forays inspired him to write his most famous poem, called ‘Die 
Alpen’, the fi rst example of lyrical apprecia  on of the natural beauty of the high mountains 
in European literature[236,237]. At the  me, the rela  on between high al  tude and 
hyperplasia of the caro  d body had yet to be discovered.
5.2 The discovery of the caro  d body func  on
A  er the discovery of the caro  d body and its descrip  on in 1743, it has taken considerable 
 me before its func  on was elucidated. The fi rst to hypothesize that the caro  d body had 
chemorecep  ve proper  es was De Castro, who in 1926 stated that the glomus caro  cum 
could ‘taste the blood’[238]. It was Corneille J.F. Heymans, a Flemish physiologist, who in 
the 1920’s was the fi rst to fully appreciate the func  on of the caro  d body as a peripheral 
chemoreceptor of oxygen, carbon dioxide and acidity in the arterial blood and its role in 
the refl exogenic regula  on of ven  la  on and blood pressure[5].
 
Corneille J.F. Heymans (1892-1968)
The discovery of the caro  d body as a regulator of ven  la  on occurred rather by chance, as 
Heymans later claimed, by doing a ‘foolish experiment’ at the end of a day experimen  ng 
on the severed heads of dogs. Spurred on by his father and principle teacher to ‘never kill 
an animal at the end of an experiment if the animal may s  ll be used for any experimental 
purpose.. even if it looks foolish’, he injected some cyanide that happened to be standing 
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on the laboratory desk into the caro  d artery of a dog with- and a dog without intact 
innerva  on of the caro  d body area, and was surprised by the diff erence in ven  latory 
response. This observa  on lead Heymans to perform the experiments that ul  mately won 
him the Nobel Prize in 1938[239,240].
5.3 The Warburg controversy
In 1926, the biochemist O  o Warburg observed that hypoxia alone was not suffi  cient 
to kill cancer cells, and that even in aerobic condi  ons when oxida  ve phosphoryla  on 
would be more effi  cient, they display high rates of glycolysis, a process he called ‘aerobic 
glycolysis’[241]. For this discovery of ‘the nature and mode of ac  on of the respiratory 
enzyme’, he was awarded the Nobel Prize in 1931. Warburg believed that the metabolic 
shi   form oxida  ve phosphoryla  on to glycolysis in cancer cells, now called the ‘Warburg 
eff ect’, was the fundamental cause of cancer (in the words of Warburg at a lecture in 
of Nobel-Laureates in 1966: “Cancer, above all other diseases, has countless secondary 
causes. But, even for cancer, there is only one prime cause. Summarized in a few words, the 
prime cause of cancer is the replacement of the respira  on of oxygen in normal body cells 
by a fermenta  on of sugar”)[241,242]. The conten  on that mitochondrial dysfunc  on 
and disrupted metabolism is the ‘only one prime cause of cancer’ was disputed by many 
(as summarized by one of Warburg’s most prominent opponents, the biochemist Sidney 
Weinhouse: “at present the whole concep  on of cancer ini  a  on or survival by “faulty” 
respira  on and high glycolysis seems too simplis  c for serious considera  on” and “it has 
led far too many researchers into dead-end avenues of fruitless, ill-conceived a  empts at 
the understanding or treatment of the neoplas  c process”)[243]. With the discovery of 
gene  c mechanisms and environmental factors as causes of cancer, Warburg’s hypothesis 
on the origin of cancer faded to the background, much to the dismay of its discoverer, who 
in 1956 even stated: “…there is today no other explana  on for the origin of cancer cells, 
either special or general. From this point of view, muta  on and carcinogenic agents are 
not alterna  ves, but empty words, unless metabolically specifi ed. Even more harmful in 
the struggle against cancer can be the con  nual discovery of miscellaneous cancer agents 
and cancer viruses, which, by obscuring the underlying phenomena, may hinder necessary 
preven  ve measures and thereby become responsible for cancer cases”[242]. Warburg 
died in 1970, at a  me when his hypothesis was largely replaced by the idea that cancer 
was caused by abnormali  es in genes and gene expression, not metabolism.
Although nowadays it is widely accepted that mitochondrial dysfunc  on is not the ‘only one 
prime cause of cancer’, as Warburg stated, it is also recognized that a high rate of glycolysis 
is a feature of many cancer types, a characteris  c that today is exploited by the FDG-PET 
imaging of tumors (see paragraph 2.1: ‘paragangliomas of the head and neck’). Indeed, in 
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the 2011 revision of their infl uen  al publica  on ‘The hallmarks of cancer’, Hanahan and 
Weinberg acknowledge the ability of cancer cells to reprogram energy metabolism as an 
‘emerging hallmark of cancer’[185,217]. What is more, the iden  fi ca  on of defects in the 
mitochondrial SDH as a cause of paragangliomas and pheochromocytomas, as well as the 
iden  fi ca  on in 2002 of defects in fumarate hydratase (FH), another TCA cycle component, 
as a cause of leiomyoma, leiomyosarcoma, and clear cell renal carcinoma, have confi rmed 
Warburg’s’ hypothesis that defects in the cellular metabolism can actually ini  ate tumor 
growth. These discoveries have contributed to the revival of the scien  fi c interest in the 
role of the metabolism in the neoplas  c cell, both as a possible cause of cancer as well as 
a poten  al therapeu  c target, just as Warburg envisioned[176,177,185,197,244]. 
 
O  o Warburg (1883-1970)
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6. Outline of the thesis
The aim of this thesis is to gain insight in the gene  cs, inheritance and tumor biology of 
head and neck paragangliomas and the clinical consequences for paraganglioma pa  ents, 
with a focus on hereditary paraganglioma syndrome in the Netherlands. 
Chapter one consists of a general introduc  on into the current insights in head and neck 
paragangliomas, the diagnosis and treatment, the causa  ve genes and their phenotypes, 
the heredity of paraganglioma syndromes, and an a  empt is made to link gene muta  ons 
to tumor forma  on and behavior through the molecular biology of paragangliomas. 
In chapter two, the current insights in the gene  cs of paragangliomas are reviewed, with 
an emphasis on the most recent developments. 
In chapter three, the muta  on frequency of SDH genes in the Netherlands is analyzed, 
using the data acquired by the Department of Human Gene  cs and the Laboratory for 
DNA Diagnos  cs of the LUMC, the primary Dutch na  onal referral center for SDH muta  on 
scanning. Using this SDH muta  on database we evaluate the rela  ve role of each of the 
SDH genes in the Dutch paraganglioma and pheochromocytoma popula  on and the 
contribu  on of Dutch SDH founder muta  ons.
In chapter four, the clinical characteris  cs of Dutch head and neck paraganglioma pa  ents 
treated at the Leiden University Medical Center (LUMC) are evaluated and correlated to 
their gene muta  on status. It describes the unusual gene  c make-up of the Dutch head 
and neck paraganglioma popula  on and the consequences for the clinical characteris  cs 
of paraganglioma syndrome in the Netherlands.
In chapter fi ve, the phenotype of the SDHD.D92Y (Asp92Tyr) Dutch founder muta  on, 
the most prominent cause of paraganglioma syndrome in the Netherlands, is studied in a 
large mul  genera  onal paraganglioma family, with a focus on the penetrance and the risk 
of developing symptoma  c disease. 
In chapter six, gene expression of SDHAF2- (formerly known as the PGL2 locus) and SDHD-
linked paragangliomas as well as sporadic head and neck paragangliomas is inves  gated 
using RNA-microarrays, a high-throughput gene expression profi ling technique. An a  empt 
is made to dis  nguish these gene  c subgroups on the basis of their gene expression 
profi le and to link muta  ons in SDHD and SDHAF2 to specifi c tumorigenic pathways. 
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In chapter seven, the unusual parent-of-origin-dependent inheritance that is observed in 
SDHD-linked paraganglioma kindreds is further inves  gated. A hypothesis is put forward 
that explains the exclusive paternal transmission of paragangliomas in SDHD-linked 
families, a pa  ern consistent with maternal imprin  ng, in the absence of imprin  ng of 
the SDHD gene itself.
Chapter eight consist of a summary of the thesis, its general implica  ons for head and neck 





FAD fl avin-adenine-dinucleo  de, cofactor of SDHA
HO-2 hemoxygenase 2
HIF hypoxia inducible factor
HRCT high resolu  on computed tomography
KIF1B kinesin family member 1B
LOH loss of heterozygosity
MAPK mitogen-ac  vated protein kinase
MEN mul  ple endocrine neoplasia
MRI magne  c resonance imaging
mTOR mammalian target of rapamycin
NF1 neurofi bromatosis type 1, may also refer to neurofi bromin 1 gene or protein
NOS nitric oxide synthetase
PET positron emission tomography
PHD prolyl hydroxylase
RET proto-oncogene (REarranged during Transfec  on)
ROS reac  ve oxygen species
SDH succinate dehydrogenase; complex II in the electron transport chain
SDHA succinate dehydrogenase subunit A; cataly  c fl avoprotein subunit of SDH
SDHAF2 succinate dehydrogenase assembly factor 2; factor in the fl avina  on of SDHA
SDHB succinate dehydrogenase subunit B; cataly  c iron sulphur subunit of SDH
SDHC succinate dehydrogenase subunit C; anchoring subunit of SDH
SDHD succinate dehydrogenase subunit D; anchoring subunit of SDH
TCA tricarboxylic acid (cycle), or Krebs cycle
TMEM127 transmembrane protein 127, may refer to gene or protein
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The last 10 years have seen enormous progress in the fi eld of paraganglioma and 
pheochromocytoma gene  cs. The iden  fi ca  on of the fi rst gene related to paraganglioma, 
SDHD, encoding a subunit of mitochondrial succinate dehydrogenase (SDH), was quickly 
followed by the iden  fi ca  on of muta  ons in SDHC and SDHB. Very recently several new 
SDH-related genes have been discovered. The SDHAF2 gene encodes an SDH co-factor 
related to the func  on of the SDHA subunit, and is currently exclusively associated with 
head and neck paragangliomas. SDHA itself has now also been iden  fi ed as a paraganglioma 
gene, with the recent iden  fi ca  on of the fi rst muta  on in a pa  ent with extra-adrenal 
paraganglioma. Another SDH-related co-factor, SDHAF1, is not currently known to be a 
tumor suppressor, but may shed some light on the mechanisms of tumorigenesis. An 
en  rely novel gene associated with adrenal pheochromocytoma, TMEM127, suggests 
that other new paraganglioma suscep  bility genes may await discovery. In addi  on to 
these recent discoveries, new techniques related to muta  on analysis, including gene  c 
analysis algorithms, SDHB immunohistochemistry, and dele  on analysis by MLPA have 
improved the effi  ciency and accuracy of gene  c analysis. However, many intriguing 
ques  ons remain, such as the striking diff erences in the clinical phenotype of genes that 
encode proteins with an apparently very close func  onal rela  onship, and the lack of 
expression of SDHD and SDHAF2 muta  ons when inherited via the maternal line. Li  le is 
s  ll known of the origins and causes of truly sporadic tumors, and the role of oxygen in the 
rela  onships between high al  tude, familial and truly sporadic paragangliomas remains 
to be elucidated. 
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Introduc  on
Prior to the year 2000, knowledge of the gene  cs of paraganglioma and pheochromocytoma 
was confi ned to muta  ons of the VHL, RET and NF1 genes. The iden  fi ca  on of 
muta  ons in the succinate dehydrogenase subunit D gene (SDHD) in pa  ents with head 
and neck paraganglioma was therefore a major breakthrough[1]. The associa  on of 
paraganglioma with muta  ons in SDHD, and later with muta  ons in other SDH subunits, 
has helped elucidate both the role of the mitochondrial SDH complex and intermediary 
metabolism in tumorigenesis. The subsequent discovery of SDH muta  ons in pa  ents 
with pheochromocytomas and extra-adrenal paragangliomas led to a recogni  on that 
paragangliomas and pheochromocytomas share not only similar cellular origins, but can 
also have a comparable gene  c basis[2]. 
Paragangliomas of the head and neck are generally benign tumors that arise in the 
paraganglion  ssue associated with the autonomic nervous system. Paragangliomas 
most frequently arise in the head and neck region, as caro  d body tumors in the caro  d 
bifurca  on (approximately 80%). Other frequently seen loca  ons within the head and 
neck region are along the jugular bulb or tympanic nerve (17.5%), or the paraganglia 
along the vagal nerve (4.5%)[3]. 
Pheochromocytomas and extra-adrenal paragangliomas are tumors associated with the 
sympathe  c nervous system, are commonly described as sympathe  c paragangliomas 
(sPGLs), and show a close embryological and physiological rela  onship to head and neck 
paragangliomas. They are most commonly derived from the chromaffi  n cells of the adrenal 
medulla (pheochromocytoma). Approximately 10-20% occur elsewhere in the abdomen, 
but they can occur in any of the sympathe  c paraganglia from the neck to the pelvic 
fl oor[4]. Extra-adrenal sympathe  c paragangliomas show a greater degree of malignancy 
than either pheochromocytomas or head and neck paragangliomas[5].
Here we discuss recent advances in the understanding of the gene  c basis of both head 
and neck paragangliomas and pheochromocytomas, and further developments relevant 
to the gene  c diagnosis of these tumors. 
Gene  cs
Presently, causa  ve gene muta  ons can be iden  fi ed in around 32% of paraganglioma 
pheochromocytomas[6]. Hereditary tumor syndromes which have pheochromocytoma 
within their spectrum include the mul  ple endocrine neoplasia syndromes, MEN2A and 
MEN2B, caused by muta  ons of the RET (Rearranged in Transfec  on) proto-oncogene, 
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subtypes of von Hippel-Lindau (VHL) disease, caused by muta  ons of the VHL tumor 
suppressor gene, and neurofi bromatosis type 1 (NF1) resul  ng from muta  ons of the NF1 
tumor suppressor gene[7]. These syndromes account for around 17% of cases but are 
rarely associated with head and neck or extra-adrenal paragangliomas[6]. 
More recently, muta  ons in genes associated with the mitochondrial succinate 
dehydrogenase (SDH) complex (SDHA, SDHB, SDHC, SDHD and SDHAF2) have been 
shown to cause head and neck paragangliomas, extra-adrenal paragangliomas, and 
pheochromocytomas (Table 1)[1,2,8-11]. These genes account for the remaining 15% of 
cases[6]. All of these genes are tumor suppressors, showing loss of heterozygosity (LOH), 
the loss of the normal allele in the tumor, in conjunc  on with the germline muta  on. 
This results in loss of a protein subunit, which in turn destabilizes the SDH complex and 
abolishes its enzyma  c ac  vity[12]. 
Succinate dehydrogenase is an enzyme of the mitochondrial tricarboxylic acid cycle, and 
also plays an important role as the complex II component of the electron transport chain, 
contribu  ng to the genera  on of ATP by oxida  ve phosphoryla  on. These combined roles 
place SDH at the center of two of the essen  al energy producing processes of the cell. 
SDHA, a fl avoprotein, and SDHB, an iron-sulfur protein, together form the main cataly  c 
domain, while SDHC and SDHD are the membrane-anchoring subunits of SDH and play 
a role in passing electrons through the electron transport chain. Despite the fact that 
SDH proteins are all components of the same protein complex, muta  ons lead to clear 
diff erences in clinical phenotype. The molecular basis for this clinical divergence is not 
currently known. 
SDHD
Researchers in the Netherlands were the fi rst to successfully tackle the gene  cs of 
head and neck paraganglioma and they were greatly assisted by the unusual social and 
demographic history of the country[13-18]. Un  l rela  vely recently, the Netherlands was 
characterized by signifi cant religious, social, and geographic obstacles to intermarriage, 
leading to the crea  on of many gene  cally isolated popula  ons[19]. Such popula  ons 
facilitate the prolifera  on of founder muta  ons, one of them being the well-known Dutch 
SDHD founder muta  on, p.Asp92Tyr[20]. The increased prevalence of this and other 
SDHD founder muta  ons, rela  ve to SDHB muta  ons, facilitated the ini  al mapping of 
the SDHD locus[13,14]. 
The subsequent iden  fi ca  on of the gene in 2000 represented a signifi cant discovery as 
it was the fi rst  me that a mitochondrial protein was shown to be a tumor suppressor[1]. 
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It was also the fi rst protein with a role in intermediary metabolism to be directly linked 
to tumorigenesis. Muta  ons in SDHD most frequently result in benign head and neck 
paragangliomas and are much less commonly associated with sympathe  c paragangliomas 
and adrenal pheochromocytomas[21]. The propor  on of SDHD muta  on carriers that will 
develop a tumor (penetrance) is high (87-100%), although not all carriers with a tumor 
will develop addi  onal tumor-related symptoms[22,23]. 
SDHB
The iden  fi ca  on of muta  ons in SDHD as a cause of hereditary paraganglioma syndrome 
quickly led to the discovery of the role of other SDH subunits. SDHB plays a major role in 
hereditary paraganglioma syndrome, and is now known to be a signifi cant cause of adrenal 
pheochromocytomas, but is chiefl y associated with extra-adrenal paragangliomas[2,6]. 
Since its discovery, SDHB has been found to be the dominant gene in hereditary 
paraganglioma syndrome in many parts of the world, despite a rela  vely low penetrance 
of SDHB muta  ons of 25-40%[24-26]. Due to their lower penetrance, SDHB muta  ons are 
o  en found in apparently sporadic pa  ents[27]. SDHB muta  ons primarily predispose to 
sPGLs, and around 20% of SDHB muta  on carriers will develop metasta  c disease[5,6]. 
SDHC
SDHC was the second SDH subunit gene iden  fi ed as a cause of paragangliomas[11]. 
Paragangliomas due to muta  ons in SDHC are much rarer than SDHB- and SDHD-related 
paragangliomas, accoun  ng for less than 1% of all pa  ents in a recent study[6]. SDHC 
muta  ons result primarily in head and neck paragangliomas, but have also been iden  fi ed 
in pa  ents with sympathe  c paragangliomas[28,29]. 
SDHAF2
While the role of the SDHB, SDHC and SDHD genes in paraganglioma/pheochromocytoma 
has been known for a number of years, several novel SDH-related genes have only been 
iden  fi ed very recently. The fi rst was a gene encoding a novel protein involved in the 
addi  on of the fl avin-adenine dinucleo  de (FAD) prosthe  c group to form the ac  ve SDHA 
fl avoprotein[10]. While the approximate loca  on of this paraganglioma-associated gene 
had been known for over a decade, referred to as PGL2 locus, a yeast screen of respira  on 
defi cient mutants facilitated the fortuitous discovery of a conserved mitochondrial 
protein of unknown func  on that physically associated with the SDHA fl avoprotein[15,16]. 
Ini  ally named SDH5, the succinate dehydrogenase complex assembly factor 2 (SDHAF2) 
was shown to be essen  al for the correct fl avina  on of SDHA and func  on of the SDH 
complex. The c.232G>A (p.Gly78Arg) missense muta  on in SDHAF2, iden  fi ed in a large 
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Dutch head and neck paraganglioma kindred, results in the loss of SDHA fl avina  on and 
ac  vity of the SDH complex[10]. 
In a follow-up study with the joint aims of iden  fying new muta  on carriers and assessing 
the frequency of SDHAF2 muta  ons amongst 443 paraganglioma and pheochromocytoma 
pa  ents, it became clear that muta  ons in this gene make a very modest contribu  on 
to the overall gene  c burden in these syndromes[8]. No muta  ons of SDHAF2 were 
iden  fi ed in any pa  ent with a pheochromocytoma, and all currently aff ected muta  on 
carriers have head and neck paraganglioma exclusively. Only one addi  onal SDHAF2 
related family was iden  fi ed, which interes  ngly carried the exact muta  on, p.Gly78Arg, 
previously found in the Netherlands, but without evidence of a familial rela  onship to 
the Dutch kindred[8]. Although apparently a simple loss of func  on muta  on in yeast, 
the recurrence of this muta  on and absence of other muta  ons may suggest that the 
SDHAF2 protein with the specifi c p.Gly78Arg muta  on retains residual ac  vity, allowing 
the protein to par  cipate in other, currently unknown, cellular ac  vi  es, most feasibly the 
addi  on of FAD prosthe  c groups to other fl avoproteins[8,10,30]. 
A striking aspect of SDHAF2 muta  ons, and the probable explana  on for the rapid 
iden  fi ca  on of all muta  on carriers, is the very high penetrance. Of the 42 iden  fi ed 
muta  on carriers thought to be at risk, 37 are known to have developed a tumor. All 
currently unaff ected muta  on carriers are under the age of 45. This level of penetrance 
will usually lead to a familial presenta  on and such families will have already come to 
the a  en  on of clinicians. Seven muta  on carriers are known to have inherited the 
muta  on via the maternal line, and are not thought to be at risk of tumor development 
(see ‘‘Inheritance’’ below). 
The studies above suggest that SDHAF2 muta  on screening should only be considered in 
pa  ents who suff er exclusively from head and neck paragangliomas, who have familial 
antecedents, mul  ple tumors, or a very young age of onset, and in whom the SDHB, 
SDHC and SDHD genes have been shown to be nega  ve for muta  ons and dele  ons by 
sequencing and mul  plex liga  on-dependent probe amplifi ca  on (MLPA).
SDHA
The iden  fi ca  on of SDHAF2 as a paraganglioma-related tumor suppressor that interacts 
with SDHA was unexpected, as SDHA itself was the only SDH subunit not known to 
be mutated in paraganglioma cases. SDHA is the largest gene and protein of the SDH 
complex and is the major cataly  c subunit of the enzyme. For 10 years following the 
discovery of SDHD, it remained a mystery why no muta  ons of SDHA could be found in 
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paraganglioma pa  ents, a mystery which deepened with the iden  fi ca  on of SDHAF2 as 
a paraganglioma related tumor suppressor gene. Recently the fi rst SDHA muta  on was 
reported, (c.1765C>T, p.Arg589Trp-exon 13) in a pa  ent with a catecholamine secre  ng 
extra-adrenal paraganglioma[9]. This pa  ent had no family history of paraganglioma or 
any related endocrine syndrome. 
It remains unclear why SDHA muta  ons in paragangliomas are so rare, but the pa  ent 
above may suggest that SDHA muta  ons show reduced penetrance and most muta  on 
carriers escape the development of clinical symptoms. Equally, and as suggested above 
for SDHAF2, the scarcity of SDHA muta  ons could be a  ributable to a secondary cellular 
func  on of SDHA, leading to intolerance for missense and trunca  ng muta  ons that 
eliminate all enzyme ac  vity. 
The most stable of the SDH proteins when soluble, SDHA has been reported to be a 
component of a mitochondrial ATP-sensi  ve potassium channel[31]. While SDHB also 
seemed to be involved in this complex, the main protein interac  on was between SDHA 
and the mitochondrial ATP-binding casse  e protein 1 (mABC1), and the complex could 
be inhibited by 3-nitropropionate (NPA), a specifi c inhibitor of SDHA[32]. Whether the 
maintenance of this complex is essen  al to cell viability remains to be determined.
Alterna  vely, if we assume that an LOH event which deletes the remaining normal allele 
is required for tumorigenesis, loss of essen  al genes in the proximity of SDHA may not be 
tolerated, or other local genomic factors may be preven  ng the secondary LOH event. An 
exact molecular descrip  on of the LOH event in the case described by Burnichon et al. and 
in any subsequent cases may provide useful insights[9]. 
A few rare cases of congenital SDHA defi ciency due to homozygous recessive muta  ons 
are known[33-35]. While the pa  ents themselves tend to be severely aff ected by 
developmental abnormali  es or cardiomyopathy early in life, due to mitochondrial 
defi ciency, the heterozygous parents of these pa  ents have never been reported to 
develop paraganglioma, perhaps sugges  ng that LOH events are indeed rare in conjunc  on 
with muta  ons of SDHA.
Muta  ons seen in these pa  ents are generally missense and the only known trunca  ng 
muta  on in a pa  ent was found together with a missense muta  on on the opposing allele 
sugges  ng that complete loss of SDHA func  on may not be compa  ble with life[36].
Whether the pa  ent described by Burnichon et al. will prove to be fi rst of many 
paraganglioma cases related to SDHA muta  ons is presently unclear[9]. The current 
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signifi cance of SDHA in the clinical management of paraganglioma-pheochromocytoma is 
minimal, but this may change if future studies iden  fy addi  onal muta  on carriers. 
SDHAF1
The iden  fi ca  on of SDHAF2 as a paraganglioma gene underlines the curious fact that 
another recently iden  fi ed gene is not currently known to be involved in paraganglioma, 
but may nevertheless further our understanding of the role of SDH in paraganglioma 
forma  on. Succinate dehydrogenase complex assembly factor 1 (SDHAF1) is a novel 
LYR-mo  f protein; the fi rst SDH assembly factor iden  fi ed in any organism, and is 
located within the mitochondrial matrix[37]. Iden  fi ed in consanguineous families of 
Turkish and Italian origin, homozygous muta  ons of the SDHAF1 gene result in infan  le 
leukoencephalopathy in aff ected children, and symptoms include rapidly progressive 
psychomotor regression beginning in the fi rst year of life, reminiscent of the clinical 
symptoms seen in homozygous SDHA muta  ons carriers[38]. Pa  ents show defec  ve 
succinate dehydrogenase (complex II), with only 20-30% residual ac  vity in muscle and 
fi broblasts, and the accumula  on of lactate and succinate in the brain white ma  er. 
Disrup  on of the homologous gene or expression of the mutated gene in yeast caused 
SDH defi ciency and failure of oxida  ve phosphoryla  on-dependent growth. Because the 
LYR tripep  de mo  f found in SDHAF1 is also seen in several iron-related proteins and 
may be a signature for proteins involved in Fe-S metabolism, this protein may well be 
associated with the SDHB subunit. 
Loss of SDHB is currently thought to be central to tumorigenesis in paragangliomas, but 
none of the parents in SDHAF1 families, who are heterozygous muta  on carriers, have 
been reported to develop paragangliomas[39]. The explana  on for the lack of tumor 
development in these muta  on carriers and heterozygous SDHA muta  on carriers may 
lie in the biochemical ac  vity of SDH-complex II. SDHA homozygous muta  on carriers 
generally show reten  on of complex II ac  vity of at least 20% (range 20-61%), and 
likewise, homozygous SDHAF1 muta  on carriers show 20-30% residual ac  vity[33,35]. In 
contrast, SDH related tumors, including those related to SDHD, SDHB, SDHA and SDHAF2 
carry an inac  va  ng muta  on which, combined with the loss of the wild type allele (LOH), 
results in almost complete loss of ac  vity[9,12,40]. As SDHAF1 and most SDHA muta  ons 
do not eliminate all enzyme func  on, even allowing for LOH in a specifi c cell, a residual 
ac  vity of 10-30% is apparently suffi  cient to prevent the development of paragangliomas. 
A further interes  ng aspect of the biochemical profi le of SDHAF1 and SDHA muta  on 
carriers is the accumula  on of succinate. In both cases succinate will accumulate and can 
lead to the nuclear transloca  on of hypoxia-inducible factor 1 (HIF-1)[37,41]. The nuclear 
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transloca  on of HIF-1 may be an important mechanism in triggering tumorigenesis in 
paraganglioma progenitor cells, but its occurrence in SDHAF1 and SDHA muta  on carriers 
may suggest that complete loss of SDH ac  vity is required to achieve levels of succinate 
accumula  on suffi  cient to drive HIF-1 transloca  on to the extent needed to ini  ate 
tumorigenesis[42,43]. For a detailed discussion of these and other recent developments 
in the understanding of the molecular basis of tumorigenesis, we refer readers to a recent 
review[43]. 
Although none of the heterozygous muta  on carriers in SDHAF1 families currently seem 
suscep  ble to the development of paragangliomas-pheochromocytomas, the recent 
example of SDHA emphasizes that no SDH-related gene can be en  rely excluded when 
one is considering the gene  cs of these tumors[9].
TMEM127
In addi  on to the recently reported genes related to succinate dehydrogenase, a 
novel tumor suppressor gene associated with a clinical phenotype of exclusively 
adrenal pheochromocytoma has also been described[44]. The gene encodes a puta  ve 
transmembrane protein, TMEM127, and is found on chromosome 2q11. TMEM127 is a 
highly conserved and broadly expressed protein with three transmembrane regions, but 
has no known func  onal domains. Transfec  on experiments showed that the protein is 
found in both the plasma membrane and the cytoplasm, and suggested that TMEM127 
may par  cipate in protein traffi  cking between the plasma membrane, golgi and lysosomes.
Previous gene expression studies have indicated that pheochromocytomas fall into two 
broad categories based on the transcrip  onal profi le, which may translate to the molecular 
pathways leading to tumorigenesis[45]. SDH and VHL associated tumors show a signature 
of angiogenesis, hypoxia, enhanced expression of the extracellular matrix, and reduced 
expression of components of the oxida  ve response and tricarboxylic cycle. Tumors linked 
to NF1 or RET muta  ons show an upregula  on of biological pathways including genes 
that mediate transla  on ini  a  on, protein synthesis, and kinase signaling, and are both 
associated with the RAS/RAF/MAP kinase signaling pathway[45]. 
TMEM127-related pheochromocytomas show a transcrip  onal profi le similar to NF1 and 
RET related tumors[44]. However, neither RAS ac  va  on nor AKT phosphoryla  on was 
seen, indica  ng that TMEM127 loss is not iden  cal to either NF1 or RET. The authors focused 
on the mammalian target of rapamycin (mTOR), which is deregulated on loss of NF1, and 
could show that the C1 mTOR complex is specifi cally aff ected by TMEM127 knockdown, 
leading to increased phosphoryla  on of targets of mTORC1. Knockdown of TMEM127 also 
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resulted in larger cells with higher rates of prolifera  on. Pheochromocytomas carrying a 
TMEM127 muta  on showed hyperphosphoryla  on of mTOR eff ector proteins, all these 
data together indica  ng that TMEM127 is a nega  ve regulator of mTOR. 
The authors were able to iden  fy muta  ons in 4 out of 12 families without known 
muta  ons in other suscep  bility genes, and in 3 of 83 apparently sporadic pa  ents. Of 
the seven dis  nct germline muta  ons iden  fi ed, six were trunca  ng, and the dele  on of 
the wild-type allele in tumor DNA indicates that this is a bone fi de tumor suppressor gene. 
The iden  fi ca  on of TMEM127 underlines that there are several pathways that can lead to 
adrenal, extra-adrenal, and head and neck paragangliomas. Whether there are important 
links between the essen  al molecular pathways of NF1, RET, and TMEM127 on the one 
hand and the VHL and SDH-related proteins on the other, is presently unclear, but hypoxia 
can regulate both HIF-1 and mTORC1, perhaps related to expression of BCL2/Adenovirus 
E1B 19-KD protein-interac  ng protein 3 (BNIP3)[46,47]. As each of these genes is 
associated with pa  erns of biological and clinical expression that are not yet understood, 
it is clear that we are only at the beginnings of our knowledge of these syndromes. 
Inheritance
Inheritance of paraganglioma syndrome diff ers signifi cantly dependent on the gene 
involved. While SDHB- and SDHC-linked paraganglioma families show normal autosomal 
dominant inheritance, SDHD- and SDHAF2-linked families show an exclusively paternal 
transmission of tumor suscep  bility[10,18]. The recogni  on of this phenomenon was made 
possible by the same social and demographic factors in the Netherlands that facilitated 
the ini  al mapping of the SDHD locus, and specifi cally by the increased prevalence of 
SDHD muta  ons, rela  ve to SDHB muta  ons. Although muta  ons in SDHD and SDHAF2 
can be inherited via the maternal and paternal lines, tumor forma  on following maternal 
transmission of a muta  on is extremely rare[18,48]. 
The failure of maternally transmi  ed muta  ons to ini  ate tumorigenesis ini  ally suggested 
that an imprinted gene expressed only from the paternal allele could be the underlying 
cause of the tumor[18]. The subsequent iden  fi ca  on of SDHD, with its central role in cell 
biology, called this assump  on into ques  on. It was also established that the gene does not 
show mono-allelic expression, at least in the  ssues analyzed to date[1,49]. The concept 
of gene expression of SDHD exclusively from the paternal allele is also contradicted by the 
normal development of muta  on carriers with a paternally inherited muta  on. 
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The addi  onal occurrence of this phenomenon in paraganglioma families linked to 
SDHAF2, (like SDHD, located on chromosome 11), while it is absent in SDHB- and SDHC-
related tumors (both genes located on chromosome 1), suggested that chromosomal 
loca  on could be a factor in SDHD- and SDHAF2-related tumors. 
It is known that the en  re maternal copy of chromosome 11 is lost in many para-
gangliomas[49-51]. Although SDHD and SDHAF2 themselves seem not to be imprinted, 
the main cluster of imprinted genes in the human genome is located on the same 
chromosome, at 11p15.5. This suggests a model in which a maternally expressed, 
paternally imprinted gene is an essen  al ini  ator or modifi er of tumor development in 
these syndromes[48,49]. Indeed, the only report to date that has claimed to show the 
maternal transmission of tumor suscep  bly together with an SDHD muta  on showed that 
the pa  ent had also acquired an altered methyla  on profi le and therefore probably an 
altered imprinted status of H19, a known paternally imprinted tumor suppressor gene on 
11p15[48,52]. In addi  on, it is known that VHL-related pheochromocytoma also show loss 
of the maternal copy of the chromosome 11p15.5 region specifi cally, indica  ng that this 
model may have wider importance[53,54]. 
High al  tude paraganglioma 
Long before the iden  fi ca  on of any of the genes now known to play a role in para-
ganglioma, it was recognized that living at high al  tude can have a profound infl uence on 
the development of caro  d body hyperplasia and caro  d body tumors[55-57]. A number 
of mammalian species are known to develop pronounced hyperplasia or tumors with a 
prevalence of up to 10% in humans and up to 40% in bovines, in contrast to an es  mated 
low al  tude prevalence of head and neck paraganglioma of 1 in 500,000 or less[58,59].
This increased prevalence and the central role of the caro  d body in oxygen sensing 
suggested a role for oxygen sensing in the tumorigenesis of paragangliomas. The 
iden  fi ca  on of succinate dehydrogenase and subsequent molecular studies has affi  rmed 
this link. A number of studies have linked the central mediator of cellular hypoxia, HIF-
1, to defects in succinate dehydrogenase[60]. These studies postulate that a so-called 
‘pseudohypoxia’ results from the inhibi  on of succinate dehydrogenase, leading to the 
accumula  on of succinate, resul  ng in the ac  va  on of HIF-1 through the inhibi  on of 
prolyl hydroxylase-mediated degrada  on[42,61]. The HIF-1 transcrip  on factor complex 
ini  ates the transcrip  on of a range of genes that mediate an adap  ve response to 
reduced oxygen[62]. How the ac  va  on of the HIF-1 protein may lead to the ini  a  on 
of tumorigenesis in the caro  d body and the exact rela  on of physiological hypoxia to 
molecular ‘pseudo-hypoxia’ awaits further inves  ga  on. Despite this sugges  ve link, 
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the possible role of succinate dehydrogenase muta  ons in high al  tude paraganglioma 
cases has received li  le a  en  on and the fi rst gene  c analysis failed to iden  fy any 
muta  ons[63]. Recently, Cerecer-Gil et al. iden  fi ed a family with two SDHB-linked cases 
of high al  tude paraganglioma, residing at eleva  ons of up to 2,200 m[64]. These are the 
fi rst cases to link high al  tude paraganglioma to muta  ons of the succinate dehydrogenase 
genes. While the occurrence of paraganglioma in this family could be purely coincidental 
to their place of residence, two factors indicated that eleva  on may be playing a role in 
the expression off  these tumors. One of the pa  ents showed a remarkably aggressive 
recurrent tumor, which achieved a volume almost equivalent to the original tumor 
within 2 months of excision. This behavior is in sharp contrast with the indolent growth 
pa  ern normally seen in head and neck paragangliomas, with a mean doubling rate of 4.2 
years[65]. In addi  on, both pa  ents developed head and neck tumors, while abdominal 
tumors occur much more frequently in SDHB muta  on carriers. The iden  fi ca  on of SDHB 
muta  ons in high al  tude paraganglioma may serve to renew interest in this fascina  ng 
but underappreciated fi eld of paraganglioma research, and refocus a  en  on on the role 
of oxygen levels in the ini  a  on and development of these tumors. 
New strategies in muta  on analysis
The importance of the SDH-related genes in paraganglioma-pheochromocytoma has led to 
extensive gene  c screening of pa  ents, even in the absence of clear familial antecedents. 
In pa  ents with pheochromocytomas, in addi  on to the SDH genes, the RET and VHL 
genes should also be screened. The costs involved in analyzing all of these genes can be 
considerable, and are increasing with each new gene iden  fi ed. Eff orts have been made 
to use clinical data to derive algorithms to guide ra  onal gene  c tes  ng, with the aims of 
effi  ciency and cost reduc  on[6,21,66]. Perhaps the most comprehensive of these is that 
proposed by Mannelli et al., but even this is now in need of upda  ng[6]. Such algorithms 
are now widely used and assist the rapid iden  fi ca  on of muta  on carriers, but many 
pa  ents may provide few useful clinical parameters, or may not conform to the rather 
broad criteria of these algorithms. 
Muta  on analysis is generally carried out using DNA sequencing, but this technique 
can rarely detect large dele  ons. Both MLPA and similar mul  plex PCR methods have 
been applied in SDH dele  on analysis, and have led to the recogni  on that dele  ons can 
represent up to 10% of all muta  ons[67-69]. 
While algorithms have improved the effi  ciency of gene  c tes  ng, recently a supplementary 
approach has been developed with the use of SDHB immunohistochemistry. As 
originally noted by Douwes Dekker et al., paragangliomas show loss of staining for the 
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iron protein component of SDH, encoded by SDHB[12]. This fi nding was subsequently 
explored by van Nederveen et al. who showed that in a series of 220 paragangliomas and 
pheochromocytomas, 102 tumors with known muta  on of one of the SDH genes were 
nega  ve for SDHB staining while RET, VHL and NF1 cases were uniformly posi  ve[39]. 
Only 6 cases were found to be nega  ve and not explained by a known muta  on in one of 
the SDH genes. This translates to a sensi  vity of 95% (C.I. 87-100%) and specifi city of 84% 
(C.I. 60-97%). 
The u  lity of this approach was subsequently confi rmed in an independent series of 
tumors by Gill et al. and was also shown to be useful in iden  fying the gastrointes  nal 
stromal tumor (GIST) component of the Carney triad (CT)[70,71]. Showing that a GIST is a 
legi  mate cons  tuent of this tumor syndrome would poten  ally allow earlier diagnosis, 
when compared to current methods which focus on clinical criteria and require the co-
occurrence of paraganglioma and pulmonary chondroma. These authors also showed that 
some cases of apparently sporadic GISTs also show loss of SDHB staining and propose that 
these represent a new subtype of GISTs. 
The development of a reliable SDHB immunohistochemical procedure and the demon-
stra  on that SDHB staining can accurately dis  nguish SDH-related cases from other groups 
represents an important advance, where tumor material is available. As head and neck 
paragangliomas are o  en not operated for a considerable period a  er ini  al diagnosis, 
while most pheochromocytomas will be removed upon diagnosis, phaeochromocytomas 
represent the most useful group of tumors for the applica  on of this technique. 
Conclusion
The last 10 years have seen enormous progress in the fi eld of head and neck paraganglioma 
and pheochromocytoma gene  cs. Six new genes have been added to a list that previously 
included only VHL, RET and NF1, and the number of pa  ents in whom a gene muta  on can 
be iden  fi ed has doubled, and now stands at around 30-35%. New techniques related to 
muta  on analysis, including analysis algorithms, MLPA and SDHB immunohistochemistry, 
have improved the effi  ciency and accuracy of gene  c analysis. 
The iden  fi ca  on of muta  ons in SDHAF2 has revealed that proteins ancillary to succinate 
dehydrogenase can also be tumorigenic, and the belated iden  fi ca  on of a muta  on in 
SDHA in a paraganglioma pa  ent has demonstrated that no SDH-related gene can be 
83
Recent advances in paraganglioma gene  cs
en  rely excluded from considera  on when thinking about the gene  cs of these tumor 
syndromes.
Finally, the recent iden  fi ca  on of TMEM127 by Dahia et al. has shown that en  rely novel 
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High prevalence of founder muta  ons of the succinate dehydrogenase genes in the 
Netherlands.




Muta  ons in four genes encoding subunits or cofactors of succinate dehydrogenase (SDH) 
cause hereditary paraganglioma and pheochromocytoma syndromes. Muta  ons in SDHB 
and SDHD are generally the most common, whereas muta  ons in SDHC and SDHAF2 are 
far less frequently observed. A total of 1045 DNA samples from Dutch paraganglioma and 
pheochromocytoma pa  ents and their rela  ves were analyzed for muta  ons of SDHB, 
SDHC, SDHD or SDHAF2. Muta  ons in these genes were iden  fi ed in 690 cases, 239 of which 
were index cases. The vast majority of muta  on carriers had a muta  on in SDHD (87.1%). 
The second most commonly aff ected gene was SDHAF2 (6.7%). Muta  ons in SDHB were 
found in only 5.9% of samples, whereas SDHC muta  ons were found in 0.3% of samples. 
Remarkably, 69.1% of all carriers of a muta  on in an SDH gene in the Netherlands can be 
a  ributed to a single founder muta  on in SDHD, c.274G>T (p.Asp92Tyr). Moreover, 88.8% 
of all SDH muta  on carriers carry one of just six Dutch founder muta  ons in SDHB, SDHD 
and SDHAF2. The dominance of SDHD muta  ons is unique to the Netherlands, contras  ng 
with the higher prevalence of SDHB muta  ons found elsewhere. In addi  on, we found 
that most SDH muta  on-related paragangliomas-pheochromocytomas in the Netherlands 
can be explained by only six founder muta  ons in SDHAF2, SDHB and SDHD. The fi ndings 
underline the regional diff erences in the SDH muta  on spectrum, diff erences that should 
be taken into account in the development of eff ec  ve screening protocols. The results 
show the crucial role that demographic factors play in the frequency of gene muta  ons. 
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Introduc  on 
Muta  ons in genes encoding subunits or cofactors of succinate dehydrogenase (SDH), an 
enzyme complex bound to the inner membrane of the mitochondria, are an important 
cause of hereditary paraganglioma syndrome[1-3]. SDH plays an important dual role 
as complex II in the electron transport chain and as an enzyme of the tricarboxylic acid 
(TCA) cycle, catalyzing the oxida  on of succinate to fumarate. It consists of four subunits: 
a fl avoprotein (SDHA) and iron-sulphur protein (SDHB), which together make up the 
cataly  c domain, and SDHC and SDHD, both transmembrane proteins. In addi  on to the 
SDHB, SDHC and SDHD genes, an addi  onal SDH-related paraganglioma tumor suppressor 
was recently iden  fi ed[4]. An important cofactor in SDH stability and func  onality, 
SDHAF2 resides as a soluble protein within the mitochondrial matrix and plays a role in 
the a  achment of the fl avin adenine dinucleo  de (FAD) cofactor to SDH[5]. 
Hereditary paragangliomas in the Netherlands are frequently caused by muta  ons in the 
SDHD gene, but muta  ons in SDHAF2, SDHB and SDHC are also found[4,6-9]. Founder 
muta  ons in SDHD including the c.274G>T, p.Asp92Tyr muta  on and the c.416T>C, 
p.Leu139Pro muta  on play a major role in the prevalence of hereditary paraganglioma 
in the Netherlands[8]. More recently, two founder muta  ons in SDHB were iden  fi ed in 
Dutch paraganglioma and pheochromocytoma families[6,10]. The c.232G>A, p.Gly78Arg 
muta  on is the only SDHAF2 muta  on found in Dutch paraganglioma pa  ents, and all 
pa  ents share a common ancestor[4]. To date, no SDHC-linked paraganglioma families 
have been described in the Netherlands. 
In this study, we describe the frequency of muta  ons in SDHB, SDHC, SDHD or SDHAF2 
in 1045 paraganglioma and pheochromocytoma pa  ents and their rela  ves. The results 
were obtained from the Leiden University Medical Center (LUMC), a dedicated referral 
center for paragangliomas and the primary referral laboratory for SDH muta  on analysis 
in the Netherlands. As almost all Dutch paraganglioma pa  ent samples are analyzed here, 
the results represent the actual prevalence of muta  ons in genes encoding subunits of 
the SDH complex in the Netherlands. 
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Materials and methods 
Pa  ents
Peripheral blood leukocyte DNA samples were collected from pa  ents with paraganglioma 
and pheochromocytoma, and their rela  ves, from 1990 to 2009, at the Department 
of Human Gene  cs and the Laboratory for DNA Diagnos  cs of the LUMC, the primary 
na  onal referral center for SDH muta  on scanning. The majority of DNA samples from 
pa  ents and their rela  ves were sent for gene  c analysis only, with only summary clinical 
data. The reason for referral was diagnosis of ‘paraganglioma’, ‘pheochromocytoma’, 
‘chemodectoma’ or ‘glomus tumor’ in all cases. As the nomenclature of paragangliomas 
is not unequivocal and has changed over  me, exact data regarding tumor loca  on (i.e. 
head-and-neck region, adrenal medulla or extra-adrenal) are therefore unavailable for 
many pa  ents, and are not further discussed. Cases were considered to be familial if two 
or more aff ected individuals were iden  fi ed within the same kindred. An index case is 
defi ned as the ini  al pa  ent who presented with paraganglioma. 
Muta  on and dele  on screening 
The SDHB, SDHC, and SDHD genes were scanned for the presence of muta  ons from 2000 
to 2009. All exonic regions of these genes were tested by direct sequencing using the 
Sanger method on an ABI 377 Gene  c Analyzer, star  ng with the exons containing the 
known Dutch founder muta  ons in SDHD followed by exons that had previously been 
found to contain pathogenic muta  ons in SDHB, SDHC, and SDHD (in that order) in the 
Dutch popula  on. If this analysis was nega  ve, scanning was completed by analyzing the 
remaining exons of these genes. A  er the iden  fi ca  on of large founder muta  on-related 
families in the Netherlands, the current strategy is to scan the SDHB, SDHC, and SDHD 
genes as indicated by the clinical phenotype or as requested by the submi   ng clinician. 
In 2007, muta  on-nega  ve cases were retrospec  vely analyzed with mul  plex liga  on 
dependent probe amplifi ca  on (MLPA) for the presence of large dele  ons in SDHB, SDHC, 
and SDHD. MLPA has been carried out on all muta  on-nega  ve cases since then, using 
the P226 MLPA kit (MRC Holland, Amsterdam) containing probes for all exons and the 
promoter of each of these genes (27 diff erent probes), according to the manufacturer’s 
protocol. In cases with a nega  ve SDHB, SDHC and SDHD muta  on analysis, SDHAF2 was 
tested, as recently described[5]. Informed consent was obtained for DNA tes  ng according 
to protocols approved by LUMC Ethics Review Board.
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Results
A total of 1045 samples from paraganglioma and/or pheochromocytoma pa  ents and 
their rela  ves were analyzed for muta  ons in SDH-related genes. Muta  ons in SDHB, 
SDHC, SDHD or SDHAF2 were found in 690 cases, 239 of whom were index cases (Table 1). 
No muta  ons in SDH genes were found in 101 index cases and 254 family members of SDH 
muta  on carriers (Table 1). The majority of SDH muta  on carriers in the Netherlands carry 
a muta  on in SDHD (87.1%), followed by muta  ons in SDHAF2 (6.7%), SDHB(5.9%) and 
SDHC (0.3%). By far the most prevalent muta  on is the c.274G>T, p.Asp92Tyr muta  on in 
SDHD, accoun  ng for 69.1% of all SDH muta  on carriers (Figure 1). Altogether, 88.8% of 
the SDH muta  on carriers in the Netherlands carried one of six Dutch founder muta  ons 
in the SDHD, SDHB or SDHAF2 genes (Table 2 and Figure 1). 
A total of 340/1045 cases tested for SDH muta  ons were index cases. Muta  ons in SDHAF2, 
SDHB, SDHC or SDHD were iden  fi ed in 239/ 340 (70.2%) index cases, most frequently a 
muta  on in SDHD (62.1%; Table 1). The most prevalent muta  on among index cases was 
also the c.274G>T, p.Asp92Tyr muta  on in SDHD, accoun  ng for 157/239 index muta  on 
carriers (65.6%). 
Figure 1. Rela  ve frequencies of Dutch succinate dehydrogenase (SDH) founder muta  on carriers. 
The graph includes a total of 613 carriers of a founder muta  on in an SDH-related gene.
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Table 1. Muta  ons in SDHAF2, SDHB, SDHC, and SDHD. In total, 690 Dutch paraganglioma and 
pheochromocytoma pa  ents tested posi  ve for a muta  on in SDHAF2, SDHB, SDHC or SDHD, of 
which 239 are index cases. One muta  on was iden  fi ed in SDHAF2, 9 diff erent muta  ons in SDHB, 
2 muta  ons in SDHC and 16 muta  ons in SDHD. No SDH muta  ons were iden  fi ed in 254 family 
members of SDH muta  on carriers and 101 index cases.




SDHAF2 4 c.232G>A p.Gly78Arg 46 4
SDHB 2 c.136C>T p.Arg46X 3 2
2 c.141G>A p.Trp47X 1 1
3 c.201-4429_287-933del exon 3 dele  on 5 5
3 c.268C>T p.Arg90X 5 1
4 c.343C>T p.Arg115X 2 1
4 c.423+1G>A Splicesite 22 9
6 c.574T>C p.Cys192Arg 1 1
6 c.590C>G p.Pro197Arg 1 1
7 c.653G>C p.Trp218Ser 1 1
SDHC 4 c.214C>T p.Arg72Cys 1 1
5 and 6 c.242-241_510+1978del exon 5 and 6 dele  on 1 1
SDHD 1 and 2 c.1-8828_169+442 del exon 1 and 2 dele  on 1 1
2 c.112C>T p.Arg38X 8 1
2 c.120_121insC p.Glu42ArgfsX27 6 3
2 c.169_169+9 del TGTATGTTCT unknown 4 1
2 c.54_55dupC p.Leu19ProfsX50 8 1
2 c.64C>T p.Arg22X 3 1
3 c.181delG p.Ala61LeufsX25 2 1
3 c.208A>G p.Arg70Gly 1 1
3 c.209G>T p.Arg70Met 1 1
3 c.242C>T p.Pro81Leu 16 8
3 c.274G>T p.Asp92Tyr 477 157
3 c.279T>G p.Tyr93X 7 1
3 c.284T>C p.Leu95Pro 4 2
3 c.287dupC p.Ala97fs 1 1
4 c.337_340 del GACT p.Asp113Me  sX21 3 1
4 c.416T>C p.Leu139Pro 59 30
SDH, succinate dehydrogenase.
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Discussion
The majority of SDH muta  on carriers in the Netherlands harbor the c.274G>T, p.Asp92Tyr 
muta  on in SDHD. Several very large families residing in the western part of the Netherlands 
are known to carry this muta  on, all linked by a strong founder eff ect[12]. The second 
most widespread SDH muta  on in the Netherlands is the c.416T>C, p.Leu139Pro founder 
muta  on in SDHD, but this muta  on accounts for hardly more than 10% of the number 
of p.Asp92Tyr muta  on carriers, emphasizing the dominant role of the la  er muta  on. 
Compared with the high prevalence of SDHD muta  ons, SDHB muta  ons are far less 
common (87.1% vs. 5.9%), but the majority of SDHB muta  on carriers also harbor known 
founder muta  ons, specifi cally the intron 4 splice site muta  on, c.423+1G>A or the exon 
3 dele  on, c.201-4429_287-933del (6,9) (Tables 1 and 2). 
Table 2. Dutch founder muta  ons of the SDHAF2, SDHB and SDHD genes.
Gene DNA muta  on Protein muta  on References
SDHAF2 c.232G>A p.Gly78Arg Hao et al.[5] and Bayley et al.[4] 
SDHB c.423+1G>A Intron4 splicesite Hes et al.[10]
c.201-4429_287-933del exon 3 dele  on Bayley et al.[6]
SDHD c.274G>T p.Asp92Tyr Baysal et al.[2] and Taschner et al.[8]
c.284T>C p.Leu95Pro Dannenberg et al.[11] and Taschner et 
al.[8]
 c.416T>C p.Leu139Pro Cremers et al.[7], Dannenberg et al.[11] 
and Taschner et al.[8]
SDH, succinate dehydrogenase.
The diff erence in prevalence between SDHB and SDHD muta  on carriers may in part be 
a  ributable to the lower penetrance of SDHB muta  ons[10,13-15]. Despite their common 
forebears, most pa  ents with a Dutch founder muta  on in SDHB present without a family 
history of paraganglioma, sugges  ng that many more SDHB muta  on carriers await 
discovery[13-17]. 
We noted a remarkable 14-fold diff erence in the number of SDHD and SDHB muta  on 
carriers, and even taking only index cases into account, SDHD muta  on carriers s  ll 
predominate with a ra  o of around 10:1 (Table 1). None of the interna  onal studies 
that have reported varia  on in the rela  ve frequencies of SDHB and SDHD muta  ons 
in head-and-neck paraganglioma cases have described such a large diff erence. A recent 
large Italian study iden  fi ed a twofold higher prevalence of SDHD muta  ons[18], whereas 
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a broader European study showed an approximate 1:1 distribu  on of SDHB and SDHD 
muta  on carriers[14]. Other studies have shown a 2.7- to 4.5-fold higher frequency of 
SDHB muta  on carriers[13,15]. In general, SDHB muta  ons are more common than SDHD 
muta  ons, indica  ng that SDHB muta  on carriers in the Netherlands only appear to be 
scarce because of the higher prevalence of SDHD founder muta  ons. 
Haplotype studies of the most prevalent founder muta  ons have shown unequivocally 
that muta  on carriers share a common haplotype surrounding the muta  ons, and 
therefore share a common ancestor. The Dutch SDHD muta  on, p.Asp92Tyr, is es  mated 
to be 200-960 years old based on coalescence  me calcula  ons, and all known Dutch 
carriers of the SDHAF2 muta  on, p.Gly78Arg, share a common haplotype and have also 
been linked to a common ancestor[12,19]. 
In addi  on to muta  ons of SDHB and SDHD, we iden  fi ed 46 carriers of the 
c.232G>A, p.Gly78Arg muta  on in SDHAF2. Four large SDHAF2-linked paraganglioma 
families from the south-east Netherlands are now known to share a common ancestor, 
a male, born in 1771 and who married three  mes[20]. These families have remained 
largely in the same area and the p.Gly78Arg muta  on is a founder muta  on in the south-
east Netherlands, accoun  ng for a signifi cant propor  on of the paraganglioma cases seen 
in the region. 
Paraganglioma syndrome due to muta  ons in SDHC is extremely rare in the Netherlands. 
We have iden  fi ed only two SDHC muta  ons, c.242- 241_510+1978del and c.214C>T, in 
two pa  ents (0.3%). Like SDHB, SDHC muta  ons may have been under-reported because 
of the o  en sporadic-like presenta  on of SDHC-linked paraganglioma syndrome[3,21]. 
The remarkable prevalence of Dutch SDH founder muta  ons is most probably because of 
the unusual social and demographical history of the Netherlands. Un  l only a genera  on 
ago, Dutch society was highly segregated, primarily on the basis of religious diff erences. 
This segrega  on aff ected social, poli  cal and cultural life, and was further aided by socio-
economic, geographic, and linguis  c factors. These factors limited intermarriage un  l well 
into the twen  eth century, and led to the crea  on of gene  cally isolated popula  ons, 
facilita  ng the prolifera  on of Dutch founder muta  ons, both in SDHD and other disease 
genes[22]. The p.Asp92Tyr founder muta  on in SDHD shows a strong geographic focus 
even today[8,12]. 
Muta  ons of SDHB, SDHC, SDHD and SDHAF2 each result in dis  nct hereditary 
paraganglioma syndromes, with diff ering modes of inheritance, penetrance, risk 
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of pheochromocytoma, and risk of malignant paraganglioma, meaning that prior 
iden  fi ca  on of the aff ected gene is essen  al to provision of eff ec  ve gene  c counseling 
to the individual pa  ent[14,15,21]. Several algorithms priori  zing gene-specifi c 
muta  on tes  ng in paraganglioma pa  ents have been proposed, based on phenotypic 
characteris  cs, and with the dual objec  ves of minimizing muta  on screening and cost 
reduc  on[23,24]. Although these algorithms represent a useful star  ng point for gene  c 
analysis, it is doub  ul whether the eff ec  veness and outcome of such algorithms are 
universally applicable, as the a priori chance of fi nding a muta  on in a specifi c gene 
diff ers from country to country. Recogni  on of regional diff erences in the prevalence of 
muta  ons will allow the tailoring of gene  c screening on the basis of local knowledge. 
This study shows that the majority of muta  ons in SDH subunits or cofactors in the 
Netherlands involve SDHD, followed by SDHAF2, SDHB and SDHC, and the majority of 
muta  on carriers harbor the Dutch SDHD founder muta  on, p.Asp92Tyr. This fi nding is in 
stark contrast with the extensive gene  c heterogeneity found elsewhere and underlines 
the importance of regional diff erences in the muta  on spectrum of genes associated with 
hereditary paraganglioma syndrome. 
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Muta  ons in SDHD are the major determinants of the clinical characteris  cs of Dutch head 
and neck paraganglioma pa  ents.




Objec  ve. Head and neck paragangliomas (HNPGL) are associated with muta  ons in 
genes encoding subunits of succinate dehydrogenase (SDH). The aim of this study was 
to evaluate SDH muta  ons, family history and phenotypes of pa  ents with HNPGL in the 
Netherlands.
Design. We evaluated the clinical data and the muta  on status of 236 pa  ents referred 
between 1950 and 2009 to the Leiden University Medical Center.
Results. The large majority of the pa  ents carried muta  ons in SDHD (83%), and the 
p.Asp92Tyr Dutch founder muta  on in SDHD alone accounted for 72% of all pa  ents with 
HNPGL. A muta  on in SDHAF2 was found in 4%, muta  ons in SDHB in 3% and a muta  on 
in SDHC was iden  fi ed in a single pa  ent (0.4%). Over 80% of pa  ents presented with 
posi  ve family history, of whom 99.5% carried a muta  on in an SDH gene. SDH muta  ons 
were also found in 56% of isolated pa  ents, chiefl y in SDHD (46%), but also in SDHB 
(8%) and SDHC (2%). The clinical parameters of these diff erent subgroups are discussed: 
including the age at diagnosis, associated pheochromocytomas, tumor mul  focality and 
malignancy rate.
Conclusion. The majority of Dutch pa  ents with HNPGL present with a posi  ve family 
history, in contrast to other European countries. The clinical characteris  cs of pa  ents 
with HNPGL are chiefl y determined by founder muta  ons in SDHD, the major causa  ve 
gene in both familial and isolated pa  ents with HNPGL. The high frequency of founder 
muta  ons in SDHD suggests a higher absolute prevalence of paraganglioma syndrome in 
the Netherlands.
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Introduc  on
Paragangliomas are rare, slow-growing and usually benign tumors that arise in the 
paraganglion  ssue associated with the autonomic nervous system. Paragangliomas most 
frequently arise in the head and neck region, where they originate from the paraganglia 
in the bifurca  on of the caro  d artery, the jugular foramen, along the vagal nerve or 
along the tympanic nerve[1]. The closely related tumor, pheochromocytoma, may also 
arise in the adrenal medulla or less frequently in the extra-adrenal orthosympathe  c 
paraganglia of the abdomen or thorax where they are generally referred to as extra-
adrenal paragangliomas. Recent studies report a posi  ve family history in 10% to 20% of 
pa  ents with head and neck paraganglioma and indicate that family history can predict 
aspects of the clinical presenta  on[2-4]. In the case of familial paraganglioma, the male-
to-female ra  o is higher, the age at diagnosis lower and pa  ents present more frequently 
with mul  ple paragangliomas[5-7]. Hereditary paraganglioma syndrome is caused 
by muta  ons in genes encoding subunits or cofactors of the mitochondrial succinate 
dehydrogenase (SDH): SDHA, SDHB, SDHC, SDHD or SDHAF2[8-13]. Muta  ons of RET, NF1 
and VHL have also been noted in rare cases of head and neck paragangliomas (HNPGL) 
associated with mul  ple endocrine neoplasia(MEN2), neurofi bromatosis (NF1) and Von 
Hippel-Lindau (VHL) tumor syndromes[14]. 
Muta  ons in the diff erent SDH genes are associated with specifi c clinical characteris  cs; 
head and neck paragangliomas and mul  ple concurrent paragangliomas are most 
frequently observed in SDHD-linked cases, whereas extra-adrenal abdominal and thoracic 
paragangliomas are most frequently found in SDHB-linked cases. Muta  ons in SDHB, 
SDHC and SDHD, but not in SDHAF2, are associated with the development of adrenal 
pheochromocytomas[9,15-17]. Malignancy, defi ned as metasta  c paraganglioma, is 
most frequently found in SDHB-linked paraganglioma syndrome, but may also occur in 
SDHD-linked pa  ents[18-23]. SDH muta  on-nega  ve paraganglioma cases also show a 
dis  nct clinical profi le, characterized by a late age at diagnosis and lower risk of mul  ple 
tumors[2]. It remains unclear whether there is a gene  c basis for diff erences in ini  al 
clinical presenta  on between clearly hereditary cases and isolated cases in which a gene  c 
factor is later iden  fi ed. These diff erences could be a  ributed to addi  onal, protec  ve 
gene  c factors or to ascertainment bias working against the clinical iden  fi ca  on of 
isolated pa  ents with HNPGL.
In contrast to other European countries, the majority of Dutch pa  ents with HNPGL 
carry founder muta  ons, predominantly in SDHD[24,25]. It has been suggested that the 
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high prevalence of founder muta  ons in the Netherlands can be explained by a milder 
phenotype of paraganglioma syndrome because of the low residen  al al  tudes[26]. 
Here, we evaluate family history, muta  on spectrum and clinical characteris  cs of 
a series of 236 pa  ents with paraganglioma referred to the Leiden University Medical 
Center (LUMC), a ter  ary referral centre for paraganglioma and pheochromocytoma in 
the Netherlands. We characterize the clinical presenta  on and gene  c background of 




We analyzed data on 366 consecu  ve pa  ents with a diagnosis of head and neck 
paraganglioma who were diagnosed or referred between 1950 and 2009 to the LUMC; a 
dedicated ter  ary referral centre for pa  ents with paraganglioma in the Netherlands. In all 
cases, clinical characteris  cs including gender, age at diagnosis, family history, number of 
paragangliomas and metasta  c disease were recorded. Of the 366 pa  ents screened, 130 
pa  ents were excluded because of a lack of data on muta  on status (n = 47), incomplete 
descrip  on of clinical data (n = 58) or uncertain diagnosis (n = 25). In total, 236 pa  ents 
with head and neck paragangliomas were included in this study. The muta  on analysis of 
some of these pa  ents (n = 87) has been described in a previous study of SDH muta  ons 
in the Netherlands[25]. The diagnosis of paraganglioma was based on clinical and family 
history, otolaryngologic examina  on including otoscopy and laryngoscopy, magne  c 
resonance imaging (MRI) and/or an angiogram of the head and neck region including the 
skull base. In cases with resec  on of the paraganglioma, the diagnosis was confi rmed 
by histopathology. From 1989, all pa  ents with HNPGL were followed up with MRI at 
intervals of 1-3 years, depending on the clinical status and growth rate of the tumor 
(1 year for growing tumors, 2-3 years for stable tumors). Extra-adrenal paraganglioma 
and pheochromocytoma screening was performed using 24-h urine analysis, in duplicate, 
for excess catecholamines and metanephrines. From 2002, all pa  ents with HNPGL 
underwent a muta  on-specifi c screening programme consis  ng of biannual 24-h urine 
analysis in SDHAF2, SDHC and SDHD muta  on carriers, and annual 24-h urine analysis 
combined with biannual CT or MRI of the abdomen in SDHB muta  on carriers. If the result 
of the biochemical analysis was above the reference limit, an MRI or CT of the abdomen, 
chest and pelvis was performed in combina  on with an 131I-meta-iodobenzylguanidine 
(MIBG) scan to visualize poten  al extra-adrenal paragangliomas or pheochromocytomas. 
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If this inves  ga  on iden  fi ed a suspect lesion, a resec  on was performed and the 
diagnosis was confi rmed by histopathology. In all cases of known or suspected malignant 
paraganglioma, the diagnosis was confi rmed by histology of the tumor material in non-
neuroendocrine  ssue. 
Muta  on analysis
All pa  ents with paraganglioma were off ered muta  on analysis and gene  c counseling. 
If pa  ents consented to DNA analysis, the SDHB, SDHC and SDHD genes were scanned 
for the presence of muta  ons at the laboratory for DNA diagnos  cs at the LUMC. All 
exonic and adjacent intronic regions of these genes were tested by direct sequencing 
using the Sanger method on an ABI 377 Gene  c Analyzer (Applied Biosystems, Carlsbad, 
CA, USA), star  ng with the exon containing the known Dutch founder muta  ons in SDHD 
and followed by exons that had previously been found to contain pathogenic muta  ons in 
SDHD, SDHB and SDHC (in that order) in the Dutch popula  on. If this ini  al analysis was 
nega  ve, the analysis was completed by scanning the remaining exons of these genes. 
Muta  on-nega  ve cases were analyzed for the presence of large dele  ons in SDHB, SDHC 
and SDHD by mul  plex liga  on-dependent probe amplifi ca  on (MLPA). MLPA was carried 
out with the P226 MLPA kit (MRC Holland, Amsterdam, the Netherlands), containing 
probes for all exons and the promoter of each of these genes (27 diff erent probes), 
according to the manufacturer’s protocol. In cases with a nega  ve SDHB, SDHC and SDHD 
muta  on analysis, SDHAF2 was tested by sequencing, as recently described[12]. No 
DNA analysis was performed in 51 pa  ents because the muta  on type could be reliably 
inferred from a posi  ve muta  on analysis of the pa  ent’s family members and pedigree 
informa  on. Informed consent for DNA tes  ng was obtained according to protocols 
approved by the LUMC Ethics Review Board. All tumor specimens were handled according 
to the ethical guidelines described in the Code for Proper Secondary Use of Human Tissue 
in the Netherlands of the Dutch Federa  on of Medical Scien  fi c Socie  es (FEDERA).
Results
Muta  ons and family history
A total of 236 pa  ents with paraganglioma belonging to 124 diff erent families were 
eligible for evalua  on in this study, of whom 120 were men and 116 women. Of these, 
80% presented with a posi  ve family history while the remaining 20% had no known 
family history (Table 1). 
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Table 1. Clinical characteris  cs of head and neck paraganglioma pa  ents with a nega  ve vs a posi  ve 
family history. Screening for pheochromocytomas or extra-adrenal catecholamine producing 
paragangliomas was performed in 158 pa  ents.
Pa  ent characteris  cs Nega  ve family history 
(n = 48)
Posi  ve family history 
(n = 188)
Male/female 22/26 98/90
Mean age at onset (years) (95% C.I.) 44.0 (39.7-48.2) 38.1 (36.3-40.0)
Malignant paraganglioma (%) 1 (2) 3 (2)
Mul  ple paragangliomas (%) 24 (50) 137 (73)
Adrenal pheochromocytoma (%) 3/36 (8) 14/122 (11)
Extra-adrenal paraganglioma (%) 2/36 (6) 8/122 (7)
Pathogenic muta  ons in SDHAF2, SDHB, SDHC or SDHD were iden  fi ed in 214 of the 
236 pa  ents (91%) and in 102 of the 124 diff erent families (82%). DNA analysis or family 
history failed to reveal muta  ons in only 22 pa  ents (9%) (Table 2). The vast majority of 
pa  ents with HNPGL carried muta  ons in SDHD (83%), 4% carried muta  ons in SDHAF2, 
3% in SDHB and one muta  on in SDHC was iden  fi ed in a single pa  ent (0.4%) (Tables 2 
and 3). The p.Asp92Tyr Dutch founder muta  on in SDHD was the most common muta  on, 
accoun  ng for 72% of all pa  ents with HNPGL (Table 3).
Table 2. Clinical characteris  cs of 235 pa  ents with head and neck paraganglioma. A single SDHC 
muta  on carrier is excluded. ‘No muta  on’ is defi ned as the group of pa  ents without a muta  on 
in SDHB, SDHC, SDHD, or SDHAF2.






No muta  on 
(n = 22)
Male/female 6/2 100/95 5/5 9/13
Mean age at onset (years) 
(95% C.I.)
47.1 (41.2-53.0) 37.9 (36.3-39.5) 33.6 (21.3-45.9) 52.0 (46.3-57.7)
Malignant paraganglioma (%) 0 4 (2) 0 0
Mul  ple paragangliomas (%) 4 (50) 144 (74) 7 (70) 7 (32)
Adrenal pheochromocytoma 
(%)
0/8 (0) 17/127 (13) 0/5 (0) 0/17 (0) 
Extra-adrenal paraganglioma 
(%)
0/8 (0) 10/127 (8) 0/5 (0) 0/17 (0) 
Evalua  ng families only, SDHD muta  ons were found in 73%, SDHAF2 muta  ons in 
2%, SDHB muta  ons in 6%, SDHC muta  ons in 1% and no SDH muta  ons in 18%. The 
p.Asp92Tyr muta  on accounted for 75 of the 124 families (60%) (Table 3). 
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Table 3. Muta  ons iden  fi ed in SDHAF2, SDHB, SDHC and SDHD. Pathogenic muta  ons in succinate 
dehydrogenase-related genes could be iden  fi ed in 214 of the 236 pa  ents (91%); 187 of which had 
a posi  ve family history (87%). The 214 succinate dehydrogenase (SDH) muta  on carriers belong to 
102 diff erent families.
Gene Muta  on type Protein Posi  ve family 
history 
(n = 187)





SDHAF2 c.232G>A p.Gly78Arg  10  0  3
SDHB c.423+1G>A Splice site, intron 4   2  2  4
c.201-4429_287-933del del exon 3   1  0  1
c.574T>C p.Cys192Arg   0  1  1
c.590C>G p.Pro197Arg   1  0  1
c.649C>T p.Arg217Cys   0  1  1
SDHC c.242-241_510+1978del del exon 5 & 6   0  1  1
SDHD c.274G>T p.Asp92Tyr 152 19 75
c.416T>C p.Leu139Pro  14  1  8
Del promoter, exon 1 en 2 Unknown   0  1  1
c.120_121insC p.Glu42Argfs   2  1  2
c.169_169+9delTGTATGTTCT Unknown   1  0  1
c.242C>T p.Pro81Leu   2  0  2
c.337_340delGACT p.Asp113fs   2  0  1
In pa  ents with a posi  ve family history, muta  ons in SDHAF2, SDHB or SDHD could be 
iden  fi ed in 99.5% of the pa  ents with HNPGL and 99% of the families with HNPGL. By 
far the most frequently aff ected gene was SDHD, found in 92% of pa  ents with HNPGL 
and 89% of families with HNPGL. The p.Asp92Tyr muta  on was predominant amongst the 
familial SDHD muta  on carriers, found in 152 of 173 pa  ents with HNPGL (88%) and in 56 
of 68 SDHD-linked families (82%) (Table 3). All pa  ents with a nega  ve family history were 
found to be unrelated. Of these pa  ents, 56% showed muta  ons in SDHB, SDHC or SDHD, 
with 46% a  ributable to muta  ons of SDHD. The SDHD p.Asp92Tyr founder muta  on 
accounted for 86% of all SDHD-linked pa  ents with an isolated presenta  on (Table 3). No 
pa  ent with a nega  ve family history had a muta  on in SDHAF2. 
Age at diagnosis
The mean age at diagnosis of pa  ents with paraganglioma was 39.3 years (95% CI: 37.6-41.0). 
Age at diagnosis was higher in pa  ents with a nega  ve family history than in pa  ents 
with a posi  ve family history (44.0 vs. 38.1 years) (Table 1). Age at diagnosis also diff ered 
according to the gene  c subgroup, ranging from 33.6 years in SDHAF2-linked pa  ents, 
37.9 years in SDHD-linked pa  ents, to 52.0 years without a muta  on in SDHAF2, SDHB, 
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SDHC or SDHD (Table 2). Within the SDHD-linked pa  ent group, the mean age at diagnosis 
was comparable for pa  ents with an isolated presenta  on (35.5 years; 95% CI: 30.6-40.4) 
and for those with a posi  ve family history (38.2 years; 95% CI: 36.3-40.1) (data not 
shown). Similarly, in SDHB-linked pa  ents, we found no signifi cant diff erence between the 
mean age at diagnosis of isolated cases (47.3 years; 95% CI: 31.9-59.6) and that of familial 
cases (47.0 years; 95% CI: 43.6-50.4) (data not shown). 
Mul  focality
Mul  ple synchronous or metachronous paragangliomas were found in 162 of 236 pa  ents 
with paraganglioma (69%), up to a maximum of six metachronous paragangliomas. The 
majority of pa  ents with a posi  ve family history were diagnosed with mul  ple tumors 
(73%). Signifi cant mul  focality was also present in HNPGL pa  ents with an isolated 
presenta  on, aff ec  ng 24 of the 48 cases (50%) (Table 1), with 14 of those 24 (58%) 
accounted for by muta  ons in SDHD, while the remaining cases showed either muta  ons 
in SDHB (three of 24) or no muta  on in any of the SDH related genes (data not shown). 
We found a clear associa  on between the risk of mul  ple paragangliomas and gene  c 
subgroup; mul  ple tumors were most frequently observed in SDHD- and SDHAF2-linked 
pa  ents (74% and 70% respec  vely) (Table 2). Within the group of SDHD muta  on carriers, 
mul  ple tumors were a frequent fi nding both in isolated pa  ents (14 of 22; 64%) and 
pa  ents with a posi  ve family history (130 of 173; 75%) (data not shown).
Concurrent pheochromocytomas and extra-adrenal paragangliomas
Screening for concurrent pheochromocytomas and catecholamine producing extra-
adrenal paragangliomas was performed in 158 of the 236 pa  ents with HNPGL (Tables 
1 and 2). Pheochromocytomas were iden  fi ed in 17 of these 158 pa  ents (11%), extra-
adrenal paragangliomas in 10 of 158 pa  ents (6%). Pheochromocytomas were only found 
in pa  ents with SDHD muta  ons and were present in both familial SDHD-linked pa  ents 
(14 of the 113 screened pa  ents, 12%) and in isolated SDHD-linked pa  ents (3 of the 14 
screened pa  ents, 21%) (data not shown). Pheochromocytomas were diagnosed in 14 
carriers of the p.Asp92Tyr muta  on, in two carriers of the p.Leu139Pro muta  on and 
in one pa  ent with a dele  on of exon 1 and 2 of SDHD. Extra-adrenal catecholamine 
producing paragangliomas were only diagnosed in carriers of the SDHD p.Asp92Tyr 
muta  on, in eight of 113 (7%) familial cases and in two of 14 (14%) isolated cases (data 
not shown).
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Malignancy
Malignant paragangliomas were diagnosed in only four of 236 pa  ents (2%) (Tables 1 
and 2). In three cases, the metasta  c lesion was discovered on MIBG scan; in one case, the 
metasta  c lesion was discovered on MRI. The metasta  c lesion was confi rmed to consist 
of paraganglioma  ssue by histopathology of cervical lymph nodes (n = 2) or the pelvic 
bone (n = 2). All pa  ents developing malignant paraganglioma carried the p.Asp92Tyr 
muta  on in SDHD.
Discussion
In this study, we present the clinical characteris  cs and gene  c background of 236 Dutch 
pa  ents with paraganglioma, including the largest series of SDHD muta  on carriers 
described to date. Almost 80% of Dutch pa  ents with HNPGL have a posi  ve family 
history, in contrast to various European studies (performed in France, Italy, Germany and 
Spain) which iden  fi ed 11-23% of pa  ents with HNPGL as familial cases[2-4]. A muta  on 
in an SDH gene could be iden  fi ed in all but one of our familial pa  ents with HNPGL, 
most frequently in SDHD (92%). Even if family members are excluded from the analysis, 
SDHD muta  ons s  ll represent 89% of paraganglioma families. Muta  ons in SDH genes 
were also iden  fi ed in a surprising number of isolated Dutch pa  ents with HNPGL (56%), 
contras  ng sharply with the 22-25% of isolated cases previously reported to be muta  on-
posi  ve[4,27]. 
This predominance of SDHD muta  ons in pa  ents with HNPGL (82% of all pa  ents with 
HNPGL and 73% of all families with HNPGL this series) accords well with a recent report 
on SDH muta  ons in the Netherlands and with muta  on screening in pa  ents with HNPGL 
performed elsewhere (70-75%)[2,4,24]. In contrast to the study by Burnichon et al. which 
iden  fi ed 98 diff erent muta  ons in a series of 242 muta  on carriers, each accoun  ng for 
a maximum of six cases, the spectrum of SDHD muta  ons in the Netherlands is limited, 
with only seven diff erent SDHD muta  ons iden  fi ed in the current study (Table 3)[2]. In 
accordance with earlier reports, we found that the most prevalent muta  ons in SDHD are 
the Dutch founder muta  ons p.Asp92Tyr and p.Leu139Pro (Table 3)[24,25]. 
The clinical characteris  cs found in both familial and isolated SDHD-linked pa  ents were 
very similar, with a comparable low mean age at diagnosis, a high risk of mul  ple tumors, 
and a risk of concurrent pheochromocytomas or catecholamine producing extra-adrenal 
paragangliomas. As factors such as early diagnosis through family screening and pa  ent 
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or doctor awareness do not play a role in isolated cases, these characteris  cs can be seen 
as a true feature of the SDHD-linked phenotype. 
One of the hypotheses put forward to explain the remarkable clustering of SDHD founder 
muta  ons in the Netherlands proposes that the high incidence of hereditary paraganglioma 
syndrome can be explained by low residen  al al  tudes[26]. The rela  vely high oxygen 
pressure at sea level was postulated to result in a milder disease phenotype, reducing 
penetrance and nega  ve selec  on. This proposal is not supported by our data, as we found 
the clinical characteris  cs of the Dutch SDHD-linked phenotype to be comparable to other 
studies, including the mean age at diagnosis (37.9 vs. 24.9-35.7 years found elsewhere), 
the risk of developing mul  ple paragangliomas (74% vs. 23-74% in other studies) and 
a malignancy rate of 2%, compared to 0-10% found elsewhere[2,3,18,19,26,28,29]. The 
dominance of SDHD founder muta  ons in the Netherlands is therefore most probably 
because of socio-demographic factors. Dutch society was characterized un  l the middle 
of the twen  eth century by limited intermarriage and a strong segrega  on by religious 
affi  lia  on and socio-economic, geographic and linguis  c factors. These same factors have 
contributed to the crea  on of gene  cally isolated popula  ons and a high prevalence of 
many other founder muta  ons in disease-related genes in the Netherlands[30]. Carriers 
of the most common Dutch founder muta  ons share a common haplotype surrounding 
the muta  ons and therefore share a common ancestor. Coalescence  me calcula  ons 
have shown that the Dutch SDHD founder muta  on, p.Asp92Tyr, is between 200 and 960 
years old[31]. 
A further striking feature of paraganglioma syndrome in the Netherlands is the prevalence 
of the p.Gly78Arg muta  on in SDHAF2, iden  fi ed in 10 of 236 pa  ents (4%) and three of 
124 families (2%) in this study. It is the only pathogenic muta  on of SDHAF2 currently 
known and has been iden  fi ed in one Dutch kindred and an unrelated Spanish family[32]. 
All known Dutch carriers of the p.Gly78Arg muta  on in SDHAF2 share a common haplotype 
and have been linked to a common ancestor[31,33]. Like SDHD, SDHAF2 is characterized 
by an exclusively paternal transmission of symptoma  c paraganglioma syndrome. This 
similarity in inheritance pa  ern has been hypothesized to be because both genes are 
located on chromosome 11 and may follow the same route to tumorigenesis[34,35]. 
In this study, we observed interes  ng clinical similari  es between SDHAF2 and SDHD 
muta  on carriers: both pa  ent groups are characterized by a high percentage of mul  ple 
paragangliomas (74% and 70% respec  vely) and an early mean age at diagnosis (38 
and 34 years respec  vely) (Table 2). However, whereas SDHD-linked pa  ents showed 
concurrent pheochromocytomas in 13%, extra-adrenal paragangliomas in 8% and 
metasta  c paraganglioma in 2%, SDHAF2 muta  on carriers showed no paragangliomas 
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outside the head and neck region, in accordance with a recent report on a Dutch SDHAF2-
linked kindred[17]. 
The number of HNPGL pa  ents with muta  ons of SDHB found in this study is remarkably 
low (3% of pa  ents with HNPGL and 6% of families with HNPGL) compared with recent 
studies performed elsewhere, which found 22% to 34% of all HNPGL cases to be SDHB 
muta  on carriers[2,4]. This contrast is puzzling, but it is also refl ected in the rela  vely 
low numbers of muta  on-nega  ve cases (9%). As we have recently conducted several 
studies focused on SDHB muta  on carriers, it seems unlikely that these pa  ents have 
simply escaped our a  en  on[36,37]. This suggests that the apparent rela  ve scarcity of 
both SDHB-linked and muta  on-nega  ve cases may result from excess SDHD-linked cases, 
compared to surrounding countries. It follows that the absolute prevalence of HNPGL may 
be higher in the Netherlands than in other European countries. The true prevalence of 
rare diseases is notoriously diffi  cult to es  mate and is prone to a plethora of acquisi  on 
biases. Nevertheless, in a recent study on SDH muta  on frequencies in the Netherlands, 
we iden  fi ed 601 SDHD muta  on carriers, while recent large studies from Italy and 
France iden  fi ed only 47 and 130 SDHD muta  on carriers, respec  vely, despite the fact 
that these countries have approximately four-fold higher popula  ons than that of the 
Netherlands[2,3,24]. While details of the selec  on and acquisi  on of each cohort could 
have a signifi cant impact on prevalence data, the large number of Dutch SDHD muta  on 
carriers iden  fi ed and the overwhelming predominance of SDHD-linked HNPGL over 
SDHB and muta  on-nega  ve cases are sugges  ve of a signifi cantly increased prevalence 
of HNPGL in the Netherlands.
In this study, we evaluate the SDH muta  on status and the clinical presenta  on of a large 
series of pa  ents with head and neck paraganglioma collected over a 59-year period. 
In contrast to other European countries, the majority of head and neck paragangliomas 
are a  ributable to Dutch founder muta  ons in SDHD, most prominently the p.Asp92Tyr 
muta  on. SDHD muta  ons are also a major factor in HNPGL pa  ents with an isolated 
presenta  on. We fi nd that the clinical characteris  cs of SDHD-linked pa  ents with 
an isolated presenta  on are iden  cal to those of clearly hereditary cases, and the 
consequences of the dominance of SDHD muta  ons are therefore an early age at diagnosis, 
a high risk of mul  ple paragangliomas including pheochromocytomas, and an exclusive 
paternal transmission of disease in the large majority of Dutch pa  ents with HNPGL. 
Moreover, the very high frequency of familial presenta  on, the high prevalence of SDHD 
muta  ons, the rela  vely high frequency of muta  ons in SDHAF2 and the rela  ve lack 
of muta  on-nega  ve cases and SDHB muta  on carriers all strongly suggest an increased 
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The Dutch founder muta  on SDHD.D92Y shows a reduced penetrance for the development 
of paragangliomas in a large mul  genera  onal family.




Germline muta  ons in SDHD predispose to the development of head and neck 
paragangliomas, and phaeochromocytomas. The risk of developing a tumor depends on 
the sex of the parent who transmits the muta  on: paragangliomas only arise upon paternal 
transmission. In this study, both the risk of paraganglioma and phaeochromocytoma 
forma  on, and the risk of developing associated symptoms were inves  gated in 243 
family members with the SDHD.D92Y founder muta  on. By using the Kaplan-Meier 
method, age-specifi c penetrance was calculated separately for paraganglioma forma  on 
as defi ned by magne  c resonance imaging (MRI) and for paraganglioma-related signs 
and symptoms. Evalua  ng clinical signs and symptoms alone, the penetrance reached a 
maximum of 57% by the age of 47 years. When MRI detec  on of occult paragangliomas 
was included, penetrance was es  mated to be 54% by the age of 40 years, 68% by the 
age of 60 years and 87% by the age of 70 years. Mul  ple tumors were found in 65% 
and phaeochromocytomas were diagnosed in 8% of paraganglioma pa  ents. Malignant 
paraganglioma was diagnosed in one pa  ent (3%). Although the majority of carriers of a 
paternally inherited SDHD muta  on will eventually develop head and neck paragangliomas, 
we fi nd a lower penetrance than previous es  mates from studies based on predominantly 
index cases. The family-based study described here emphasizes the importance of the 
iden  fi ca  on and inclusion of clinically unaff ected muta  on carriers in all es  mates of 
penetrance. This fi nding will allow a more accurate gene  c counseling and warrants a 
‘wait and scan’ policy for asymptoma  c paragangliomas, combined with biochemical 
screening for catecholamine excess in SDHD-linked pa  ents.
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Introduc  on
Paragangliomas of the head and neck are rare, usually benign tumors that arise in the 
paraganglion  ssue associated with the parasympathe  c nervous system[1]. The caro  d 
body in the caro  d bifurca  on is most frequently aff ected, followed by the jugulo-
tympanic bodies at the jugular bulb and tympanic nerve, and the vagal bodies at the 
ganglions of the vagal nerve. Symptoms are usually mild and tumor progression is 
characteris  cally slow, and therefore diagnosis of the disease is o  en not made before 
adulthood[2]. An es  mated 10-50% of head and neck paragangliomas are hereditary[3]. 
The natural course of the disease in hereditary cases does not seem to be diff erent from 
sporadic paragangliomas, but pa  ents with inherited disease are more likely to develop 
mul  ple paragangliomas[4]. Hereditary head and neck paragangliomas can be caused by 
germline muta  ons in several genes encoding subunits of the mitochondrial succinate 
dehydrogenase (SDH) complex: the SDHB, SDHC and SDHD gene[5-7]. SDHB (1p36.1-p35), 
encodes a cataly  c subunit, whereas SDHC (1q21) and SDHD (11q23) encode membrane-
anchoring subunits of SDH involved in electron transport. Furthermore, a yet uniden  fi ed 
gene (PGL2) on 11q13.1 causes paraganglioma in at least one family[8]. Muta  ons in 
SDHB, SDHC and SDHD are also associated with the development of (extra-) adrenal 
paragangliomas or phaeochromocytomas[9-12]. 
As paragangliomas can cause incapacita  ng symptoms, accurate disease risk es  mates 
are of paramount importance in clinical decision making and gene  c counseling of para-
ganglioma pa  ents. The chance of developing disease is dependent on the gene that is 
aff ected: in SDHB- and SDHC-linked families, inheritance is autosomal dominant, whereas 
in SDHD- and PGL2-linked families, the inheritance pa  ern shows a parent-of-origin 
eff ect[6,12]. As a rule, individuals are at risk only when they inherit the mutant SDHD allele 
from the father (regardless of his clinical status) and not when the muta  on is maternally 
inherited[13,14]. Thus, proper gene  c counseling of SDHD-linked paraganglioma families 
requires knowledge about the risk of developing head and neck paraganglioma upon 
paternal transmission of a SDHD muta  on (penetrance), the risk of developing clinical 
symptoms, the age at onset of the disease, the risk of developing mul  ple tumors and 
the risk of developing phaeochromocytoma. To date, two reports have discussed the 
risk of developing paraganglioma or phaeochromocytoma upon inheritance of a SDHD 
muta  on[15,16]. Both studies found that no tumors developed a  er maternal transmission 
of the SDHD muta  on, and that penetrance of disease was 100% at the age of 70 years 
upon paternal transmission. However, both studies have evaluated a heterogeneous 
popula  on of SDHD muta  on carriers with diff erent SDHD muta  ons, rela  vely large 
numbers of index cases (16 diff erent SDHD muta  ons in 19 index pa  ents and 15 diff erent 
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SDHD muta  ons in 24 index cases, respec  vely) and small numbers of asymptoma  c 
family members[15,16]. This study design is prone to overes  ma  on of penetrance 
if the index cases are selected from families with mul  ple aff ected individuals and if 
insuffi  cient asymptoma  c family members are included. Moreover, diff erent muta  ons 
may confer diff erent risks[17]. In this study, we have therefore evaluated age-specifi c 
risk of developing a paraganglioma and/or phaeochromocytoma in an extended family 
consis  ng of 243 family members, in which the D92Y germline muta  on in the SDHD 
gene segregates. As a signifi cant number of paragangliomas remain asymptoma  c even 
at advanced ages, the age-specifi c risk of developing paraganglioma-related symptoms is 
as important in counseling paraganglioma pa  ents as the age-specifi c risk of developing 
a paraganglioma. For that reason, we have evaluated the penetrance of symptoma  c 
disease and the penetrance of tumor development separately. 
Materials and methods
Clinical status
The disease status of 243 rela  ves belonging to a seven-genera  on family with head 
and neck paragangliomas (family FGT189) was established between 1990 and 2008. The 
pedigree of this family has been published before and was updated for this study (Figure 
1)[18-20]. For the evalua  on of clinical characteris  cs, data from the family members 
of genera  ons V, VI and VII were used, because pa  ents in older genera  ons were not 
available for adequate clinical analysis. Family members from genera  on V, VI and VII 
underwent magne  c resonance imaging (MRI) of the head and neck if they showed signs 
or symptoms of paragangliomas. All non-symptoma  c carriers of a paternal muta  on, 
who were iden  fi ed during gene  c counseling, were off ered clinical evalua  on and MRI 
screening as well. In addi  on, the data acquired in a previous research protocol were 
used, in which 83 members of this family were examined with MRI, regardless of their 
disease status and sex of the carrier parent[18]. To detect occult phaeochromocytomas, 
head and neck paraganglioma pa  ents were biochemically screened for catecholamine 
excess. If screening was posi  ve, MRI of the abdomen and 123I-MIBG scin  graphy was 
performed. 
Age at onset
As ini  al symptoms can be very mild and growth of paragangliomas is usually slow, 
there may be a substan  al delay before a pa  ent comes under medical a  en  on. It can 
therefore be diffi  cult to establish the exact age at onset of paraganglioma forma  on. We 
have defi ned ‘age at onset’ as the age at onset of complaints and/or symptoms, that
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Figure 1. Pedigree of family FGT189. Roman numerals 
correspond to the subsequent genera  ons of the 
FGT189 family. Squares depict males, circles depict 
females and diamonds depict mul  ple siblings of 
both sexes. Open symbols represent unaff ected 
family members, do  ed symbols represent 
unaff ected obligate carriers of a paternally inherited 
SDHD muta  on and solid symbols represent aff ected 
family members. A ques  on mark within a symbol 
stands for a possibly aff ected family member, as 
inferred from carrier status of off spring. A number 
within a symbol indicates the number of siblings. 
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is, the age at which the pa  ent retrospec  vely fi rst experienced complaints of a head 
and neck paraganglioma or phaeochromocytoma, as opposed to the age at diagnosis, 
that is, the age at which the pa  ent came under medical a  en  on and the diagnosis of 
paraganglioma and/or phaeochromocytoma was established.
Gene  c status
Paraganglioma pa  ents in family FGT189 were shown to harbor the D92Y missense 
muta  on (g.7882 T>C; p.Asp92Tyr) in the SDHD gene[21]. This Dutch founder muta  on 
was detected by direct sequencing of PCR products obtained from peripheral blood 
lymphocyte DNA, as described previously[7].
Penetrance
For penetrance calcula  ons, only the data from genera  ons VI and VII were used, 
because insuffi  cient data were available to iden  fy asymptoma  c muta  on carriers in 
older genera  ons (Figure 1). In this way, the risk of bias in penetrance calcula  ons is 
minimized. Given the typical inheritance pa  ern of SDHD-linked paragangliomas, children 
of female muta  on carriers were considered not to be at risk[13,22]. For children of 
aff ected fathers, the risk of inheri  ng the muta  on was es  mated to be 50%. Penetrance 
was calculated by comparing the actual number of pa  ents with and without symptoms 
with the expected number of family members at risk of inheri  ng the muta  on[23]. 
Next, we combined gene  c and clinical data to calculate age-related penetrance in this 
family. Penetrance was expressed as a Kaplan-Meier curve, represen  ng the probability 
of a SDHD muta  on carrier to have developed either paraganglioma-related signs or 
symptoms, or a detectable paraganglioma at a given age. Calcula  ons were performed 
for symptoma  c and asymptoma  c paragangliomas confi rmed by radiology and for 
symptoma  c paragangliomas alone.
Results
Clinical status
Figure 1 shows the pedigree of family FGT189. In genera  ons V, VI and VII, paragangliomas 
were diagnosed in 40 family members (25 men, 15 women). Seven of these individuals 
(18%) had no signs or symptoms, and their diagnosis was made only a  er MRI screening. 
Mul  ple tumors were present in 26/40 pa  ents (65%), to a maximum of fi ve per 
pa  ent. The most frequently encountered loca  on was the caro  d body (29 pa  ents, 
39 tumors) followed by jugulo-tympanic tumors (20 pa  ents, 23 tumors) and the vagal 
body (13 pa  ents, 16 tumors). Furthermore, 3/40 pa  ents (8%) with head and neck 
121
Penetrance and phenotype of the SDHD.D92Y muta  on
paragangliomas also had an adrenal phaeochromocytoma as diagnosed by 123I-MIBG 
scin  graphy and MRI. In 1/40 paraganglioma pa  ents (3%), metasta  c paraganglioma 
 ssue was found in the lung and spinal column, and this tumor was thus classifi ed as 
malignant paraganglioma. 
Age at onset of symptoms 
In genera  ons V, VI and VII, 33 paraganglioma pa  ents experienced symptoms. The age at 
onset of symptoms ranged from 14 to 47 years (mean 26.5 years; 95% CI, 23.5-29.6 years), 
with a mean delay of 2.6 years (95% CI, 1.4-3.7 years) un  l diagnosis (Figure 2). 
Figure 2. Age at onset of symptoms in SDHD-linked paraganglioma pa  ents. Cumula  ve chart of the 
age at which the fi rst symptoms of a head and neck paraganglioma or phaeochromocytoma became 
evident in the symptoma  c family members in genera  on V, VI and VII (n = 33).
Gene  c status 
In genera  on VI and VII, a total of 211 family members were alive at ascertainment and in 
Mendelian line of inheri  ng the D92Y founder muta  on in the SDHD gene. Of these 211, 
22 asymptoma  c family members declined the invita  on to be tested for the muta  on. 
A total of 63 of the remaining 189 family members tested posi  ve, 52 of whom inherited 
the muta  on from their father. One of the 22 asymptoma  c family members who could 
not be tested was iden  fi ed as an obligate carrier of a paternally inherited muta  on, 
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because of aff ected off spring. In all, 53 paternal and 11 maternal muta  on carriers were 
thus iden  fi ed in genera  on VI and VII. 
Penetrance
As expected, penetrance of the disease was parent-of-origin-dependent. No para-
gangliomas were found by clinical inves  ga  on or MRI in the off spring of female SDHD 
muta  on carriers, and they were therefore not included in the risk calcula  ons. We 
iden  fi ed 11 male muta  on carriers in genera  on V and 17 in genera  on VI on the 
basis that they were either aff ected themselves or had an aff ected off spring. In total, we 
iden  fi ed 138 children of male muta  on carriers (83 in genera  on VI and 55 in genera  on 
VII), who were thus all at 50% risk of inheri  ng the SDHD muta  on. Of the 138 family 
members, 36 (26%) had one or more radiologically proven head and neck paragangliomas 
and/or a phaeochromocytoma. A total of 30 of these 36 pa  ents (83%) experienced 
symptoms at the  me of diagnosis or developed symptoms in the follow-up period. 
Under the assump  on that 50% of the children of paternal muta  on carriers are at risk, 
this corresponds with an es  mated overall penetrance of 36/69 (52%) and an es  mated 
overall clinical penetrance of 30/69 (43%)[23].
Using the gene  c data, 53 of the 138 children (38%) at risk of a paternally transmi  ed 
muta  on in genera  on VI and VII were shown to actually have inherited the muta  on 
(Table 1). A total of 30 of these carriers at risk presented with paraganglioma- or 
phaeochromocytoma- related symptoms, accoun  ng for an overall clinical penetrance of 
30/53 (57%). To correct for the age at onset, a Kaplan–Meier curve was made represen  ng 
the chance to be symptom free as a func  on of  me (Figure 3). As none of the carriers 
developed symptoms a  er the age of 47 years, the penetrance reached a maximum of 
57% at this age. Of the 23 clinically non-penetrant carriers of the disease gene, 12 were 
examined with MRI. In six cases (50%), one or more paragangliomas were diagnosed, 
raising the overall penetrance to 36/53 (68%) (Table 1). If these cases were included in a 
Kaplan–Meier curve, the penetrance increased to 87% by 70 years of age (Figure 3). 
Table 1. Penetrance in genera  ons VI and VII.
Carriers of a paternally inherited 
SDHD muta  on (n)  
Symptoma  c paraganglioma 
pa  ents (n)  
MRI diagnosed paraganglioma 
pa  ents (n)
total male female total male female total male female
53 31 22 30(57%) 18 12 36(68%) 21 15
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Figure 3. Penetrance of SDHD-linked head and neck paragangliomas. Inverted Kaplan–Meier curve 
indica  ng the probability of developing a MRI-detectable paraganglioma (do  ed line) or the 
probability of developing paraganglioma-related symptoms (solid line) at a certain age for carriers 
of a paternally inherited SDHD muta  on. Ver  cal markers indicate censored pa  ents.
Discussion
SDHD-linked paragangliomas and phaeochromocytomas present a unique tumor syndrome 
with a specifi c, parent-of-origin-dependent risk of inheri  ng disease. In this study, we did 
not observe the development of paragangliomas or phaeochromocytomas in 11 instances 
of maternal transmission of the SDHD muta  on. This parent-of-origin-dependent 
inheritance seems to be the norm in SDHD-linked paraganglioma families, although one 
case of a tympanic paraganglioma a  er maternal transmission has been reported[13,14]. 
Recently, new insights in the mechanisms behind this peculiar inheritance pa  ern have 
emerged. We have shown previously that in SDHD-linked paragangliomas, not only the 
wild-type maternal SDHD allele on 11q23 but the en  re maternal copy of chromosome 11 
was consistently lost[22]. A model explaining the parent-of-origin-dependent inheritance 
in SDHD-linked cases was proposed, involving a second, paternally imprinted, tumor-
suppressor gene (TSG) located on 11p15[22]. Within this model, paraganglioma forma  on 
occurs only when the wild type maternal SDHD allele on 11q23 and the ac  ve copy of 
the imprinted TSG on 11p15 are simultaneously lost. This model of inheritance has been 
supported by the report of Pigny et al., who describe the only known case of maternal 
transmission of SDHD-linked paraganglioma to date[24]. Although at fi rst sight, this unique 
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case seems to contradict the model, it was shown that the pa  ent had also acquired an 
altered methyla  on profi le and, therefore, probably an altered imprinted status of H19, 
a known paternally imprinted TSG on 11p15[24]. This suggests that the parent-of-origin-
dependent inheritance of SDHD-linked disease is caused by the paternal imprin  ng of 
H19, a TSG on the imprinted 11p15 region that seems to be essen  al for paraganglioma 
forma  on. It furthermore suggests that maternal transmission of SDHD-linked disease is 
possible only if the ‘second hit’ targets the wild-type paternal SDHD allele on 11q23 as 
well as the ac  ve status of the maternal H19 allele on 11p15. The fact that these events 
involve diff erent regions of diff erent copies of chromosome 11 simultaneously is likely to 
be the reason why maternal transmission of disease is extremely rare. 
This has considerable consequences on the gene  c counseling of the aff ected families. 
Although children of female muta  on carriers may not be completely preserved from the 
risk of developing paraganglioma, maternal transmission of disease remains extremely 
rare. Off spring of female carriers must, however, be aware that they can be muta  on 
carriers and transmit the disease gene to their children. On the other hand, carriers 
of a paternally inherited SDHD muta  on are at risk of developing a head and neck 
paraganglioma and/or phaeochromocytoma. In this study, the overall risk of developing a 
paraganglioma upon paternal transmission of the SDHD muta  on is 68%, when evalua  ng 
the results of clinical evalua  on and MRI. Age-related penetrance is 54% at the age of 
40 years and 68% at the age of 60 years, reaching a maximum of 87% by the age of 70 
years, that is, the large majority of pa  ents with a paternally derived disease gene will 
eventually develop one or more paragangliomas and/or a phaeochromocytoma (Figure 
3). These fi gures may represent an underes  ma  on, because MRI scanning and screening 
for catecholamine excess was declined by 11 of the 23 asymptoma  c paternal muta  on 
carriers. Even in the unlikely event that all these would have had one or more occult 
paragangliomas or a phaeochromocytoma, overall penetrance is raised only marginally 
up to a maximum of 89%. Hence, this cannot fully explain why our es  mates are slightly 
lower compared with those reported in the literature. Benn et al. reported an es  mated 
age-related penetrance for SDHD-linked disease of 73% at the age of 40 years and 100% at 
the age of 70 years, whereas Neumann et al. reported a penetrance of 86% at the age of 
50 years and 100% at the age of 70 years[15,16]. In the la  er two studies, mul  ple families 
with mul  ple index pa  ents and diff erent SDHD muta  ons were inves  gated. In contrast, 
we have evaluated a single extended family with the D92Y Dutch founder muta  on in 
the SDHD gene for the calcula  on of penetrance in SDHD-linked disease[15,16]. There is 
evidence that this family based approach yields more accurate es  mates, because less 
index cases and more asymptoma  c muta  on carriers are included[25]. However, bias may 
arise if family members share unknown gene  c or environmental factors that infl uence 
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disease risk[25,26]. This could lead to overes  ma  on of penetrance in SDHD-linked 
disease, especially when high-risk families are used for penetrance calcula  ons[25,27]. 
In this respect, it is interes  ng to note that age-related penetrance es  mates of SDHD-
linked disease found in this study are lower compared with those reported by Benn et 
al. and Neumann et al.[15,16]. This may refl ect an upward bias in the la  er two studies 
because of the inclusion of large numbers of index cases and rela  vely low numbers of 
asymptoma  c muta  on carriers. Further posi  ve bias may have arisen in these studies 
because all risk factors tend to be overrepresented in case pa  ents[28]. 
The risk of developing head and neck paraganglioma and/or phaeochromocytoma, or 
penetrance of the disease, is not the only feature that is important in counseling SDHD 
muta  on carriers. The risk of developing associated symptoms is at least as relevant 
in counseling and clinical decision making. In this study, evalua  on of the age-related 
occurrence of clinical symptoms upon paternal transmission of a SDHD muta  on reveals 
that a signifi cant number of individuals at risk did not develop clinical symptoms despite the 
fact that some of them have reached advanced ages. In actual fact, no pa  ents developed 
fi rst symptoms a  er the age of 47 years, and clinical penetrance reaches a maximum 
of 57% at this age (Figure 3). Clinical penetrance might even have been overes  mated 
in our study, because 21 asymptoma  c family members at risk of inheri  ng the SDHD 
muta  on through the father were not tested for the SDHD muta  on and their carrier 
status could not be inferred from their off spring. Assuming that 50% of these 21 untested 
family members would have inherited the muta  on, the clinical penetrance decreases to 
50%. In the unlikely event that all 21 untested family members would have inherited the 
SDHD muta  on, clinical penetrance is at least 41%. 
Astrom et al. observed that pa  ents with mul  ple SDHD-linked tumors or a concurrent 
phaeochromocytoma at the  me of diagnosis had lived at higher mean al  tudes as 
compared with those with single tumors[29]. They postulated that the low al  tudes found 
in the western part of the Netherlands cause a milder disease phenotype, manifes  ng 
as reduced penetrance and a be  er fi tness of SDHD muta  ons. This would explain the 
rela  vely high incidence of hereditary paragangliomas and the remarkable clustering of 
founder muta  ons in the SDHD gene in the Netherlands[29]. However, despite the fact 
that most family members of family FGT189 live in the western part of the Netherlands, 
a region situated at sea level, mul  ple tumors were ascertained in 65% of its pa  ents, 
as compared with 30-74% in other studies[15,16,29]. In addi  on, the risk of developing 
phaeochromocytoma is 8% for paraganglioma pa  ents in this family, at the lower end of 
the spectrum of published risk es  mates (7-53%), but comparable with that of pa  ents 
living at higher al  tudes (10%)[10,15,16,29]. Remarkably, Astrom et al. did not observe 
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an eff ect of al  tude on age at onset, although age-dependent caro  d body hyperplasia at 
high al  tudes has been observed by others[29,30]. However, they did fi nd a correla  on 
between age at onset and muta  on type[29]. Pa  ents harboring missense muta  ons in 
the SDHD gene seemed to develop symptoms later in life than those harboring nonsense 
or splicing muta  ons (mean age at onset of 34.3 years vs. 25.8 years, respec  vely)[29]. 
In the present family, pa  ents harboring the D92Y missense muta  on had a mean age 
at onset of 26.5 years (95% CI, 23.5-29.6 years), which was in good agreement with 
other studies that have evaluated paraganglioma pa  ents with diff erent SDHD muta  ons 
(25.8-30.6 years)[15,16,29]. Malignancy or metasta  c disease, a rare fi nding in SDHD-
linked disease with an es  mated prevalence of 0-10%, has not been associated with 
residen  al al  tude, nor with muta  on type[15,16,29,31]. In the present family too, only 
one pa  ent (3%) was diagnosed with a paraganglioma metastasis. All in all, the disease 
phenotype of the SDHD.D92Y muta  on in this extended family residing at sea level does 
not seem to represent a milder or otherwise diff erent phenotype than that of pa  ents 
living at high al  tudes or those carrying other muta  on types, and hence al  tude is 
unlikely to explain the observed lower penetrance. Probably, more relevant is the fact 
that the SDHD.D92Y missense muta  on has a detrimental eff ect on the func  onality of 
the SDH-complex[32]. Moreover, as most pa  ents develop fi rst symptoms a  er reaching 
reproduc  ve age, and symptoms are usually mild and slowly progressive even at high 
al  tudes, it is doub  ul whether nega  ve selec  on plays a decisive role in the geographical 
distribu  on of SDHD muta  ons. Rather, the high incidence of founder muta  ons in the 
Netherlands is explained by specifi c historic and demographic factors, such as migra  onal 
pa  erns, endogamy and rapid popula  on growth, factors that have contributed to the 
existence of a striking number of Dutch founder muta  ons in other disease genes[33].
In summary, we have provided risk es  mates for a well-defi ned SDHD-linked popula  on 
and have shown that penetrance of disease diff ers considerably depending on whether or 
not MRI-screening results are included. Whereas the large majority of paternally inherited 
SDHD muta  on carriers may eventually develop one or more paragangliomas (87%), 
symptoms do not occur in substan  al propor  on of these carriers at risk (43%), probably 
because of the characteris  c indolent growth pa  ern of paragangliomas[2]. Pa  ents who 
do develop complaints associated with paraganglioma or phaeochromocytomas generally 
do so before the age of 50 years; the risk of developing symptoms later in life seems small. 
This knowledge might reassure especially older non-symptoma  c carriers and warrants 
a ‘wait and scan’ policy for pa  ents with asymptoma  c head and neck paragangliomas. 
Because of the elevated risk of developing a phaeochromocytoma in SDHD-linked 
disease, surveillance should include screening for the detec  on of asymptoma  c 
phaeochromocytomas[2,10].
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Similar gene expression profi les of sporadic, PGL2-, and SDHD-linked paragangliomas 
suggest a common pathway to tumorigenesis.




Background. Paragangliomas of the head and neck are highly vascular and usually clinically 
benign tumors arising in the paraganglia of the autonomic nervous system. A signifi cant 
number of cases (10-50%) are proven to be familial. Mul  ple genes encoding subunits of 
the mitochondrial succinate-dehydrogenase (SDH) complex are associated with hereditary 
paraganglioma: SDHB, SDHC and SDHD. Furthermore, a hereditary paraganglioma family 
has been iden  fi ed with linkage to the PGL2 locus on 11q13. No SDH genes are known to 
be located in the 11q13 region, and the exact gene defect has not yet been iden  fi ed in 
this family.
Methods. We have performed a RNA expression microarray study in sporadic, SDHD- and 
PGL2-linked head and neck paragangliomas in order to iden  fy poten  al diff erences in 
gene expression leading to tumorigenesis in these gene  cally defi ned paraganglioma 
subgroups. We have focused our analysis on pathways and func  onal gene-groups that 
are known to be associated with SDH func  on and paraganglioma tumorigenesis, i.e. 
metabolism, hypoxia, and angiogenesis related pathways. We also evaluated gene clusters 
of interest on chromosome 11 (i.e. the PGL2 locus on 11q13 and the imprinted region 
11p15). 
Results. We found remarkable similarity in overall gene expression profi les of SDHD-
linked, PGL2-linked and sporadic paraganglioma. The supervised analysis on pathways 
implicated in PGL tumor forma  on also did not reveal signifi cant diff erences in gene 
expression between these paraganglioma subgroups. Moreover, we were not able to 
detect diff erences in gene expression of chromosome 11 regions of interest (i.e. 11q23, 
11q13, 11p15). 
Conclusion. The similarity in gene expression profi les suggests that PGL2, like SDHD, is 
involved in the func  onality of the SDH complex, and that tumor forma  on in these 
subgroups involves the same pathways as in SDH-linked paragangliomas. We were not 
able to clarify the exact iden  ty of PGL2 on 11q13. The lack of diff eren  al gene expression 
of chromosome 11 genes might indicate that chromosome 11 loss, as demonstrated in 
SDHD-linked paragangliomas, is an important feature in the forma  on of paragangliomas 
regardless of their gene  c background.
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Background
Paragangliomas are tumors origina  ng in cells of neural crest origin in the extra-adrenal 
paraganglia associated with the autonomic nervous system. Most paragangliomas arise in 
the parasympathe  c paraganglia of the head and neck region, but they can also arise in the 
parasympathe  c paraganglia of the medias  num or in the orthosympathe  c para-aor  c 
and retroperitoneal paraganglia. They are highly vascular and usually characterized by an 
indolent, non-invasive growth pa  ern. Most cases are sporadic, but a signifi cant number 
(10-50%) have been shown to be familial. Muta  ons in 3 of the 4 genes encoding subunits 
of succinate dehydrogenase (SDH, complex II in the mitochondrial respiratory chain) 
have been implicated in the familial forms of the disease: SDHB, SDHC, and SDHD[1-3]. 
In our popula  on, the majority of hereditary paraganglioma cases are associated with 
two founder muta  ons in the SDHD gene on 11q23[4]. In addi  on to these SDH related 
cases, another hereditary paraganglioma family has been iden  fi ed with linkage to a 
region on 11q13, the PGL2 locus[5]. No mitochondrial complex II genes, including SDHA, 
are located in the 11q13 region, and the iden  ty and func  on of the PGL2 gene are yet 
unknown. Muta  ons in SDHB, SDHC and SDHD are also implicated in the forma  on of 
phaeochromocytomas, tumors arising in cells derived from the neural crest in the adrenal 
medulla[6-8]. In PGL2-linked cases no associa  on with phaeochromocytoma forma  on 
has been found to date. 
A recent genome-wide expression study of phaeochromocytomas iden  fi ed two dis  nct 
clusters: one containing SDH- and VHL-associated phaeochromocytomas and another 
containing MEN2- and NF1-associated phaeochromocytomas, while both clusters contained 
sporadic cases[9]. The cluster containing SDH- and VHL-associated phaeochromocytomas 
was characterized by a transcrip  on signature of reduced oxidoreductase ac  vity and 
increased angiogenesis and hypoxia[9]. In order to gain further insight into PGL2 func  on 
and iden  ty, we have performed a gene expression study evalua  ng gene expression in 
head and neck paragangliomas of diff erent gene  c backgrounds: SDHD-linked, PGL2-linked 
and sporadic cases without a muta  on in the SDHB, SDHC or SDHD gene. In addi  on to 
a supervised gene-based analysis, a supervised pathway-based analysis was performed, 
evalua  ng diff erences in gene expression for predefi ned pathways and func  onal gene 
groups. We evaluated in more detail gene groups that are known to be associated with 
SDH func  on and paraganglioma-or phaeochromocytoma forma  on, i.e. metabolism, cell 
cycle, hypoxia, and angiogenesis related pathways. In addi  on, we evaluated the gene 
sets that diff eren  ate the SDH/VHL- from the NF1/MEN2-associated phaeochromocytoma 
cluster in the aforemen  oned phaeochromocytoma gene expression study, using our 
dataset[9]. Finally, gene clusters located within or close to the PGL2 locus on 11q13, the 
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SDHD locus on 11q23, and the imprinted 11p15 region were assessed. The la  er region 
has previously been implicated in SDHD-linked paraganglioma forma  on[10]. The results 
of both gene- and pathway-based analyses show remarkable similarity in the gene-
expression profi les of SDHD-linked , PGL2-linked and sporadic paragangliomas, sugges  ng 




Samples from head and neck paragangliomas were obtained from the  ssue banks of the 
department of Pathology at the Leiden University Medical Center (LUMC) (all sporadic 
and SDHD-related cases and one PGL2-linked case) or the University Medical Center 
(UMC) St. Radboud (all but one PGL2-linked cases). All specimens were handled according 
to the ethical guidelines, as described in the Code for Proper Secondary Use of Human 
Tissue in the Netherlands of the Dutch Federa  on of Medical Scien  fi c Socie  es (FEDERA). 
Diagnosis of paraganglioma was confi rmed by histology in all cases. All paragangliomas 
were caro  d body tumors arising in the caro  d bifurca  on in the neck. No malignant 
paragangliomas were included in the study. Eighteen paraganglioma cases were selected: 
7 cases with a known D92Y founder muta  on in the SDHD gene, 6 cases from the family 
with signifi cant linkage tot the PGL2 locus on 11q13, and 5 sporadic cases[5]. The la  er 
were defi ned as ‘sporadic’ because muta  on scanning of SDHB, SDHC, and SDHD was 
nega  ve, while the family histories of these cases were nega  ve for HN-paraganglioma or 
any of the other clinical s  gmata that would suggest the involvement of VHL, NF1 or the 
RET gene. 
Muta  on scanning 
SDHB, SDHC, and SDHD genes were scanned for the presence of muta  ons at the 
laboratory for DNA diagnos  cs at the LUMC. All exonic regions of these genes were tested 
by direct sequencing using the Sanger method on an ABI 3177 Gene  c Analyzer, star  ng 
with the exon containing the known Dutch founder muta  ons in SDHD followed by exons 
that had previously been found to contain pathogenic muta  ons in SDHD, SDHB, and 
SDHC (in that order) in the Dutch popula  on[4,11]. If that remained nega  ve, scanning 
was completed by analyzing the remainder of exons of these genes. More recently, the 
sporadic, muta  on-nega  ve cases were also examined by MLPA for the presence of large 
dele  ons in SDHB, SDHC, and SDHD[12]. MLPA was carried out with the P226 MLPA kit, 
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containing probes for all exons and the promoter of each of these genes (27 diff erent 
probes), according to the MRC Holland protocol[13]. 
RNA isola  on and microarray hybridiza  on 
Tissue samples were snap frozen in liquid nitrogen and stored at -70°C. An experienced 
pathologist (PCWH) es  mated the tumor percentage of the samples. Only samples with 
a tumor percentage of more than 70% were included in the study. Sample prepara  on 
was performed according to the Aff ymetrix protocol (Aff ymetrix Inc., Santa Clara, CA)
[14]. In brief, 30 5 μm sec  ons were taken from each frozen  ssue sample and total RNA 
was extracted using Trizol (Life Technologies, Inc., Rockville, MD), and purifi ed using 
RNeasy columns according to the manufacturers protocol (Qiagen, Valencia, CA). A 
minimum of 10 μg of total RNA was used to synthesize cDNA with the Superscript Choice 
system (Life Technologies, Rockville, MD). First strand cDNA synthesis was performed 
with T7-(dT)24 oligomer primer, followed by second strand synthesis using T4 DNA 
polymerase. The resultant was purifi ed using Phase Lock Gel and precipitated in ethanol. 
Synthesis of bio  ne labeled cRNA was performed using the BioArray HighYield Transcript 
Labeling Kit (Enzo Diagnos  cs, Inc., Farmingdale, NY) according to the protocol of the 
manufacturer. In vitro transcrip  on (IVT) reac  ons took place at 37°C for 4,5 hours. The 
labeled cRNA was purifi ed using RNeasy columns (Qiagen, Valencia, CA) and fragmented 
in fragmenta  on buff er at 94°C for 35 minutes. Fragmented cRNA prepared from each 
individual sample was then transferred to a specialized Aff ymetrix hybridiza  on centre 
(Leiden Genome Technology Centre, LGTC). Here the samples were hybridized according 
to the manufacturers’ protocol in a concentra  on of 0,5 μg/μl to a human GeneChip 
U95A-v2 (Aff ymetrix), containing approximately 8500 probe sets. The data discussed in 
this publica  on have been deposited in NCBIs Gene Expression Omnibus (GEO), and are 
accessible through GEO Series accession number GSE12921[15]. 
Sample size calcula  on 
Sample size calcula  ons were performed according to the method described by Pounds 
and Cheng[16]. 
Normaliza  on and expression analysis 
Acquisi  on and quan  fi ca  on of array images was performed using the MAS so  ware 
package (Aff ymetrix). All arrays were normalized with gcrma normaliza  on using the R 
sta  s  cal so  ware package available from Bioconductor[17-19]. 
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Unsupervised clustering analysis 
Unsupervised two-way hierarchical clustering was performed with complete linkage 
and Euclidian distance metrics, using the R sta  s  cal so  ware package available from 
Bioconductor[18,19]. 
Supervised analysis
The R package ‘Linear Models for Microarray Data’ (LIMMA) was used for the assessment 
of diff eren  al expression of individual genes between paraganglioma subgroups[20]. 
Overall gene expression diff erences between paraganglioma subgroups were evaluated 
with the ‘global test’ designed by J.J. Goeman using the R package ‘global test’ available on 
Bioconductor[18,19,21]. In order to evaluate subtle diff erences between paraganglioma 
subgroups, we analyzed all pathways in the Catalog of Human Gene Sets v2.0, containing 
1687 gene sets, available from the Broad Ins  tute as part of their publicly accessible Gene 
Set Enrichment Analysis (GSEA) so  ware package[22,23]. Instead of the sta  s  cal method 
used in the GSEA so  ware, we used the global test developed by Goeman et al., because 
the la  er tends to have more power to detect gene sets with small eff ect sizes[24-26]. 
Specifi c a  en  on was paid to the gene sets that were signifi cantly represented in SDH-
linked phaeochromocytomas in a recent gene expression study by Dahia et al.[9]. Next, we 
applied the gene set that diff eren  ated SDH- from MEN2-associated phaeochromocytomas 
in the aforemen  oned study to our data using the global test[9,21]. Furthermore, we 
performed a pathway-based analysis using the global test on manually curated gene sets, 
focusing specifi cally on pathways involved in processes or condi  ons that are known or 
assumed to play a role in paraganglioma forma  on, i.e. prolifera  on, survival, apoptosis, 
cell cycle regula  on, metabolism and hypoxia, based on pathways described in literature 
and the publicly available pathway databases KEGG and Biocarta[27-29]. In addi  on to 
the evalua  on of func  onally related genes we also performed the global test on some 
topographically related gene groups on chromosome 11, i.e. the PGL2 minimal haplotype 
on 11q13, the SDHD region on 11q23, and 11p15, an imprinted region that has been 
implicated in SDHD-linked paraganglioma and phaeochromocytoma forma  on[10,21]. In 
all, 264 manually curated pathways and func  onally related gene sets were tested. All 
tests, both for genes and pathways, were corrected for mul  ple tes  ng based on the false 
discovery rate (FDR) criterion, using the method of Benjamini and Hochberg[30]. 
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Table 1. Clinicopathological characteris  cs and muta  on status.
Sample Tumor Loca  on Family history Muta  on Sex Age at onset 
(yrs)
Mul  ple 
paragangliomas
1 PGL04 CBT PGL2 – f 28 yes
2 PGL01 CBT PGL2 – f 28 yes
3 PGL02 CBT PGL2 – m 37 yes
4 PGL19 CBT PGL2 – f 32 yes
5 PGL05 CBT SDHD D92Y m 43 yes
6 PGL06 CBT SDHD D92Y m 47 yes
7 PGL13 CBT SDHD D92Y f 29 yes
8 PGL14 CBT SDHD D92Y f 45 no
9 PGL16 CBT SDHD D92Y f 47 yes
10 PGL17 CBT SDHD D92Y f 74 no
11 PGL10 CBT SPOR – f 44 no
13 PGL12 CBT SPOR – f 49 no
14 PGL15 CBT SPOR – f 38 no
15 PGL23 CBT SPOR – f 70 no
16 PGL20 CBT SPOR – m 27 no
CBT = caro  d body tumor; PGL2 = posi  ve family history for PGL2-linked paragangliomas; SDHD = posi  ve family 
history for SDHD-linked paragangliomas; SPOR = sporadic sample, nega  ve family history of paraganglioma or 
phaeochromocytoma and no muta  on in the SDHB, SDHC or SDHD gene; D92Y = p.Asp92Tyr, a Dutch founder 
muta  on in the SDHD gene; m = male pa  ent, f = female pa  ent.
Results 
Due to the rarity of PGL2-linked paragangliomas, sample sizes in this study are inevitably 
limited. In all, 21 samples were hybridized including 3 duplicates. Four samples (1 SDHD-
linked sample, 2 PGL2-linked samples and 1 duplicate experiment) were excluded because 
of poor RNA or hybridiza  on quality, leaving 15 diff erent tumors in the analysis (5 sporadic, 
6 SDHD-linked and 4 PGL2-linked samples) (Table 1). 
Sample size calcula  on 
Calcula  ons showed that with this sample set and assuming that at least 30 to 35 genes 
are truly diff eren  ally expressed between subgroups with a fold change of 2.0 or more, 





Two-way hierarchical clustering of SDHD-linked, PGL2-linked and sporadic paragangliomas 
revealed no clear clusters. No grouping according to gene  c background was found (Figure 
1). In fact, overall gene expression was very similar in all paraganglioma samples, with 
high correla  on coeffi  cients for overall gene expression between all tumors irrespec  ve 
of gene  c background.
Supervised analysis
Using the LIMMA analysis, we did not fi nd individual genes that are signifi cantly diff eren  ally 
expressed between sporadic, SDHD- and PGL2-linked paragangliomas. The global test 
did not reveal signifi cant diff erences in overall gene expression between paraganglioma 
subgroups. Using all 1687 func  onal gene sets from the Catalog of Human Gene Sets 
incorporated in the GSEA so  ware, analysis with the global test revealed no signifi cant 
diff erences in gene expression between SDHD- and PGL2-linked tumors, SDHD-linked and 
sporadic tumors, or PGL2-linked and sporadic tumors for any gene set when corrected 
for mul  ple tes  ng. In a recent phaeochromocytoma gene expression study, several gene 
sets from the Catalog of Human Gene Sets were found to be signifi cantly represented 
in SDH-associated phaeochromocytomas[9]. These gene sets comprise microtubule 
ac  vity, oxidoreductase ac  vity, HIF1α, angiogenesis, proteasome degrada  on, electron 
transport chain, CCR3, collagen and glutathione metabolism[9]. In our study, no signifi cant 
diff eren  al expression between sporadic, SDHD- and PGL2-linked paragangliomas was 
found for these gene sets. Dahia et al. also iden  fi ed a gene set diff eren  a  ng SDH- from 
MEN2-associated phaeochromocytomas[9]. This gene set contained 400 probes, encoding 
288 diff erent annotated genes. 212 of these 288 genes were also represented on the 
Aff ymetrix U95A chip used in this study. No signifi cant diff eren  al expression between 
sporadic, SDHD- and PGL2-linked head and neck paragangliomas was observed for this 
gene set (data not shown). Next, we performed the global test on manually selected 
pathways assumed to play a role in paraganglioma forma  on, i.e. prolifera  on-, survival-, 
apoptosis-, cell cycle regula  on-, metabolism- and hypoxia-related pathways. In all, 264 
pathways and func  onal gene sets were tested. No signifi cant diff eren  al expression was 
observed for any of these gene sets between the paraganglioma subgroups (data par  ally 
shown in Figure 2). Last, we performed a more detailed evalua  on of genes located on 
chromosome 11 loci of interest (11q23, 11q13 and 11p15). This analysis also did not 
reveal signifi cant diff erences between paraganglioma subgroups (data par  ally shown in 
Figure 3). 
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Figure 1. Two way hierarchical clustering analysis of gene  cally defi ned paraganglioma subgroups. 
Two way hierarchical clustering of PGL2-linked (yellow squares in the top row), SDHD-linked (blue 
squares in the top row), and sporadic (grey squares in the top row) head and neck paragangliomas. 
Samples are represented as columns and genes as rows. Expression levels are normalized for each 
gene. The mean is zero, and the color scale indicates the expression of the gene rela  ve to the 
mean. Red indicates high expression, black indicates mean expression, and green indicates low 
expression levels. Overall gene expression is very similar for all samples, no well defi ned sample 
clusters can be found.
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Figure 2. Heatmap of HIF1α target genes. Samples are represented as columns and genes as 
rows. Samples are ordered from le   to right: PGL2-linked paragangliomas (yellow), SDHD-linked 
paragangliomas (blue), and sporadic paragangliomas (grey). In all, 264 pathways and func  onal 
gene sets related to processes that are assumed to play a role in paraganglioma forma  on (i.e. 
prolifera  on, survival, apoptosis, cell cycle regula  on, metabolism and hypoxia) were tested (data 
not shown). None of them showed signifi cant diff eren  al gene expression between SDHD-linked, 
PGL2-linked and sporadic paragangliomas, including the gene sets encoding SDH and HIF1α target 
genes involved in the processes of angiogenesis, glucose metabolism and prolifera  on. 
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Figure 3. Heatmap of chromosome 11 genes located on 11p15 and the PGL2 minimal haplotype 
on 11q13. The upper heatmap represents genes located on chromosome 11 region 11p15, and 
the lower heatmap the PGL2 minimal haplotype located on 11q13. Samples are represented as 
columns and genes as rows. Samples are ordered from le   to right: PGL2-linked paragangliomas 
(yellow), SDHD-linked paragangliomas (blue), and sporadic paragangliomas (grey). No signifi cant 
diff erences in gene expression can be observed for genes located on the 11p15 region, which has 
been implicated in SDHD-linked paraganglioma forma  on, or for genes within the PGL2 minimal 




In our gene expression analysis of sporadic, SDHD- and PGL2-linked paragangliomas of the 
head and neck, no signifi cant diff erences in gene expression profi le were observed between 
these gene  cally defi ned paraganglioma subgroups. Instead, we found considerable 
similarity between PGL2-linked, SDHD-linked and sporadic tumor samples in both 
unsupervised and supervised analyses (Figures 1, 2 and 3). This correlates well with the 
observa  on that sporadic as well as SDHD-linked and PGL2-linked paragangliomas of the 
head and neck share important clinical characteris  cs like the age of onset of symptoms, 
the indolent growth pa  ern, and a usually benign behavior of the tumor, although 
mul  ple paragangliomas are less o  en observed in sporadic cases[31-34]. Furthermore, 
all head and neck paraganglioma subtypes share the typical histological architecture of 
the ‘zellballen’, groups of neoplas  c chief cells surrounded by sustentacular cells[35,36]. 
In a recent gene expression study by Dahia et al. of sporadic, SDHB-, SDHD-, VHL-, MEN2- 
and NF1-associated phaeochromocytomas, two phaeochromocytoma clusters were 
iden  fi ed: a cluster containing VHL- and SDH-linked tumors and another containing MEN2- 
and NF1-linked tumors[9]. Gene set enrichment analysis showed that microtubule ac  vity, 
oxidoreductase ac  vity, HIF1α, angiogenesis, proteasome degenera  on, electron transport 
chain, chemokine CCR3, collagen and glutathione metabolism gene sets were signifi cantly 
represented in the gene expression signature of SDH-linked phaeochromocytomas[9]. In 
our study, the GSEA pathway-based supervised analysis of sporadic, PGL2- and SDHD-
linked paragangliomas did not reveal signifi cant diff erences between the subgroups for 
all GSEA gene sets, including the gene sets that characterized SDH tumors in the study by 
Dahia et al.[9]. The authors also iden  fi ed a gene set that diff eren  ated SDH-linked tumors 
from MEN2-linked phaeochromocytomas[9]. When applying this diff eren  a  ng gene 
set to our dataset, signifi cant diff erences in gene expression could not be found. These 
fi ndings suggest that all paraganglioma subgroups in our study share the characteris  cs 
that defi ned the SDH-linked tumors in the study by Dahia et al., i.e. a signature of hypoxia, 
reduced oxidoreductase, and increased angiogenesis[9]. Further characteriza  on of the 
gene expression profi les of head and neck paragangliomas would require comparison with 
normal paraganglionic  ssue. However, due to the microscopic size of normal paraganglia 
and their close anatomical rela  ons with essen  al nerves and blood vessels it is not 
feasible to acquire this in suffi  cient quan  ty and quality to reliably perform RNA-based 
tests such gene expression microarrays. 
In the present study, more detailed analysis of manually selected pathways and func  onal 
gene sets that are assumed to play a role in paraganglioma forma  on, i.e. processes of 
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metabolism, angiogenesis and hypoxia as well as prolifera  on, survival, apoptosis and 
cell cycle related pathways also did not reveal signifi cant diff eren  al expression between 
sporadic, SDHD-linked and PGL2-linked paragangliomas. A striking fi nding is that there is 
no signifi cant diff eren  al expression of SDH genes between paraganglioma subgroups. This 
is in agreement with prior observa  ons of SDHB suppression and enhanced expression of 
SDHA in sporadic, SDHD- and PGL2-associated tumors[9,37]. Of further interest is the 
observed similar gene expression between all paraganglioma subgroups for HIF1α and 
HIF1α downstream target genes (Figure 2). HIF1α and HIF1α downstream target genes 
have been shown to be upregulated in SDH-linked tumors[9,38-40]. The mechanism of 
HIF1α induc  on in tumors with SDH muta  ons has recently been shown to be succinate 
accumula  on resul  ng from loss of SDH func  on, leading to inhibi  on of HIF-α-prolyl 
hydroxylases and thus to elevated HIF1α ac  vity[39,41]. The transcrip  on factor HIF1α 
regulates a host of genes that are involved in prolifera  on and survival, angiogenesis and 
glucose metabolism, and the elevated HIF1α ac  vity or pseudo hypoxic drive is thought 
to be the basic mechanism of tumorigenesis in SDH-linked paragangliomas[39,42,43]. It 
has been demonstrated that in PGL2-linked tumors SDH func  on is disrupted, as it is in 
SDHD-linked paragangliomas[37]. PGL2- and SDHD-linked tumors also appear to share 
the features of increased HIF1α ac  vity and upregula  on of HIF1α targets that results 
from SDH inac  vity[9,37,41]. These fi ndings may hold important clues for the func  on of 
the yet uniden  fi ed PGL2 gene on 11q13, as a defect in the yet uniden  fi ed PGL2 gene 
seems to have consequences similar to a muta  on in the SDHD gene. No mitochondrial 
complex II genes are known to be located in the 11q13 region, but the PGL2 gene could 
aff ect SDH func  on by interfering with SDH assembly, transport or inser  on into the 
mitochondrial membrane, or encode a cofactor that is essen  al for proper SDH func  on. 
Alterna  vely, PGL2 gene func  on could be more directly associated with HIF1α stability 
and thus cons  tute the pseudohypoxic drive that leads to paraganglioma forma  on. We 
did not fi nd signifi cant diff erences in expression between paraganglioma subgroups for 
the PGL2 minimal haplotype on 11q13, and further research to clarify the exact PGL2 
iden  ty is currently ongoing. 
Another important clinical feature shared by both SDHD- and PGL2-linked tumors 
is the remarkable parent-of-origin-dependent inheritance of disease. Inheritance 
of paraganglioma occurs in an autosomal dominant way only when paternally 
transmi  ed, while no phenotype develops a  er maternal transmission[44,45]. 
Previously, we demonstrated that in SDHD-linked head and neck paragangliomas and 
phaeochromocytomas this exclusive paternal transmission of the disease is caused by 
consistent loss of the en  re maternal chromosome 11[10]. We hypothesized that selec  ve 
loss of an as yet uniden  fi ed, imprinted gene on the 11p15 region drives this selec  ve 
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chromosome loss, and may also be important in the forma  on of non-SDHD-linked 
paraganglioma[10]. In line with this hypothesis, recently H19, a paternally imprinted gene 
on 11p15, has been put forward as the tumor suppressor gene responsible for the parent-
of-origin-dependent inheritance in SDHD-linked head and neck paragangliomas[46]. In 
the present study, supervised analysis of all chromosome 11 probe sets on the array, as 
well as more detailed analysis of genes on chromosome 11p15, 11q23 (loca  on of the 
SDHD gene) and 11q13 (loca  on of the PGL2 locus), did not show signifi cant expression 
diff erences between sporadic, PGL2- and SDHD-linked tumors (Figure 3). It is possible 
that this result refl ects the loss of chromosome 11 in all these paraganglioma subgroups. 
As the rela  on between chromosome loss and gene expression altera  ons is complex, 
we must interpret the observed lack of gene expression diff erences between these 
groups cau  ously in this context. It has been shown previously that all SDHD-linked HN-
paragangliomas show loss of the en  re copy of the wildtype maternal chromosome 11, 
and the same applies to PGL2-linked paragangliomas[10]. Par  al or en  re chromosome 
11 loss has also been observed in sporadic paragangliomas, although only in 2 out of 
9 cases[47]. Chromosome 11 loss could thus be an important step in paraganglioma 
forma  on irrespec  ve of the gene  c background. 
Conclusion
In this study of sporadic, SDHD- and PGL2-linked paragangliomas of the head and neck, 
we have found very similar gene expression profi les for all three gene  c subgroups. This 
correlates well with observa  ons of comparable histopathology and clinical behavior. 
More detailed analysis of gene sets that have previously been shown to characterize SDH-
linked tumors, as well as pathways known to be implicated in SDH-linked paraganglioma 
forma  on, show no diff eren  al gene expression for these paraganglioma subgroups. This 
suggests that a defect in the yet uniden  fi ed PGL2 gene, like a muta  on in the SDHD gene, 
disrupts normal SDH func  on. Further gene expression analysis of the PGL2 locus on 11q13 
in this study did not reveal the PGL2 iden  ty. The lack of diff eren  al gene expression of 
chromosome 11 genes between the paraganglioma subgroups might further indicate that 
chromosome 11 loss, as demonstrated in SDHD-linked paragangliomas, is an important 
feature in the forma  on of a paraganglioma regardless of the gene  c background.
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Soma  c loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in 
SDHD-linked paraganglioma and phaeochromocytoma families. 




Germline muta  ons in succinate dehydrogenase subunits B, C and D (SDHB, SDHC 
and SDHD), genes encoding subunits of mitochondrial complex II, cause hereditary 
paragangliomas and phaeochromocytomas. In SDHB (1p36)- and SDHC (1q21)-linked 
families, disease inheritance is autosomal dominant. In SDHD (11q23)-linked families, 
the disease phenotype is expressed only upon paternal transmission of the muta  on, 
consistent with maternal imprin  ng. However, SDHD shows biallelic expression in brain, 
kidney and lymphoid  ssues. Moreover, consistent loss of the wild-type (wt) maternal 
allele in SDHD-linked tumors suggests expression of the maternal SDHD allele in normal 
paraganglia. Here we demonstrate exclusive loss of the en  re maternal chromosome 11 
in SDHD-linked paragangliomas and phaeochromocytomas, sugges  ng that combined 
loss of the wt SDHD allele and maternal 11p region is essen  al for tumorigenesis. We 
hypothesize that this is driven by selec  ve loss of one or more imprinted genes in the 
11p15 region. In paternally, but not in maternally derived SDHD muta  on carriers, this can 
be achieved by a single event, that is, non-disjunc  onal loss of the maternal chromosome 
11. Thus, the exclusive paternal transmission of the disease can be explained by a soma  c 
gene  c mechanism targe  ng both the SDHD gene on 11q23 and a paternally imprinted 
gene on 11p15.5, rather than imprin  ng of SDHD. 
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Introduc  on
Paragangliomas (PGL) of the head and neck are neuroendocrine tumors arising in 
branchiomeric and intravagal paraganglia. They are rare, highly vascular, mostly benign 
tumors usually characterized by an indolent growth pa  ern. Paragangliomas, like normal 
paraganglia, consist of two cell types: the type I or chief cells, which represent the 
neoplas  c popula  on in paragangliomas, and the type II or sustentacular cells[1]. The 
most common site is the caro  d body, a chemorecep  ve organ in the bifurca  on of the 
caro  d artery that senses oxygen levels in peripheral blood in a way that is not yet fully 
understood. Most paragangliomas appear to be sporadic, but a signifi cant minority of 
the cases (10-50%) has been shown to be familial. Recently, several genes have been 
implicated in these familial forms of the disease. Analysis of families carrying the PGL1 
gene revealed germline muta  ons in the succinate dehydrogenase complex-subunit 
D (SDHD) gene on 11q23[2]. This gene encodes a mitochondrial protein, an anchoring 
subunit of the mitochondrial respiratory chain complex II. 
Subsequently, muta  ons in other subunits of the same mitochondrial complex II were 
also found to be associated with hereditary paraganglioma. The SDHB gene (1p36.1-p35) 
encodes a cataly  c subunit of mitochondrial complex II and has been implicated in familial 
paraganglioma of the head and neck as well as in familial paraganglioma of the adrenal 
medulla, be  er known as pheochromocytoma[3]. Both SDHD and SDHB appear to act 
as tumor suppressor genes in hereditary paraganglioma. The SDHC gene (1q21) encodes 
the second anchoring subunit of the mitochondrial complex II and muta  ons in this gene 
have recently been shown to cause hereditary paraganglioma as well[4]. Furthermore, a 
hereditary paraganglioma family with linkage to a region on 11q13.1, the PGL2 locus, has 
been described[5]. However, no mitochondrial complex II genes are known to be located 
in this region. 
Interes  ngly, strikingly diff erent inheritance pa  erns have been found for paragangliomas 
of diff erent gene  c background. Whereas SDHB- and SDHC-linked pedigrees show 
autosomal dominant inheritance, SDHD- and PGL2-linked pedigrees exhibit a clear parent-
of-origin eff ect: inheritance of paraganglioma occurs in an autosomal dominant way only 
when paternally transmi  ed, while no phenotype develops a  er maternal transmission. 
This pa  ern is consistent in all SDHD-linked pedigrees, and suggests sex-specifi c epigene  c 
modifi ca  on of the maternal SDHD allele, consistent with genomic imprin  ng[6]. However, 
no evidence of a physical imprint, for example, methyla  on of the 11q22.1-23 region, has 
been found. Furthermore, the SDHD gene is biallelicly expressed in human brain, kidney 
and lymphoid  ssue[2]. It has been suggested that the imprin  ng of SDHD is restricted 
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to the paraganglia cells, but loss of the maternal SDHD allele is frequently observed in 
paraganglioma from SDHD-muta  on carriers, an event that is unlikely to promote tumor 
growth when the maternal allele is already silenced by an imprint[2,7,8]. We hypothesized 
that soma  c, selec  ve loss of the whole maternal chromosome 11 could explain the 
exclusive paternal inheritance of the disease, mimicking maternal imprin  ng of the SDHD 
gene. We performed fl uorescent in situ hybridiza  on (FISH) studies on 23 SDHD-linked 
tumors using diff erent probe sets in order to test for loss of chromosome 11, and loss 
of heterozygosity (LOH) analysis using several microsatellite markers to determine the 
parental origin of the lost chromosome. Complete loss of a chromosome 11 copy was 
found in all tumors, and LOH analysis on a subset of seven tumors from pa  ents for whom 
parental DNA samples were available revealed the exclusive maternal origin of the lost 
chromosome. We propose that the selec  ve loss of the maternal chromosome 11 copy is 
driven by the allelic phasing of the SDHD germline muta  on and a paternally imprinted 
tumor suppressor gene on 11p15. 
Materials and methods
Pa  ents and families
Diagnosis of paraganglioma was based on medical history, physical and otolaryngological 
examina  on, radiological imaging and histopathology of the excised tumor. A  er obtaining 
informed consent, peripheral blood was obtained from pa  ents and their parents for 
genomic DNA isola  on. Rou  nely processed archival paraffi  n-embedded caro  d body 
paraganglioma or phaeochromocytoma  ssue from pa  ents with the D92Y Dutch founder 
muta  on in the SDHD gene were obtained from the archives of the Department of 
Pathology of the Leiden University Medical Center[2,29].
Muta  on detec  on
The D92Y muta  on in the SDHD gene was detected by direct sequencing of PCR products 
obtained from peripheral blood lymphocyte (PBL) DNA as described previously[2].
Interphase FISH on paraffi  n-embedded  ssue sec  ons 
We performed interphase FISH on paraffi  n-embedded sec  ons as previously described[30]. 
The pLC11A probe and the PUC1.77 probe for the centromeric alphoid repeat DNA of 
chromosomes 11 and 1, respec  vely, were kindly provided by Dr. J. Wiegant (Department 
of Molecular Cell Biology, LUMC, Leiden, The Netherlands)[31,32]. We have chosen the 
PUC1.77 probe as a reference because of our extensive experience with the interpreta  on 
of the signals given by this probe and a previous LOH study did not indicate involvement 
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of chromosome 1 in PGL1/SDHD-linked paragangliomas[33]. The probes were labeled 
by standard nick transla  on with bio  n-16-aUTP or digoxigenin-11-dUTP (Roche, Basel, 
Switzerland). A total of 200 nuclei were analyzed for each sample by two independent 
inves  gators (EFH and ESJ).
Triple color interphase FISH on nuclei isolated from paraffi  n-embedded  ssue
Isola  on of intact nuclei, hybridiza  on and immunodetec  on were performed as 
previously described, with slight modifi ca  ons[34]. The hybridiza  on mix contained 50% 
formamide, 3 ng/μl of each of the three probes (either PUC1.77, pLC11A and 3F7 or 
PUC1.77, 371C18 and 469N6) and a 50-fold excess of human Cot-1 DNA (Invitrogen Life 
tech., Paisley, UK). A volume of 5 μl of the mix was applied directly onto the slides and 
covered with an 18 x 18mm2 coverslip. A  er a denatura  on step of 8 min at 80°C, the 
slides were incubated overnight at 37°C in a moisture chamber. The BAC probes 371C18 
(telomere 11p), 469N6 (telomere 11q) and 3F7 (11q23, containing the SDHD gene) were 
obtained from the Children’s Hospital Oakland Research Ins  tute (Peter de Jong BAC 
library RP11). All probes were labeled by standard nick transla  on with bio  n-16-aUTP, 
digoxigenin-11-dUTP or fl uorescein-12-dUTP (Roche). A total of 200 nuclei were analyzed 
for each sample and probe combina  on by two independent inves  gators (EFH and ESJ).
Flow cytometry analysis and fl ow sor  ng
Cell prepara  on and staining procedures were performed as described elsewhere[35]. 
Pepsin diges  on was used to isolate whole nuclei from 45 mm thick paraffi  n sec  ons. 
Nuclei were subsequently stained with propidium iodide. DNA content was determined 
with a FACscan fl ow cytometer (Becton & Dickson, Immunocytometry Systems, San 
Jose, CA, USA). On average, 100.000 nuclei were measured in each sample. If the DNA 
histogram showed a single G0,1 and G2 peak both popula  ons were subsequently sorted 
on a FACsorter (FACSVantage SE, Becton & Dickson, Immunocytometry Systems, San 
Jose, CA, USA). Owing to the G2 arrest o  en detected in paraganglioma cells, the G2,M 
popula  on was considered enriched for tumor cells[12]. If the DNA histogram showed 
G0,1 peaks, the le   peak was considered to represent the diploid and the right peak the 
aneuploid popula  on. Cells were sorted directly into 1.5 ml microfuge tubes and DNA was 
subsequently isolated as previously described[36]. 
LOH analysis
LOH analysis was performed as previously described[1]. Genotypes of pa  ents and their 
parents were established for the markers D11S1984 and D11S2362 (11p15), D11S4183 
(11p11), D11S1335, D11S1765 and D11S4075 (11q13) and D11S1647, D11S3178 and 
pDJ159Ogt1R (11q23). Markers were informa  ve if they were heterozygous in the pa  ent, 
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and the parental origin of the alleles could be unambiguously derived. Subsequently, in 
informa  ve cases both diploid and aneuploid or diploid and the G2,M frac  ons were tested.
Results
We started with FISH experiments on  ssue sec  ons from fi ve paragangliomas from D92Y 
carriers. The ra  onale for ini  ally choosing sec  ons rather than cell suspensions was the 
expecta  on that this would facilitate the visual selec  on of nuclei of the type I (chief) 
cells. The sec  ons were hybridized with centromere probes for chromosomes 11 and 
1, the la  er chromosome serving as a ploidy reference. Loss of centromere 11 rela  ve 
to centromere 1 was found in all tumors, in 45-65% of nuclei (Figure 1). Of the nuclei 
with three signals for chromosome 1, 13-54% had two signals for chromosome 11, 5-54% 
had one signal for chromosome 11 and 5-32% had no signals for chromosome 11. Of the 
nuclei with two signals for chromosome 1, 44-66% had one signal for chromosome 11 and 
8–31% had no signals for chromosome 11, whereas of the nuclei with only one signal for 
chromosome 1, 0-7% had no signals for chromosome 11. 
To exclude the possibility that loss of signals due to  ssue sec  oning could have interfered 
with the results, we next hybridized isolated whole nuclei of 10 paragangliomas, three of 
which were also studied in the fi rst study. Whereas the use of suspensions precluded the 
selec  on of type I cells, evalua  on of an unselected sample of 200 nuclei s  ll demonstrated 
the rela  ve loss of centromere 11 in all samples in 35-63% of nuclei (Figure 2). 
To discriminate between loss of the en  re chromosome and subchromosomal loss due to 
complex rearrangements, we next analyzed isolated whole nuclei of nine paragangliomas 
and two pheochromocytomas from D92Y muta  on carriers that were not used in the 
previous studies, using a triple color FISH technique. This allows simultaneous detec  on 
of two probes on chromosome 11 and one probe on centromere 1 (Figure 3). First, we 
studied the centromere 1 and 11 probes in combina  on with a BAC probe that covers 
the SDHD gene on 11q23 (Figure 3a and c). Concomitant loss of both probes located 
on chromosome 11 rela  ve to centromere 1 was observed in all samples, in 24-65% of 
paraganglioma and 31-62% of pheochromocytoma nuclei (Figure 4a). 
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Figure 1. Results obtained from interphase FISH analysis of paraffi  n-embedded sec  ons of fi ve 
SDHD-linked paragangliomas (P1- P5). (a) Frequency distribu  on of signals obtained with the 
centromere 1 (PUC1.77) probe (upper panel) and the centromere 11 (pLC11A) (lower panel). 
Compared to chromosome 1, there is a clear loss of chromosome 11 centromere signals. More than 
two chromosome 1 signals are observed in 9-17% of the nuclei, indica  ng aneuploidy or tetraploidy. 
(b) Loss of centromere 11 rela  ve to centromere 1 signals (red and orange) is observed in 46-65% of 
the nuclei. Loss of centromere 1 signals rela  ve to centromere 11 (‘other combina  ons’) is 2-11%.
Next, we used BAC probes for the subtelomeric regions of 11p and 11q, with the centromere 
1 probe as a reference (Figure 3b and d). Concomitant loss of both probes located on 
chromosome 11 rela  ve to centromere 1 was found in 26-70% of paraganglioma and 
23-54% of pheochromocytoma nuclei (Figure 4b). In both triple-color experiments, loss 
of one of the two probes located on chromosome 11 rela  ve to the other was observed 
in only a small minority of nuclei (1-7% and 2-4%, respec  vely), demonstra  ng that the 
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observed rela  ve loss of chromosome 11 involves the en  re copy. Thus, rela  ve loss of 
chromosome 11 signals was observed in all 23 tumors, ranging from 23 to 70% (mean = 
40%).
Figure 2. Interphase FISH results from isolated whole nuclei of 10 SDHD-linked paragangliomas 
(P1- P10). (a) Frequency distribu  on of signals obtained with the centromere 1 (PUC1.77) probe 
(upper panel) and the centromere 11 (pLC11A) probe (lower panel). Compared to chromosome 1, 
there is a clear loss of chromosome 11 centromere signals. More than two chromosome 1 signals 
are observed in 12-40% of the nuclei, indica  ng aneuploidy or tetraploidy. (b) Loss of centromere 
11 rela  ve to centromere 1 signals (red and orange) is observed in 35-63% of the nuclei. Loss of 
centromere 1 signals rela  ve to centromere 11 (‘other combina  ons’) is negligible (0-1%).
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Figure 3. Triple colour FISH on whole nuclei isolated from paraffi  n-embedded  ssue. Probe/ 
colour combina  ons are centromere 11 (pLC11A, green), centromere 1 (PUC1.77, blue) and 11q23 
(RP11-3F7, red) (1a, 2a), and subtelomere 11p (RP11-645I8, green), subtelomere 11q (RP11-
469N6, red) and centromere 1 (blue) (1b, 2b). Each panel is a composite of individually captured 
nuclei. (1a) Paraganglioma cell nuclei. Top le   : diploid nucleus with two signals for each probe, 
top right: monosomy for chromosome 11, bo  om: tetraploidy for centromere 1 and diploidy for 
each chromosome 11 probe. (1b) Paraganglioma cell nuclei. Top le   : diploid nucleus, top right: 
chromosome 11 monosomy and rela  ve chromosome 11 loss in a tetraploid nucleus (bo  om). (2a) 
Phaeochromocytoma cell nuclei. Top le   : diploid nucleus, top right: chromosome 11 monosomy, 
bo  om le   : rela  ve chromosome 11 loss in a tetraploid nucleus, bo  om right: tetraploid nucleus 
without rela  ve chromosome 11 loss. (2b) Phaeochromocytoma cell nuclei. Top le   : diploid nucleus, 
top right: chromosome 11 monosomy, bo  om le   : rela  ve chromosome 11 loss in a tetraploid 
nucleus, bo  om right: a tetraploid nucleus without rela  ve chromosome 11 loss.
To determine the parental origin of the lost chromosome 11, we performed LOH 
analysis on seven paragangliomas and two pheochromocytomas that were also analyzed 
by triple-color FISH. For these cases, pa  ent- as well as parental PBL-derived DNA 
samples were available. LOH analysis was performed a  er tumor cell popula  ons were 
enriched by fl uorescence ac  vated cell sor  ng (FACS) of the aneuploid G0,1 frac  on, or 
the o  en increased G2,M frac  on of diploid tumors, with the diploid G0,1 frac  on as a 
reference[1,9]. We used three markers on 11p and fi ve on 11q. In fi ve paragangliomas 
and two pheochromocytomas, LOH analysis was informa  ve for at least one marker on 
both chromosome arms. For two paragangliomas, the analysis was informa  ve for only 
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one marker, either on 11p or 11q. In aneuploid- or G2,M-cell popula  ons, all evaluable LOH 
experiments showed loss of maternal alleles. As expected, reten  on of heterozygosity 
was not observed (Figure 5). In the diploid cell popula  ons and pa  ent PBL DNA samples, 
no LOH was found (data not shown). 
Figure 4. Counts of whole nuclei isolated from paraffi  n-embedded material of paragangliomas (P6- 
P14) and phaeochromocytomas (Ph1- Ph2), analysed by triple colour interphase FISH. (a) Results for 
centromere 11 (pLC11A), centromere 1 (PUC1.77) and 11q23 (RP11-3F7) probes. Simultaneous loss 
of both chromosome 11 probes rela  ve to centromere 1 (red and orange) was observed in 24-65% 
of paragangliomas and 31-62% of phaeochromocytomas. (b) Results for centromere 1, subtelomeric 
11p (RP11-645I8) and 11q (RP11-469N6) probes. Simultaneous loss of both chromosome 11 probes 
rela  ve to centromere 1 (red and orange) was observed in 26-70% of paragangliomas and 23-54% 
of phaeochromocytomas. For each tumor, distribu  ons are very similar in (a) and (b) indica  ng high 
reproducibility of the technique. Note that in both (a) and (b) nonsimultaneous loss of chromosome 
11 probes or loss of centromere 1 signals rela  ve to chromosome 11 signals (white) is infrequent 
(3-8% and 2-7%, respec  vely).
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Figure 5. LOH analysis of sorted aneuploid G0,1 or diploid G2,M frac  ons of isolated nuclei of paraffi  n-
embedded paragangliomas (P12- P19) and phaeochromocytomas (Ph1- Ph2). LOH involved the 
maternal allele in all cases in which the parental origin of the lost allele could be assessed (black). 
Reten  on of heterozygosity was not found for any of the informa  ve markers.
Discussion
The results obtained in this study demonstrate the loss of an en  re copy of chromosome 
11 in all inves  gated SDHD-linked paragangliomas. By LOH analysis, we were able to 
unequivocally demonstrate the maternal origin of the lost chromosome copy in a subset 
of seven paraganglioma and two phaeochromocytoma cases from which parental blood 
DNA samples were available. However, even without this direct proof, Knudson’s two-hit 
model predicts that in case of paternal transmission of the germline muta  on, loss of the 
wildtype maternal allele should have occurred in the tumor. 
Although loss of a centromere 11 already indicates loss of the en  re chromosome 11, we 
obtained addi  onal evidence by the triple color FISH experiments with telomeric probes 
and the 3F7 probe containing the SDHD gene. Since it was not possible to accurately 
discriminate type I cells in the FISH experiments on isolated nuclei, the evalua  on of an 
unselected sample of 200 nuclei unavoidably included non-neoplas  c cells as well. This 
explains most of the varia  on in loss of chromosome 11 between the diff erent cases and 
the concordance of the results obtained with diff erent probe sets for the individual tumors 
(Figure 4). FISH on  ssue sec  ons, while permi   ng selec  on of type I cell nuclei, did not 
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yield signifi cantly higher percentages of nuclei with rela  ve chromosome 11 loss because 
of loss of signals from sliced nuclei. The la  er problem would have seriously complicated, 
if not precluded, the interpreta  on of triple color FISH experiments on  ssue sec  ons and 
thus nuclear suspensions were used in all further experiments. 
The selec  ve loss of the en  re maternal chromosome 11 explains why SDHD-linked tumors 
appear to arise only upon paternal transmission of the muta  on, even though the SDHD 
gene itself is not imprinted. The la  er is supported by the observed biallelic expression of 
SDHD in several human  ssues[2]. Although it is not uncommon for the soma  c ’second hit’ 
in the Knudson model of tumorigenesis to involve a gross chromosomal mechanism such 
as non-disjunc  onal chromosome loss, it is intriguing that in SDHD-linked paragangliomas 
this appears to be the preferred mechanism for the second hit. We hypothesize that a 
second target gene on chromosome 11, which is subject to genomic imprin  ng, is involved 
in tumor forma  on. A growth advantage is gained when the wild-type maternal SDHD 
allele on 11q23 and the ac  ve maternal copy of this second, paternally imprinted gene 
are lost simultaneously. As the only region known to harbor an imprinted gene cluster 
on chromosome 11 is 11p15, we further hypothesize that this second gene is located 
here. Within that model, the most parsimonious mechanism would be a single event, 
viz. the loss of the en  re maternal chromosome 11 copy in case of a maternal wt SDHD 
allele and paternal inheritance of the SDHD muta  on (Figure 6a). Loss of the maternal 
wt SDHD allele only, for example, by loss of a part of 11q, would not target the second 
tumor-suppressor gene on 11p15 and therefore not lead to tumor forma  on (Figure 6b). 
In case of maternal inheritance of the SDHD muta  on, loss of paternal alleles would not 
lead to tumor forma  on for the same reason (Figure 6c and d). At least two events caused 
by diff erent chromosomal mechanisms will be required to inac  vate both SDHD and the 
imprinted gene on 11p15 when SDHD is maternally transmi  ed. These are successive loss 
of the paternal wt SDHD allele by, for example, mito  c recombina  on, followed by loss 
of the recombined paternal chromosome containing the paternal 11q23 region and the 
maternal 11p15 region (Figure 6e). Given the evidence for complex LOH mechanisms in solid 
tumors, it is somewhat surprising that the probability of this occurring in paraganglioma 
forma  on appears to be very low or zero, since no cases of maternal transmission have 
been reported to date[10,11]. One explana  on might be that the number of cell divisions 
in normal paraganglia is simply too low since in most head and neck paragangliomas the 
growth frac  on is lower than 1%[12]. Selec  ve loss of the whole maternal chromosome 
11 would explain the exclusive paternal transmission of disease in paraganglioma linked 
to the PGL2 locus as well, because it is also located on 11q[5]. It would also explain the 
absence of genera  on skipping of tumor suscep  bility in SDHB (1p36-p35)- and SDHC 
(1q21)-linked families. In the la  er two, loss of the maternal 11p15 region is probably 
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also essen  al for tumor development, since SDHB, SDHC and SDHD encode subunits from 
the same mitochondrial complex. Dannenberg et al. detected loss of 11p in two out of 
nine sporadic paragangliomas by compara  ve genomic hybridiza  on, but the muta  on 
status of SDHB, SDHC or SDHD was not inves  gated[8]. Furthermore, loss of 11p has been 
reported in 45% of 11 sporadic abdominal paragangliomas[13]. Since data on the parental 
origin of the 11p losses are lacking, a major role for loss of maternal 11p in sporadic 
paragangliomas, although likely, s  ll remains to be proven. 
 
Figure 6. Model for the imprinted transmission of SDHD-linked paraganglioma. Maternal (white) 
and paternal (grey) chromosomes are depicted. (a) Both the maternal 11q region, containing the 
wt SDHD allele, and the maternal 11p region, containing the ac  ve tumor suppressor allele, are 
targeted. In case of an event targe  ng only the wt maternal SDHD allele on 11q (b), the ac  ve 
maternal tumor suppressor allele on 11p15 is not aff ected and tumor development is inhibited. In 
case of maternal inheritance of the SDHD muta  on, a second hit targe  ng the wt paternal allele 
by, for example, a dele  on of the paternal 11q region (c) or even the whole paternal chromosome 
11 (d) will leave the maternal 11p15 region intact and tumor forma  on is not ini  ated. When the 
SDHD muta  on is maternally transmi  ed, at least two events caused by diff erent chromosomal 
mechanisms will be required to inac  vate both the wt SDHD allele and the ac  ve maternal allele of 
the imprinted tumor-suppressor gene on 11p15, namely loss of the paternal wild-type SDHD allele 
by, for example, mito  c recombina  on, followed by loss of the recombined paternal chromosome 
containing the paternal 11q23 region and the maternal11p15 region (e). Apparently, this sequence 
of events is very unlikely in vivo.
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Interes  ngly, a high percentage (86%) of loss of chromosome 11 was also found in 31/36 
(86%) of Von Hippel-Lindau (VHL) related pheochromocytomas, of which 25/31 had loss 
of both 11p and 11q whereas six had only 11p loss[14]. The inves  gators suggested 
that this observa  on might indicate the involvement of a diff erent but essen  al and 
complementary gene  c pathway in VHL-linked pheochromocytoma tumorigenesis. The 
results of our study emphasize a role for loss of 11p, and in par  cular the maternal copy, 
in SDHD-linked pheochromocytoma forma  on as well. LOH of maternal 11p15, o  en with 
duplica  on of paternal 11p15, occurs frequently in human pediatric tumors including 
Wilm’s tumors, embryonal rhabdomyosarcomas, hepatoblastoma and adrenocor  cal 
carcinomas[15,16].
There is convincing evidence that LOH of 11p15 leads to disrup  on of the regula  on 
of expression of oppositely imprinted genes, in par  cular H19 and IGF2, in a variety of 
tumors[15,16]. The IGF2 gene product is a survival factor and strong mitogen that is 
overexpressed in a variety of human tumors including hereditary paragangliomas and 
pheochromocytomas[17]. H19 codes for an untranslated RNA that acts a nega  ve trans 
regulator of IGF2 expression[18,19].
Disrup  on of imprinted expression of 11p15 has also been implicated in the Beckwith–
Wiedemann syndrome and focal hyperplasia of Langerhans islets causing congenital 
hyperinsulinism (FoCHI)[20-22]. There is an interes  ng parallel between our fi ndings of 
maternal chromosome 11 loss in hereditary paraganglioma and loss of maternal 11p15 
in FoCHI[22]. This disease is caused by a paternally inherited, recessive muta  on of the 
ABCC8- or KCNJ11-gene, which is located on 11p15.4, that is, outside the imprinted 
region. The lesions show a strongly decreased expression of H19 and increased expression 
of IGF2. Thus, like in paraganglioma, a single soma  c event targets the wild-type allele 
of a non-imprinted suscep  bility gene on the maternal chromosome 11 as well as the 
maternally imprinted 11p15 region, and in both types of diseases this results in exclusive 
paternal transmission. Although the development of solid tumors in general is a mul  -step 
gene  c evolu  on process, it is unclear why tumor development in SDHD muta  on carriers 
specifi cally requires loss of a puta  ve maternally expressed tumor-suppressor gene, in 
addi  on to loss of wt SDHD. It has been speculated that the tumorigenic eff ects of SDHD 
inac  va  on might be explained by either mitogenic eff ects of elevated levels of reac  ve 
oxygen species or blocking of apoptosis due to mitochondrial dysfunc  on[23,24]. On the 
other hand, oxida  ve stress may trigger pro-apopto  c signaling and create a selec  on 
pressure for muta  onal ac  va  on of an  -apopto  c pathways. Since the IGF pathway 
has found to be involved in an  -apopto  c signaling, loss of the maternally expressed 
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H19 gene, a known suppressor of IGF2, might be an essen  al step in paraganglioma 
development[25,26].
SDHD-linked paraganglioma is a striking, and to our knowledge, fi rst example of the 
eff ect of allelic phasing on the penetrance of a hereditary tumor syndrome in man. 
Recently, allelic phasing of mouse chromosome 11 defi ciency was found to infl uence p53 
tumorigenicity[27]. The dele  on on chromosome 11 elevated the tumor suscep  bility 
and modifi ed the tumor spectrum when in trans with the p53 muta  on. Many genes 
display diff eren  al expression of parental alleles, due to genomic imprin  ng or gene  c 
regula  on[28]. Conceivably, a certain dosage ra  o of cancer-related alleles, which are 
coincidentally located on the same chromosome in cis-confi gura  on, may provide 
a selec  ve growth advantage. The tumorigenic poten  al of acquired chromosome 
aneuploidy, a hallmark of many solid tumors, would then be dependent on the allelic 
phasing or imprin  ng status of these genes. Our study provides a clear-cut example of 
this mechanism, which might also apply to an individual’s overall suscep  bility to more 
common forms of cancer.
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Chapter 1 consists of a review of the present knowledge of the clinical characteris  cs, the 
gene  cs, heredity and tumor biology of paragangliomas and pheochromocytomas.
Chapter 2 is a review of the literature on recent advances in the understanding of the 
gene  cs of paragangliomas. Current insights as well as future direc  ons are discussed, 
showing that major progress has been made in this fi eld since the discovery of muta  ons 
in SDH genes as a cause of paraganglioma syndrome. 
Chapter 3 presents an overview of the rela  ve frequency of muta  ons in SDH genes that 
are associated with paraganglioma-pheochromocytoma syndrome in the Netherlands. 
In this study, we fi nd that the large majority of muta  ons in SDH subunits or co-factors 
involve SDHD, followed by SDHAF2 and SDHB, whereas SDHC muta  ons are extremely 
rare. In addi  on, we found that the overwhelming majority of SDH-muta  on carriers 
in the Netherlands carry one of only 6 Dutch founder muta  ons in SDHAF2, SDHB and 
SDHD. Out of these 6 founder muta  ons, the p.Asp92Tyr founder muta  on in SDHD is by 
far the most prevalent, accoun  ng for 69% of all Dutch SDH muta  on carriers. Both the 
dominance of SDHD founder muta  ons and the limited gene  c heterogeneity among SDH 
muta  on carriers are unique to the Netherlands. 
Chapter 4 consists of a study of the muta  on status and clinical characteris  cs of a series of 
236 Dutch head and neck paraganglioma pa  ents treated at the Leiden University Medical 
Center. In line with the fi ndings in chapter 3, this Dutch pa  ent series is characterized 
by a high prevalence of SDHD muta  ons. Contras  ng with studies performed in other 
European countries, the majority (80%) of the pa  ents in this cohort present with a family 
history posi  ve for paraganglioma syndrome. Surprisingly, we fi nd that even in pa  ents 
with a nega  ve family history for paragangliomas, hereditary forms of the paraganglioma 
syndrome are found in the majority of cases. In this pa  ent group too, the disease is 
frequently linked to muta  ons in the SDHD gene. 
The clinical consequences of SDHD muta  ons are also evaluated in this chapter: an 
early mean age at onset of paraganglioma syndrome of 38 years, a high risk of mul  ple 
paragangliomas (73%), a risk of concurrent pheochromocytomas (13%) and extra-adrenal 
paragangliomas (8%), and a small risk of metasta  c disease (2%). Carriers of muta  ons 
in SDHAF2, SDHB and SDHC are also iden  fi ed in this pa  ent series, as well as pa  ents 
without a muta  on in any of these genes, but these subgroups cons  tute a small minority 
of the Dutch head and neck paraganglioma popula  on. We argue that the high prevalence 
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Summary and conclusion
of Dutch SDHD founder muta  ons, as well as the small numbers of SDHB-linked and SDH 
muta  on-nega  ve cases imply that the prevalence of paraganglioma syndrome may be 
higher in the Netherlands than elsewhere.
In chapter 5, a large, mul  genera  onal Dutch paraganglioma family linked to the D92Y 
(also p.Asp92Tyr or c.274G>T) founder muta  on in SDHD is described. The SDHD.D92Y 
muta  on is the dominant cause of head and neck paragangliomas in the Netherlands. 
As all muta  on carriers in this family carry the same muta  on, we were able to describe 
its phenotype in detail, and found that it does not diff er much from the phenotypes of 
other SDHD muta  ons. In addi  on, by including a large number of asymptoma  c family 
members, we were able to make accurate calcula  ons of the penetrance of this founder 
muta  on, both for the occurrence of paragangliomas as well as for symptoma  c disease. 
We found, in accordance with our expecta  ons, no maternal transmission of SDHD-
linked disease. We found that a paternally transmi  ed muta  on confers a high life  me 
risk of paragangliomas of 87%, however this is lower than previous es  mates. Moreover, 
we found that the life  me risk of developing paraganglioma-associated symptoms is 
considerably lower (57%). 
Chapter 6 comprises of a gene expression study, comparing the expression levels of more 
than 8.000 genes in SDHD-linked, PGL2-linked and sporadic paragangliomas. At the  me 
of analysis, the exact iden  ty of the PGL2 gene was unknown, and an a  empt was made to 
defi ne its func  on and thus clarify its iden  ty on the basis of a dis  nc  ve gene expression 
profi le. However, no signifi cant diff erences could be iden  fi ed in the gene expression of 
these gene  c subgroups. Even in selected subsets of genes that are known or suspected 
to play a role in the pathways that lead to paraganglioma tumorigenesis, no diff erences 
could be found. We therefore hypothesized that this might be because SDHD and PGL2 
muta  ons exert a similar eff ect on the func  onality of succinate dehydrogenase. We now 
know, since the iden  fi ca  on of SDHAF2 as the PGL2 gene and the discovery of its role in 
SDH ac  vity, that this is indeed the case. 
In chapter 7, a model is put forward to explain the peculiar inheritance pa  ern in SDHD-
linked paragangliomas and pheochromocytomas. It has been known for some  me that 
tumors almost never occur in SDHD muta  on carriers that have inherited the muta  on 
via their mother. However, if the same muta  on is inherited via the father, the risk of 
developing paraganglioma syndrome is very high. This mode of inheritance causes 
paraganglioma syndrome to skip genera  ons and is consistent with maternal imprin  ng 
of the SDHD gene. However, methyla  on or imprin  ng of the SDHD gene itself has never 
been established, and bi-allelic expression of SDHD has been demonstrated in non-
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paraganglion  ssues. In addi  on, SDHD acts as a tumor suppressor gene in paraganglioma 
syndrome, i.e. the loss of the wild-type SDHD allele is a prerequisite for paraganglioma 
development, which would be counter-intui  ve if the wild type allele was already silenced 
by methyla  on. 
In this study, we observe that in SDHD-linked paragangliomas and pheochromocytomas, 
the LOH does not only target the wild-type SDHD allele, but involves the whole maternal 
chromosome 11, sugges  ng that the loss of another gene on chromosome 11 is essen  al 
for paraganglioma development. As this soma  c loss consistently aff ects the maternal 
chromosome 11 copy, it is likely that this other gene is exclusively maternally expressed, 
thus paternally imprinted. These conjectures all point in the direc  on of genes located 
within the 11p15.5 region, a major imprinted gene cluster in the human genome, and 
we hypothesize that a paternally imprinted gene on 11p15.5 acts as an addi  onal tumor 
suppressor in SDHD-linked paraganglioma syndrome. 
According to this model, loss of the wild-type SDHD allele alone is insuffi  cient for tumor 
forma  on in SDHD muta  on carriers. Only upon loss of both the wild-type SDHD allele 
on 11q23 and the ac  ve maternal copy of a tumor suppressor gene on 11p15.5, tumor 
forma  on will occur. In paternally, but not in maternally derived SDHD muta  on carriers, 
this can be achieved by a single event: non-disjunc  onal loss of the maternal chromosome 
11 (chapter 1, fi gure 6). The virtually exclusive paternal transmission of the disease can be 
thus explained by a soma  c mechanism targe  ng both the wild type SDHD gene on 11q23 
and the maternal copy of a paternally imprinted gene on 11p15.5, rather than imprin  ng 
of SDHD itself. This model could explain the parent-of-origin-dependent inheritance 
in SDHAF2-linked paraganglioma as well, as SDHAF2 is also located on the long arm of 
chromosome 11. It furthermore leaves room for maternal inheritance of disease, as other 
mechanisms inac  va  ng both the wild type SDHD allele and the maternal 11p15.5 region 
could also cause tumor forma  on, however, maternal transmission is predicted to occur 
very rarely as this would require more complex soma  c rearrangements. 
Conclusion
Since the discovery of muta  ons in SDH genes as the cause of hereditary head and neck 
paragangliomas in the year 2000, great progress has been made in the iden  fi ca  on of 
pathogenic muta  ons, the descrip  on of phenotypic diff erences in between the causa  ve 




In this thesis, the rela  ve importance of the pathogenic muta  ons in the SDH genes in 
the Netherlands is elucidated, revealing a remarkable role of founder eff ects, especially in 
SDHD, but also in SDHB and SDHAF2. The prevalence of Dutch founder muta  ons has been 
recognized before, but their absolute dominance, especially of the SDHD.D92Y muta  on, 
and the rela  ve low numbers of other SDH muta  ons in the Dutch popula  on represent a 
new insight. We argue that these fi ndings may underlie an increased prevalence of head 
and neck paragangliomas in the Netherlands. 
A comprehensive understanding of the natural course of the disease and the risk of 
developing mul  focal, adrenal, metasta  c, or symptoma  c disease is important in the 
clinical decision making in head and neck paraganglioma pa  ents. As complete eradica  on 
of paragangliomas is not always possible or may confer a high risk of morbidity, especially 
in bilateral disease, the consequences of any treatment must always be weighed against 
the consequences of no interven  on. By studying a large pa  ent cohort and an extended 
paraganglioma family, we were able to characterize SDHD-linked paraganglioma pa  ents, 
and thus the majority of the Dutch head and neck paraganglioma popula  on, by an early 
mean age at diagnosis (26.5-37.9 years), a high rate of mul  ple tumors (65-74%), an 
intermediate risk of concurrent pheochromocytomas (8-21%), and a low risk of malignancy 
(2-3%). In addi  on, we found that whereas muta  ons in SDHD confer a high life  me risk 
of developing a paraganglioma, not all paraganglioma pa  ents develop tumor-related 
symptoms. Therefore, bearing in mind the words of Le Compte (“the greatest danger to 
these pa  ents is the treatment rather than the disease”), a conserva  ve treatment strategy 
seems appropriate in the majority of Dutch head and neck paraganglioma pa  ents.
As the Dutch SDHD-linked phenotype does not diff er signifi cantly from the SDHD-linked 
phenotype found elsewhere in Europe or the United States, we furthermore conclude 
that the high prevalence of Dutch founder muta  ons in SDHD is a refl ec  on of specifi c 
aspects of the Dutch demography and socio-economic history, rather than a result of 
environmental factors such as residen  al al  tude.
Another important feature of SDHD-linked paragangliomas is the virtually absent 
maternal transmission of the disease. We have shown that the ‘second hit’ in SDHD-
linked paragangliomas involves not only the wild type SDHD allele but the whole maternal 
chromosome 11 copy, sugges  ng a model that involves the combined loss of the wild type 
SDHD allele and a maternally expressed, paternally imprinted tumor suppressor located 
on 11p15.5 as an essen  al step in SDHD-linked paraganglioma forma  on. The almost 
exclusive paternal transmission of disease would then be the result of the coloca  on of 
this imprinted tumor suppressor and the wild type SDHD allele on the maternal copy 
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of chromosome 11. As of yet, the paraganglioma tumor suppressor on 11p15.5 has 
not been iden  fi ed with certainty, but if substan  ated, this model explains the parent-
of-origin dependent inheritance in the absence of imprin  ng of the SDHD gene itself. 
The fact that exclusive paternal inheritance of disease is also found in SDHAF2-linked 
paraganglioma families supports this model, as SDHAF2, like SDHD, is located on the long 
arm of chromosome 11 (11q13).
The proposed model furthermore explains the observa  on that true maternal transmission 
of SDHD-linked disease is possible, but rare. Simultaneous loss of the wild type SDHD 
allele and the ac  ve tumor suppressor allele can be achieved in a single event in case 
of a paternally inherited SDHD muta  on (by loss of the whole maternal chromosome 
11 copy), whereas it would require at least 2 separate hits targe  ng separate regions 
and/or separate copies of chromosome 11 in case of a maternally inherited muta  on, 
a sequence of events that is almost certainly less likely to occur in vivo. In support of 
this model, addi  onal events targe  ng the maternal 11p15.5 region have indeed been 
iden  fi ed in the recently reported rare occurrences of true maternal inheritance of SDHD-
linked disease.
The model could also explain the higher penetrance of SDHAF2 and SDHD-linked 
disease as opposed to SDHB- and SDHC-linked disease. As explained above, SDHD- and 
SDHAF2-linked tumorigenesis may be ini  ated by a single event targe  ng the whole 
maternal chromosome 11 copy. Assuming that loss of the maternal tumor suppressor 
allele on 11p15.5 is a prerequisite for the development of all SDH-linked paragangliomas, 
paraganglioma forma  on would require at least 2 separate hits, targe  ng the maternal 
11p15.5 region and the SDHB or SDHC wild type allele on chromosome 1 in SDHB- and 
SDHC-linked disease. 
In broader terms, the model for the parent-of-origin-dependent inheritance of SDHD-
linked paragangliomas illustrates the importance of the loca  on of disease genes on the 
genome, and demonstrates that even in alleged monogene  c diseases, mul  ple genes 
may be involved as essen  al ini  ators of disease or modifi ers of disease risk. 
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Summary and conclusion
Future perspec  ves
In order to further clarify the problem of the parent-of-origin-dependent inheritance in 
SDHD- and SDHAF2-linked paragangliomas, future research is needed into the role of the 
11p15.5 region both in SDHD- and SDHAF2-linked paragangliomas as well as in SDHB-, 
SDHC- and VHL-linked cases. The iden  fi ca  on of the addi  onal tumor suppressor gene 
or genes responsible for this phenomenon will almost certainly shed more light on the 
molecular mechanisms that underlie paraganglioma forma  on and probably help explain 
aspects of tumor behavior. In general, it will broaden our understanding of the signifi cance 
of modifi er genes for the occurrence and form of disease. 
Paraganglioma research has improved our insight into the link between hypoxia regula  on, 
metabolic disrup  ons and tumor forma  on. However, in spite of the progress made, some 
tantalizing ques  ons s  ll remain unanswered. It is presently unknown why germ line 
muta  ons in genes encoding SDH, a complex that is so vital to the energy supply of cells, 
preferably produce tumors in the paraganglion system, and do not (with the excep  on of 
SDHA muta  ons) cause a more generalized or severe disease phenotype. It is furthermore 
surprising that muta  ons in diff erent subunits of the same complex (SDH), all resul  ng in 
SDH defi ciency, give rise to quite dis  nct paraganglioma syndromes. On the other hand, it 
is equally surprising that muta  ons in genes with such diff erent func  ons as the SDH genes 
and TMEM127 or MAX, all cause the same tumor type. These unresolved issues illustrate 
the long way to go before the diff erent, interac  ng molecular mechanisms that cause 
paraganglioma are unraveled. As hypoxia pathway signaling and the switch to aerobic 
glycolysis are characteris  cs of a large variety of neoplasms, elucida  ng these pathways 
may have ramifi ca  ons beyond the fi eld of paragangliomas and pheochromocytomas. 
Already, several agents have been iden  fi ed that exert a possible an  -cancer eff ect 
through interac  on with key components of the hypoxia pathway. By contribu  ng to the 
expanding knowledge in this fi eld, paraganglioma research will almost certainly con  nue 
to be a powerful example of the way in which the study of a rare condi  on illuminates 
basic principles in biological and pathogenic processes, and facilitates the discovery of 
causes and remedies of more common forms of disease.
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Samenva   ng en conclusie
Samenva   ng
Hoofdstuk 1 bestaat uit een overzicht van de huidige stand van kennis met betrekking 
tot de klinische kenmerken, de gene  ca en de tumorbiologie van paragangliomen en 
feochromocytomen. 
Hoofdstuk 2 is een overzicht van recente ontwikkelingen op het gebied van de gene  ca 
van paragangliomen. Zowel de huidige inzichten als de toekomstperspec  even worden 
besproken, waarbij de grote progressie in de kennis van de gene  ca van paragangliomen 
wordt belicht die is geboekt na de ontdekking van de succinaat-dehydrogenase (SDH) 
genen als veroorzakers van paragangliomen. 
In Hoofdstuk 3 wordt de rela  eve frequen  e van muta  es in de SDH genen die geassocieerd 
zijn met paragangliomen en feochromocytomen in Nederland beschreven. Uit deze 
studie blijkt dat in Nederland de overgrote meerderheid van deze muta  es het SDHD gen 
betreff en, gevolgd door muta  es in SDHAF2 en SDHB, terwijl SDHC muta  es zeer zeldzaam 
zijn. Voorts wordt aangetoond dat het merendeel van de muta  edragers één van slechts 6 
Nederlandse foundermuta  es dragen, en dat de Asp92Tyr foundermuta  e in SDHD alleen 
al 69% van alle muta  es in SDH genen vertegenwoordigt. Zowel de dominan  e van de 
foundermuta  es in de Nederlandse popula  e als ook het beperkte aantal verschillende 
muta  es dat hier wordt aangetroff en in SDH genen maken de Nederlandse situa  e uniek.
Hoofdstuk 4 betre   een studie naar de gene  sche en klinische karakteris  eken van een 
groot cohort van pa  ënten met een hoofdhals paraganglioom, behandeld in het Leids 
Universitair Medisch Centrum (LUMC). Het pa  ëntencohort wordt gekenmerkt door een 
hoge prevalen  e van muta  es in het SDHD gen, hetgeen in lijn is met de bevindingen 
in hoofdstuk 3. In tegenstelling tot onderzoek uitgevoerd elders in Europa hee   een 
hoog percentage van de pa  ënten in dit cohort een posi  eve familie anamnese. Een 
opmerkelijke bevinding is dat in Nederland ook de meerderheid van de paraganglioom 
pa  ënten die zich presenteren met een nega  eve familie anamnese een erfelijke vorm 
van de aandoening blijkt te hebben. Vaak is de onderliggende oorzaak ook dan een 
muta  e in het SDHD gen. 
In dit hoofdstuk worden vervolgens de klinische consequen  es van muta  es in het SDHD 
gen geëvalueerd: pa  ënten met een SDHD muta  e hebben bij het stellen van de diagnose 
een gemiddelde lee  ijd van 38 jaar, een hoog risico op het ontwikkelen van meerdere 
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paragangliomen (73%), een risico op het ontwikkelen van een feochromocytoom (in 13%) 
of een extra-adrenaal paraganglioom (in 8%), en een klein risico op gemetastaseerde ziekte 
(2%). Naast pa  ënten met een SDHD muta  e worden in dit cohort ook SDHAF2-, SDHB- en 
SDHC- muta  edragers en pa  ënten zonder muta  e in een SDH gen geïden  fi ceerd, maar 
zij vormen slechts kleine minderheden. Er wordt gesteld dat de hoge prevalen  e van SDHD 
founder muta  es, alsmede de kleine aantallen SDHB muta  edragers en paraganglioom 
pa  ënten zonder aantoonbare muta  e in een SDH gen, kunnen wijzen op een hogere 
prevalen  e van hoofdhals paragangliomen in Nederland ten opzichte van wat globaal als 
gemiddelde prevalen  e wordt aangenomen.
In Hoofdstuk 5 worden meerdere genera  es van een grote familie van dragers van de 
D92Y (ook wel aangeduid met p.Asp92Tyr of c.274G>T) muta  e in SDHD beschreven. 
Deze Nederlandse foundermuta  e is de meest frequent voorkomende muta  e onder 
Nederlandse pa  ënten met een hoofdhals paraganglioom. Daar in deze studie alle 
aangedane familieleden dragers zijn van dezelfde muta  e, kan een goed beeld verkregen 
worden van het fenotype van deze muta  e. Het blijkt dat dit fenotype niet erg verschilt van 
het fenotype van andere SDHD muta  es of van SDHD muta  es in andere Europese landen. 
Tevens kan een accurate scha   ng van de penetran  e van de p.Asp92Tyr muta  e gemaakt 
worden, zowel voor het vóórkomen van paragangliomen alsook voor het optreden van 
gerelateerde symptomen, omdat in deze familie ook een groot aantal asymptoma  sche 
familieleden zijn getest op dragerschap. In deze familie zijn geen paragangliomen ontstaan 
na maternale overerving van de muta  e, conform de verwach  ng. Indien de muta  e van 
de vader wordt geërfd, blijkt de kans op het ontstaan van paragangliomen gedurende het 
leven echter zeer groot (87%), hoewel dit risico toch lager is dan in andere studies wordt 
gevonden. Het risico op het ontstaan van symptoma  sche paragangliomen is aanmerkelijk 
lager (57%). 
Hoofdstuk 6 behandelt een genexpressie studie, waarin de genexpressie van 8.000 genen 
wordt onderzocht in sporadische, SDHD- en PGL2-geassocieerde paragangliomen. Op het 
moment dat deze studie werd uitgevoerd was de iden  teit van het PGL2 gen nog niet 
bekend, en in deze studie is getracht om aan de hand van verschillen in genexpressie 
de func  e van dit gen af te leiden en zo het PGL2 gen te iden  fi ceren. Er konden echter 
geen signifi cante verschillen in het genexpressie patroon worden ontdekt tussen de 
bovengenoemde subgroepen. Zelfs in geselecteerde genensets, waarvan bekend is of 
wordt vermoed dat ze een rol spelen in de vorming van paragangliomen, konden geen 
verschillen worden aangetoond. Wij stelden dat dit veroorzaakt zou kunnen worden 
doordat muta  es in het SDHD gen en het PGL2 gen een vergelijkbaar eff ect hebben op 
de ac  viteit van succinaat-dehydrogenase. Met de ontdekking van de iden  teit van het 
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PGL2 gen als zijnde het SDHAF2 gen, en het ophelderen van de rol die dit gen hee   in het 
func  oneren van het succinaat-dehydrogenase complex, is inmiddels duidelijk geworden 
dat dit inderdaad het geval is.
In Hoofdstuk 7 wordt een model voorgesteld dat het bijzondere overervingspatroon 
van SDHD-geassocieerde paragangliomen en feochromocytomen verklaart. Het is 
al enige  jd bekend dat paragangliomen niet of slechts zeer zelden ontstaan indien 
de verantwoordelijke muta  e in het SDHD gen wordt geërfd via de moeder, terwijl er 
wel een grote kans is op het ontstaan van paragangliomen als dezelfde muta  e wordt 
doorgegeven via de vader. Hierdoor kan het vóórkomen dat de aandoening genera  es 
‘overslaat’, terwijl de SDHD muta  e wel wordt doorgegeven. Deze wijze van overerving 
zou kunnen worden verklaard door maternale inpren  ng van het SDHD gen. Er zijn echter 
belangrijke bevindingen die pleiten tegen inpren  ng van het SDHD gen zelf: ten eerste is er 
geen methyla  e (en dus geen daadwerkelijke transcrip  eblokkade) van het SDHD locus op 
chromosoom 11 (11q23) aangetoond. Ten tweede komen elders in het lichaam (in andere 
weefsels dan de paraganglions) beide SDHD allelen tot expressie. Voorts wordt frequent 
het verlies van het wild type SDHD allel geobserveerd (ook wel ‘loss of heterozygosity’, 
of LOH genoemd), hetgeen tegen inpren  ng van het gen pleit omdat LOH geen selec  ef 
voordeel voor tumorgroei oplevert als het wild type allel door inpren  ng toch al niet tot 
expressie zou komen.
Uit het onderzoek dat wordt behandeld in dit hoofdstuk blijkt dat in SDHD-geassocieerde 
paragangliomen niet alleen het wild type SDHD allel verloren gaat, maar dat er sprake is 
van selec  ef verlies van de gehele maternale kopie van chromosoom 11. Dit soma  sche 
verlies van het gehele chromosoom suggereert dat een ander gen, gelegen elders op 
chromosoom 11, een essen  ële rol speelt bij de tumorvorming. Omdat het verlies steeds 
het gehele chromosoom betre  , en niet alleen de 11q23 regio waar het SDHD gen is 
gelegen, lijkt het waarschijnlijk dat dit gen zich aan de andere zijde van het centromeer op 
de korte arm van chromosoom 11 (11p) bevindt. Voorts is het aannemelijk dat alleen de 
maternale kopie van dit gen tot expressie komt, omdat juiste de maternale kopie selec  ef 
verloren gaat. De hypothese stelt derhalve dat dit tweede gen func  oneert als addi  oneel 
tumor suppressor gen en aan paternale inpren  ng onderhevig is. Dit wijst erop dat het 
gen gelokaliseerd moet worden in de 11p15.5 regio, een gebied dat bekend staat vanwege 
het uitgebreide cluster van ingeprente genen dat er gelegen is. 
Het model voorspelt dat het verlies van het wild type SDHD allel op 11q23 op zich 
onvoldoende is voor de ini  a  e van tumorgroei, en dat tumoren zich uitsluitend vormen 
als ook het ac  eve maternale allel van de tumor suppressor op 11p15 verloren gaat. 
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Alleen wanneer de muta  e in het SDHD gen via de vader wordt geërfd, kan dit simultane 
verlies van deze twee genen gerealiseerd worden in één enkele stap, namelijk het verlies 
van het gehele maternale chromosoom 11, bijvoorbeeld ten gevolge van non-disjunc  e 
 jdens celdeling (zie ook hoofdstuk 1, fi guur 6). De vrijwel exclusief paternale overerving 
van de ziekte wordt met dit model dus niet verklaard door inpren  ng van het SDHD gen 
zelf, maar door een soma  sch mechanisme dat zowel het SDHD gen op 11q23 als een 
paternaal ingeprent tumor suppressor gen op 11p15 tre  . Met dit model kan tevens 
het gelijkende overervingspatroon in SDHAF2-geassocieerde paragangliomen verklaard 
worden, daar SDHAF2 ook op de lange arm van chromosoom 11 (11q13) is gelegen. Het 
model laat voorts ruimte voor maternale overerving van SDHD-geaccocieerde ziekte, 
omdat andere mechanismen volgens dit model ook tot tumorvorming kunnen leiden, 
mits zij zowel het wild type SDHD allel als het maternale allel van de addi  onele tumor 
suppressor op 11p15 treff en. Aangezien er voor deze weg naar tumorvorming volgens het 
model meerdere complexe stappen nodig zijn, maakt het model daarbij inzichtelijk dat 
ware maternale overving van paragangliomen zeldzaam is.
Conclusie
Sinds de ontdekking in het jaar 2000 van muta  es in SDH genen die hereditaire hoofdhals 
paragangliomen veroorzaken, is er veel vooruitgang geboekt in het iden  fi ceren van 
pathogene genmuta  es, het beschrijven van verschillende fenotypen, en het begrip van 
de moleculair biologische mechanismen die tumorgroei als gevolg van defecten in SDH 
kunnen verklaren. 
In dit proefschri   wordt het rela  eve aandeel van de verschillende pathogene SDH muta  es 
in Nederland onderzocht, waarbij een grote invloed van Nederlandse foundermuta  es 
wordt gevonden, met name in het SDHD gen. Hoewel reeds eerder gewag werd gemaakt 
van een hoge prevalen  e van foundermuta  es, vertegenwoordigen de absolute 
dominan  e van met name de SDHD.D92Y muta  e, en het rela  ef geringe aantal andere 
muta  es in SDH genen nieuwe inzichten met betrekking tot de gene  ca van hoofdhals 
paragangliomen in Nederland. Er wordt gesteld dat deze beide bevindingen kunnen 
duiden op een verhoogde prevalen  e van hoofdhals paragangliomen in Nederland.
Een goed begrip van het natuurlijk beloop van de aandoening en het risico op het ontstaan 
van symptomen, mul  pele tumoren, feochromocytomen en metastasen is van essen  eel 
belang voor het maken van gedegen klinische afwegingen bij pa  ënten met een hoofdhals 
paraganglioom. Daar complete eradica  e van een paraganglioom niet al  jd mogelijk is en 
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gepaard kan gaan met een hoog risico op therapiegerelateerde morbiditeit, zeker in het geval 
van bilaterale tumoren, moeten de consequen  es van een behandeling al  jd zorgvuldig 
gewogen worden tegen de consequen  es van een expecta  ef beleid. Door het bestuderen 
van een groot cohort van paraganglioom pa  ënten en een grote paragangliomen familie, 
hebben wij de karakteris  eken kunnen evalueren van SDHD-geassocieerde ziekte, en dus 
van de meest voorkomende vorm van erfelijke paragangliomen in Nederland. De SDHD-
geassocieerde pa  ënten popula  e wordt gekenmerkt door een gemiddelde lee  ijd bij 
diagnose van 26.5-37.9 jaar, het veelvuldig vóórkomen van mul  pele paragangliomen (in 
65-74%), een risico op het ontstaan van feochromocytomen van 8-21%, en een klein risico 
van 2-3% op het ontstaan van gemetastaseerde ziekte. Tevens kwam uit deze studies naar 
voren dat hoewel het risico op het ontstaan van paragangliomen voor dragers van een 
paternaal overerfde SDHD muta  e zeer hoog is, het risico op paraganglioom-geassocieerde 
symptomen aanmerkelijk lager ligt. In de Nederlandse situa  e lijkt daarom, de woorden 
van Le Compte indach  g (“the greatest danger to these pa  ents is the treatment rather 
than the disease”), een conserva  eve behandelingstrategie voor het merendeel van de 
pa  ënten gerechtvaardigd. 
Daar het Nederlandse fenotype niet wezenlijk verschilt van het SDHD-geassocieerde 
fenotype dat gevonden wordt elders in Europa of de Verenigde Staten, is het on-
waarschijnlijk dat de hoge prevalen  e van foundermuta  es in Nederland te maken hee   
met omgevingsfactoren zoals de ligging op zeeniveau, maar lijkt dit veeleer het gevolg van 
specifi eke aspecten van de Nederlandse demografi e en sociaaleconomische geschiedenis. 
Een ander opvallend kenmerk van SDHD-geassocieerde paragangliomen is de in hoofdstuk 
7 beschreven exclusieve paternale overerving van de ziekte. In dit proefschri   wordt 
aangetoond dat in SDHD-geassocieerde tumoren niet alleen het wild type SDHD allel maar 
het gehele maternale chromosoom 11 verdwijnt, hetgeen suggereert dat tumorvorming 
alleen optreedt bij het gecombineerde verlies van het wild type SDHD allel en een 
exclusief maternaal tot expressie komend tumor suppressor gen. Dit model verklaart het 
opvallende overervingspatroon door het tezamen vóórkomen van zowel de ac  eve kopie 
van deze ingeprente tumor suppressor, alsook het wild type SDHD allel op het maternale 
chromosoom 11. Hoewel tot op heden deze tumor suppressor nog niet met zekerheid is 
geïden  fi ceerd zou dit model het overervingspatroon kunnen verklaren in afwezigheid 
van inpren  ng van het SDHD gen zelf. Het feit dat hetzelfde overervingspatroon wordt 
aangetroff en in families paragangliomen geassocieerd met het SDHAF2 gen (eveneens 
gelegen op de lange arm van chromosoom 11) ondersteunt de hypothese. 
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Het model laat daarnaast ook ruimte voor maternale overerving van SDHD-geassocieerde 
ziekte in zeldzame gevallen. Het gelijk  jdige verlies van zowel het wild type SDHD allel als 
de maternale, ac  eve kopie van een tumor suppressor gen kan worden gerealiseerd in 1 
enkele stap in geval van een paternaal overerfde SDHD muta  e (namelijk door het verlies 
van het gehele maternale chromosoom 11), terwijl er tenminste 2 separate stappen 
voor nodig zijn in geval van een maternaal overerfde muta  e, stappen die bovendien 
verschillende regio’s van chromosoom 11 en/of verschillende kopieën van chromosoom 
11 zouden moeten treff en. Het is zeer aannemelijk dat dit laatste scenario in vivo veel 
minder frequent vóórkomt. Ondersteuning voor dit model wordt gevonden in de recent 
gerapporteerde gevallen van maternale overerving van SDHD-geassocieerde ziekte, 
omdat steeds, naast het verdwijnen van het wild type allel, een tweede verandering 
wordt aangetroff en in het 11p15.5 gebied, daar waar het geïmprinte genencluster op 
chromosoom 11 is gelegen. 
Het model zou ook duidelijk kunnen maken waarom de penetran  e van muta  es in SDHD 
en SDHAF2 (beiden gelegen op chromosoom 11) zo veel hoger is dan de penetran  e van 
muta  es in SDHB en SDHC (beiden gelegen op chromosoom 1). Zoals boven beschreven is 
in het geval van paternaal overerfde SDHD en SDHAF2 muta  es slechts één gebeurtenis, 
namelijk het wegvallen van het maternale chromosoom 11, voldoende voor de ini  a  e 
van tumorgroei. Aangenomen dat het ook voor SDHB- en SDHC-geassocieerde tumorgroei 
van essen  eel belang is dat een maternaal tumor suppressor allel op chromosoom 11 
(11p15.5) wordt uitgeschakeld, zouden in SDHB- en SDHC-geassocieerde gevallen ook 2 
stappen nodig zijn om dit te bewerkstelligen: één die het wild type SDHB of SDHC allel op 
chromosoom 1 uitschakelt, en een tweede die het maternale 11p15.5 gebied tre  .
In meer algemene zin illustreert dit model het belang van de lokalisa  e van pathogene 
genen op het genoom en toont het aan dat zelfs in aandoeningen waarvan wordt 
aangenomen dat ze monogene  sch zijn, meerdere genen betrokken kunnen zijn bij het 
bepalen van het risico op het ontstaan van ziekte.
Toekomstperspec  even
Teneinde het vraagstuk met betrekking tot de overerving van SDH geassocieerde 
paragangliomen verder op te helderen, is meer onderzoek nodig naar de rol van het 
11p15.5 gebied, zowel bij het ontstaan van SDHD- en SDHAF2-, als bij SDHB-, SDHC- en 
VHL-geassocieerde paragangliomen. De iden  fi ca  e van een gen in het 11p15 gebied dat 
als een aanvullende tumor suppressor func  oneert bij de forma  e van paragangliomen, 
zou vrijwel zeker ook meer licht werpen op de onderliggende moleculaire mechanismen in 
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het ontstaan en het gedrag van paragangliomen. Meer in het algemeen zou het veel inzicht 
kunnen geven in het belang van de loca  e van een gen binnen het genoom en de invloed 
die andere genen kunnen hebben als modifi catoren van ziekterisico en verschijningsvorm.
Het paragangliomen onderzoek hee   het inzicht doen toenemen in de moleculaire 
wegen die de regula  e bij hypoxie en het cellulaire metabolisme kunnen verbinden 
met tumorgroei. Ondanks deze progressie blijven er echter nog steeds veel prangende 
vragen onbeantwoord. Zo is het heden nog onbekend waarom muta  es in genen die 
onderdelen coderen van het succinaat-dehydrogenase, een complex dat zo cruciaal is in 
de energievoorziening van de cel, leiden tot tumoren in het paraganglion systeem, en niet 
(met uitzondering van SDHA) tot een veel erns  ger of meer gegeneraliseerd ziektebeeld. 
Ook is het verrassend dat muta  es in genen die allen onderdelen van hetzelfde succinaat-
dehydrogenase complex coderen, en allen leiden tot een verstoorde func  e van dit 
enzym, toch duidelijk verschillende fenotypen veroorzaken. Anderzijds is het opvallend 
dat muta  es in genen die zulke verschillende func  es hebben als de SDH genen en 
bijvoorbeeld TMEM127 of MAX, allemaal kunnen leiden tot de vorming van hetzelfde 
type tumor. 
Deze onbeantwoorde vragen illustreren de lange weg die nog te gaan is in het ophelderen 
van de verschillende, onderling verbonden moleculaire mechanismen die aan de basis 
liggen van het ontstaan van paragangliomen en feochromocytomen. Daar hypoxische 
signalen en het inschakelen van de anaerobe glycolyse kenmerken zijn van een breed 
gamma van neoplasmen, kan het ophelderen van deze signaaltransduc  e routes ook 
consequen  es hebben buiten het veld van paragangliomen en feochromocytomen. Op dit 
moment worden verschillende middelen geïden  fi ceerd die een mogelijk an  carcinogeen 
eff ect hebben juist door hun interac  e met de hypoxische signaaltransduc  e route. Door 
bij te dragen aan de groeiende kennis op dit gebied zal het paragangliomen onderzoek 
vrijwel zeker een mooi voorbeeld blijven van de manier waarop juist het onderzoek 
naar een zeldzame condi  e opheldering kan verschaff en in basale, algemeen geldende 
biologische en pathogene mechanismen, en de ontdekking van oorzaken en remedies 
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